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ABSTRACT 
Nucleus pulposus and mesenchymal stem cell preconditioning: a focus on redifferentiation, 
wnt signaling, and immunity 
 
Low back pain is one of the most common reasons for doctor visits each year in the United States 
and consistently represents one of the leading areas of US health care spending in recent decades. 
Located at the inner space of the intervertebral discs (IVDs) of the spinal column, a soft, shocking 
absorbing tissue known as nucleus pulposus (NP) is a frequently implicated target of patient 
symptoms and comorbidities related to back pain. IVDs are quite susceptible to both acute injury, 
such as disc herniation, and chronic age-related degeneration known as intervertebral disc 
degeneration (IVDD). These conditions ultimately lead to degeneration and deterioration of the 
IVD tissue and resident NP cells (NPCs) at the biochemical and cellular level. In recent years, 
orthopaedic therapies have aspired to utilize cell-based therapies in combination with surgical 
intervention strategies for the replenishment of NP tissue, however, this approach presents several 
challenges. Studies which seek to use autologous NPCs (i.e. the patients’ own cells) must consider 
the potential implications and poor efficacy associated with harvesting NPCs from a damaged, 
typically inflamed environment. Furthermore, initial yield from such procedures is typically 
limited to the herniated portion of the NP tissue. This avoids compromising the remaining healthy 
tissue in the disc space. Ultimately, this increases the demand for preconditioning strategies which 
can effectively: (1) increase cell proliferation and yield, (2) rejuvenate harvested NPCs to a healthy 
NP phenotype to increase cell redifferentiation/regenerative potential for therapeutic utilization, 
and (3) accomplishes these goals without causing the preconditioned cells to have any adverse 
immune responses. In our laboratory, we have previously demonstrated that some of these goals 
can be accomplished by expanding harvested NPCs on decellularized extracellular matrix (dECM)
  
 
substrates from various sources, however, several key factors remained unexplored. The signaling 
roles of Wnt (Wingless-Type integration) proteins of the Wnt-signaling pathways in NP 
redifferentiation (Wnt3A, Wnt5A, and Wnt11) have been previously associated with dECM, 
however, they have not been fully elucidated or compared; the modulation of these signals could 
provide more effective and exploitable means for NPC preconditioning. Additionally, it is 
unknown whether the use of dECM from allogeneic and xenogeneic sources have immunological 
consequences in the expansion of human NPCs. To demonstrate these concepts, we evaluated 
several preconditioning strategies for proliferative and redifferentiation effects in multiple cell 
lines of NPCs and SDSCs in our studies. We also transduced NPCs with lentiviral vectors to 
overexpress or knockout key WNT genes and evaluated them for redifferentiation gene and protein 
expression. For dECM studies, we expanded NPCs on allogeneic and xenogeneic dECMs, 
evaluated NPC redifferentiation, as well as their immunophenotypes by flow cytometry, and 
assayed T-cell proliferation in a mixed lymphocyte reaction with expanded cells. In these studies, 
we have shown that it is possible to increase redifferentiation potential of human NPCs and 
synovial-derived stem cells (SDSCs), a chondrocytic stem cell population, by preconditioning 
methods including FGF-2 supplementation, dECM expansion, and hypoxic preconditioning. We 
have demonstrated key roles for Wnt signals in the redifferentiation of NPCs and its relationship 
with cell preconditioning. Furthermore, we have provided new data and insights surrounding the 
immunological implications of NPC expansion on allogeneic and xenogeneic-derived dECM 
substrates. Overall, these findings will allow researchers and clinicians to effectively target Wnt 
signals, increase redifferentiation capacity, and to understand potential underlying implications of 
dECM preconditioning for future cell-based orthopaedic therapies. 
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Specific Aims 
Low back pain (LBP) causes significant morbidity in the United States, is responsible for up to 
5% of healthcare visits [1, 2], and affects up to 80% of the population [3-4]. Additionally, LBP is 
estimated to cost over $100 billion dollars per year in lost wages and costs associated with 
treatment [1-2]. LBP has been shown to affect a wide population range, including both youth and 
adolescent individuals [5]. Intervertebral disc disease (IVDD) and degenerative disc disease 
(DDD) are also significant contributors to this widespread morbidity and financial burden. Both 
IVDD and DDD are also reliable predictors of future disc complications and injuries directly 
attributed to these conditions, most notably disc herniation, which is known to cause a significant 
loss in central NP tissue [2]. Unfortunately, when this loss of NP tissue occurs, it is difficult for 
NP to naturally heal itself due to its low regenerative capacity, caused by the disc’s inherent 
avascular structure [6] which relies on diffusion to receive nutrient supply. Once injury or 
degeneration occurs, it can lead to greater disc dysfunction; as the number of healthy NP cells 
decreases, it leads to further disc dehydration and loss of proteoglycan content, triggering more 
severe and progressive disc degeneration [2]. 
The nature of disc degeneration makes autologous cell transplantation an attractive strategy, 
especially given that autologous cell-based therapy can help to avoid immune rejection and disease 
transmission; however, a small piece of NP tissue harvested through arthroscopy can only provide 
a limited number of NPCs. One current challenge in cell transplantation therapy for herniated 
disc and intervertebral disc disease patients is the lack of healthy implantable cells, which usually 
cannot be easily harvested in sufficient numbers. Since yield obtained through patient biopsies is 
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lower than required, an in vitro expansion method that can produce high quantities of 
transplantable cells is a reasonable approach. Another challenge surrounding such cell-based 
therapies for NP repair is the harsh microenvironment of degenerated discs that is generally 
inhospitable to implanted cells. Overall, a cell expansion method that can yield high quantities of 
rejuvenated NP cells with preserved redifferentiation capacity would be highly therapeutically 
relevant for NP cell-based therapies. 
Decellularized extracellular matrix (dECM) cell expansion/preconditioning is one proposed 
solution to these challenges, and has been demonstrated in our lab to dramatically enhance cell 
proliferation, differentiation capacity, and decrease cell senescence in both NP cells and in 
synovial-derived stem cells [7-8]. By utilizing dECM expansion, cells can be expanded to acquire 
a large number of cells for future therapeutic purposes. Our recent studies found that dECM 
deposited by autologous cells can enhance both cell proliferation and differentiation potential of 
seeded cells and they engage in active Wnt-signaling during expansion and differentiation [7-8]. 
These findings are consistent with other literature, which have noted roles for canonical and 
noncanonical Wnt signaling in chondrocytes and cells undergoing chondrogenic differentiation [9-
11].  
Another more common method used for in vitro cell expansion is the supplementation of growth 
media with fibroblast growth factor 2 (FGF-2). This growth factor has been shown to cause drastic 
increases in proliferation in a variety of cell types [12-14]. Although it is well known for increasing 
cell proliferation, its effect on the differentiation capacity following expansion and 
supplementation in cartilage-like cells [such as synovial-derived stem cells (SDSCs)] is less clear. 
In a preliminary study performed in our laboratory, we evaluated the ability of FGF-2 and FGF-
10, another growth factor, to influence SDSC proliferation and differentiation. Interestingly, we 
 xix 
 
found that several WNT-family genes were stage-specifically expressed, with WNT3A and 
WNT5A upregulated and WNT11 downregulated, following several days of FGF-2 treatment 
during expansion. Later, we discovered this trend in WNT-gene expression also corresponded to 
successful chondrogenic differentiation, with significant increases in COL2A1 and ACAN mRNA 
and decreases in COL1A1 expression versus other groups. FGF-10 treatment demonstrated 
insignificant changes in WNT-gene signaling and consequentially, contrasting trends in mRNA 
expression as those observed with FGF-2 supplementation during the proliferation stage. Because 
of the similarities between hyaline cartilage and nucleus pulposus tissue, including their high ratios 
of collagen type 2, aggrecan, glycosaminoglycan content, and matrix microenvironment [15-17], 
we hypothesize that Wnt-signaling is also influential on NP redifferentiation. By determining 
which Wnt signals are most crucial to NP redifferentiation, cell expansion techniques can 
incorporate various preconditioning strategies, such as drug supplementation or gene therapy, to 
target the most critical Wnt-signaling pathways to yield the highest quality NP cells for clinical 
use. 
Despite successes with increasing redifferentiation capacity and rejuvenating seeded cells by 
dECM expansion, it is unclear whether dECM expansion leads to increased immunogenicity 
in expanded NP cells. In a recent study from our group, SDSCs expanded on xenogeneic porcine 
dECM exhibited increases in MHC class II human leukocyte antigen (HLA-DR) expression versus 
allogeneic dECM and plastic groups [18] which could pose significant challenges for clinicians 
wishing to use dECM expansion techniques, as increased HLA-DR expression has been shown to 
be involved in adverse graft rejection events [19-21]. Past studies have demonstrated that MHC 
class II-positive antigen-presenting cells, and more recently synovial fibroblasts [22] can lead to 
T-cell activation and immune rejection, although it should be noted that HLA-DR presentation 
 xx 
 
alone may not always lead to cell death or T-cell proliferation, but rather T-cell anergy [23-24]. 
The presence of complementary ligands, CD80 and CD86, B7-1 and B7-2, respectively, must be 
present in order to activate/proliferate T-cells [25-26] and, since fibroblasts have been shown to 
engage in HLA-restricted stimulation of T-cells [27], it is important to assure that dECM expansion 
does not increase the expression of these markers in NP cells. Since chondrocytes, fibroblasts, and 
synovial stem cells have a similar microenvironment to NP cells, they may experience similar 
changes in surface marker expression following dECM expansion. By assaying these markers, a 
more complete surface marker profile can be established for expanded NP cells, as well as new 
clues and insight into the effects of dECM-expansion on NP cells’ immunogenic profiles. 
In addition to HLA-DR, CD80, and CD86 expression, other immune markers may be potential 
concerns for dECM expanded NP cells and their interactions with T-cells. Fas (receptor) and its 
ligand, FasL, have been studied for many years; their interaction is known to contribute to cell 
apoptosis, as well as graft rejection and T-cell mediated toxicity [28-29]. By expressing FasL 
(CD178), cells in immune privileged areas such as the eye [30], testis [30], and intervertebral disc 
[31] are thought to be able to maintain their survival in the presence of CD95-expressing immune 
cells. For example, the expression of CD95L has been shown to promote survival of testis cells 
after implantation in the kidney [30]. It is known that normal, healthy NP cells express FasL [31] 
and some studies have concluded that NP cells from herniated discs may be susceptible to 
increased Fas-mediated apoptosis [32] and possibly autoimmunity [33]. By assaying these 
markers, the protective effects of dECM expansion can be investigated, as well as additional 
information regarding NP cell survival in the presence of immune cells. 
Injuries and degenerative conditions affecting the intervertebral disc (IVD) and, more specifically, 
the inner nucleus pulposus (NP) tissue, produces significant morbidity in both young and aging 
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patient populations. The nucleus pulposus greatly contributes to the shock absorbing capacity of 
the IVD under dynamic loading stresses, is relatively avascular, and has a low natural capacity for 
self-repair following trauma or disease. Chronic degenerative conditions, the natural aging 
process, and acute injuries such as IVD herniation can produce an inflammatory 
microenvironment, and consequentially, further contributes to this decreased natural capacity for 
the native nucleus pulposus to undergo self-repair. Current clinical treatments typically focus on 
pain management and symptom relief, rather than incorporating cellular strategies to stimulate 
repair and regeneration of the lost or damaged NP tissue. The primary challenges surrounding 
such treatments/therapies are the lack of available cells for harvest, as well as the poor cell 
morphology and low proliferative rates of NP cells obtained through biopsy. To overcome such 
challenges, the use of decellularized extracellular matrix (dECM) substrates to expand harvested 
autologous nucleus pulposus cells (NPCs) is an attractive strategy for ex vivo cell expansion; this 
allows clinicians to harvest a small number of patient cells, which frequently exhibit poor 
regenerative capacity and, after dECM expansion, yield a robust number of rejuvenated NP cells 
for future therapeutic use. 
Recent data from our laboratory suggests that the expression of several Wnt-signaling genes 
coincides with successful redifferentiation of NP cells following dECM expansion and other 
treatments in vitro. Although dECM and cell-based tissue engineering strategies have recently 
begun to provide solutions for biological repair and regeneration of NP tissue, the immunological 
feasibility surrounding the use of dECM for NP expansion and the specific role of these WNT 
signals in NP cell redifferentiation have yet to be fully elucidated. We hypothesize that dECM 
deposited by allogeneic and xenogeneic NP cells can provide superior matrix microenvironments 
for the rejuvenation of NP cells without significant immune consequences. Additionally, we 
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hypothesize that specific WNT-genes (WNT5A, WNT3A, and WNT11) play crucial roles in the 
redifferentiation of NP cells. 
To test our hypotheses, we propose the following specific aims:  
[Aim 1.] Determine if the overexpression and/or knockout of WNT3A, WNT5A, and WNT11 
in human NPCs can influence their ability to undergo successful NP redifferentiation. The 
objective of Aim 1 is to test the working hypothesis that Wnt signaling plays a crucial role in NP 
redifferentiation, with increased canonical Wnt signal (WNT3A) expression leading to less 
successful NP redifferentiation, and more successful redifferentiation occurring with increased 
noncanonical Wnt signals (WNT5A and WNT11). 
[Aim 2.] Determine if the expansion of human NPCs on plastic, allogeneic dECM, or porcine 
xenogeneic dECM substrates produces variations in the expression of surface markers 
related to immune tolerance and increases T-cell proliferation.  The objective of Aim 2 is to 
test the working hypotheses that allogeneic and xenogeneic dECM expansion are equally 
appropriate for robust NPC expansion without increasing cell immunogenicity. 
The novelty of this proposal includes (1) our investigations of NP regeneration and other closely 
related cartilage research using dECM rejuvenation; (2) further elucidation of signaling 
mechanisms related to successful NP redifferentiation and successes using Lentiviral gene 
knockout and overexpression methods for WNT-genes; (3) preliminary data evaluating the 
immunological feasibility of using allogeneic and xenogeneic dECM for NPC expansion. Our 
objective and long-term goal is to define a novel and readily (commercially) available cell 
expansion system that can provide high quantity, as well as high quality, NP cells for the treatments 
related to NP regeneration/repair, including patients suffering from chronic degenerative 
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conditions or acute disc injury. The primary impact of our expected findings would not only help 
define crucial roles of WNT-family genes in NP redifferentiation and rejuvenation, but also 
advance cell-based approaches for NP regeneration and contribute new information regarding the 
immunological consequences of expanding NP cells on decellularized matrix microenvironments.  
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Abstract 
Tissue-specific stem cells are found throughout the body and, with proper intervention and 
environmental cues, these stem cells exercise their capabilities for differentiation into several 
lineages to form cartilage, bone, muscle, and adipose tissue in vitro and in vivo. Interestingly, it 
has been widely demonstrated that they do not differentiate with the same efficacy during 
lineage-specific differentiation studies, as the tissue-specific stem cells are generally more 
effective when differentiating toward the tissues from which they were derived. This review 
focuses on four mesodermal lineages for tissue-specific stem cell differentiation: adipogenesis, 
chondrogenesis, myogenesis, and osteogenesis. It is intended to give insight into current 
multilineage differentiation and comparative research, highlight and contrast known trends 
regarding differentiation, and introduce supporting evidence which demonstrates particular 
tissue-specific stem cells’ superiority in lineage-specific differentiation, along with their resident 
tissue origins and natural roles. In addition, some epigenetic and transcriptomic differences 
between stem cells then may explain the observed trends are discussed. 
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1.1a Introduction 
Humans and other higher eukaryotes utilize various populations of stem cells throughout the 
developmental process and into adulthood. The vast repertoire of functional stem cell 
populations is imperative to normal cellular and tissue renewal. Despite possessing a high degree 
of pluripotency and proliferative potential (1), embryonic stem cell research has been met with 
various ethical concerns and strict regulations, especially in the United States, restricting the use 
of such stem cells in research and clinical settings. These obstructions have forced scientists to 
search for alternative approaches in stem cell therapy, shifting research focus to the utilization of 
somatic stem cells for regenerative medicine and tissue engineering. 
Somatic stem cells, commonly referred to as adult stem cells (ASCs) or tissue-specific stem 
cells, are present throughout various tissues in the body (2). Tissue-specific stem cells are 
multipotent and self-renewing cells which possess endogenous functions for tissue renewal and 
repair at their respective resident tissues (3). Although ASCs seem to exist ubiquitously 
throughout a variety of tissues, current literature suggests that not all are necessarily created 
equal in their differential and proliferative capacities, or their ability to respond to outside 
influences such as microenvironments. In reality, ASCs have inherent properties which greatly 
contribute to their ability to undergo successful single lineage-specific differentiation. Great 
variability in the differential capacity certainly exists between tissue-specific stem cells, which 
may vary within the same cell type. Populations and subpopulations of cells derived from the 
same tissue may exhibit slight variations in surface marker expression or in their expression of a 
single gene, which may alter their tendency to engage in uniform lineage-specific differentiation. 
For researchers investigating stem cell-based tissue engineering, it is necessary to choose the 
most appropriate type of ASCs naturally suited to the research goals and objectives. Many times, 
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the inherent properties of tissue-specific stem cells are overlooked. This review focuses on four 
mesodermal lineages for ASC differentiation: adipogenesis, chondrogenesis, myogenesis, and 
osteogenesis. It is intended to review the current multilineage differentiation and comparative 
research, highlight and contrast known trends regarding differentiation, and introduce supporting 
evidence which demonstrates particular ASCs’ superiority in lineage-specific differentiation, 
concomitant with their resident tissue origins and natural roles. In addition, some epigenetic and 
transcriptomic differences between stem cells which may explain the observed trends are 
discussed. 
 
 
 
 
 
 
 
 
 
 
 
 7 
 
Tissue-Specific Stem Cells Benefiting Lineage-Specific Differentiation 
1.1b Adipogenesis 
 Although commonly removed via liposuction surgery, newly differentiated ASCs from 
adipose tissue have therapeutic potential in cosmetic surgery (2), as well as tissue grafts for burn 
victims and autologous transplantation (4). The use of adipose-derived stem cells (ADSCs) in 
lineage-directed studies has been established, with their greatest success demonstrated along the 
adipogenic lineage (Figure 1). In a multilineage comparison study by Yoshimura and colleagues 
using murine ASCs, the greatest adipogenic potential was observed using Oil-Red-O staining in 
the groups from both synovial-derived stem cells (SDSCs) and ADSCs compared to those from 
muscle-derived stem cells (MDSCs), periosteum-derived stem cells, and bone marrow-derived 
stem cells (BMSCs). These findings were supported by reverse transcription polymerase chain 
reaction (RT-PCR) results for adipogenic markers [peroxisome proliferator-activated receptor 
gamma (PPARG) and CCAAT/enhancer binding protein alpha (CEBPA)] after four days of 
adipogenic lineage induction (5). These conclusions were consistent with the findings by 
Sakaguchi and colleagues. They found that the SDSC and ADSC groups represented the only 
groups with each of their three colonies stained positive for lipid accumulation; the BMSC group 
had one colony with a staining rate greater than 80%. In contrast, the periosteum and MDSC 
groups had zero colonies possessing a rate of Oil-Red-O staining greater than 80%, which is 
indicative of being highly inferior for adipogenesis (6). These results are further supported by the 
work of Mochizuki and colleagues, where differences between SDSCs harvested from fibrous 
synovium, SDSCs from adipose synovium, and subcutaneous ADSCs were indistinguishable in 
Oil-Red-O staining (7). In a multilineage study by Peng and colleagues, rat ADSCs exhibited the 
greatest normalized PPARG and lipoprotein lipase (LPL) levels at day 7 in an adipogenic 
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induction regimen, demonstrating superior adipogenic potential of ADSCs to BMSC and 
cartilage-derived stem cell groups, which was further confirmed by densitometric analysis of 
Oil-Red-O stained cultures (8). Based on these studies, it appears that SDSCs and ADSCs can 
each undergo successful adipogenic differentiation. More studies need to be conducted in order 
to determine if definitive adipogenic superiority exists between the two cell types. 
In another comparative study using several types of tissue-specific stem cells, ADSCs 
were directly compared with BMSCs after seeding on collagen scaffolds. Despite similar 
trilineage differentiation overall (chondrogenic, adipogenic, and osteogenic) between both 
groups, there was a significantly greater and more rapid upregulation of adipogenic genes in 
ADSCs and osteogenic genes in BMSCs after in vitro induction (9). A transcriptomics study by 
Monaco and colleagues aimed to compare the differentially expressed genes of ADSCs derived 
from adult porcine subcutaneous adipose tissue and BMSCs derived from the femur before and 
after osteogenic and adipogenic differentiation (10). Just as Vishnubalaji and colleagues 
observed (11), Monaco and colleagues found that ADSCs had greater lipid metabolism than 
BMSCs while BMSCs had an increased osteogenic and proliferative capacity; ADSCs exhibited 
significantly lower expression for osteopontin (OPN) than BMSCs, which was also confirmed by 
quantitative RT-PCR. Based upon their functional analyses, it is reasonable to suggest that 
ADSCs naturally progress toward the adipogenic lineage with greater propensity than BMSCs 
and vice versa (10). 
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1.1c Chondrogenesis 
Producing healthy, viable human cartilage for surgical repair through autologous 
transplantation has widespread therapeutic potential, especially for patients in the aging 
populations. The synovium has proved to be a valuable source of ASCs for effective induction of 
chondrogenesis and the production of high-quality cartilage in vitro (12, 13) and in vivo (14), but 
it has also been investigated in osteogenic, adipogenic, and myogenic experiments (Figure 1). 
SDSCs have a tendency to progress toward the chondrogenic lineage more effectively 
than other stem cells. Mochizuki and colleagues found that human SDSCs from both fibrous and 
adipose synovium exhibited similar superiority over subcutaneous ADSCs in chondrogenic 
potential (7). Another study comparing various human ASCs from separate sources was 
performed by Sakaguchi and colleagues, where SDSCs were once again the most superior source 
for stem cell chondrogenesis over ADSCs and MDSCs; the SDSC group yielded pellets with the 
largest size and the highest intensity for toluidine blue cartilage matrix staining (6). Similar 
conclusions were supported by Yoshimura and colleagues, who reported that rat SDSCs 
exhibited the greatest efficiency and growth kinetics, producing the heaviest chondrogenic 
pellets due to matrix formation (5). Compared to BMSCs, ADSCs exhibited a reduced 
chondrogenic potential under standard culture conditions driven by transforming growth factor 
beta (TGFβ). Hennig and colleagues found that human ADSCs had reduced expression of bone 
morphogenetic protein-2 (BMP2), -4 (BMP4), and -6 (BMP6) mRNA and did not express TGFβ-
receptor-1 protein. BMP6 treatment induced TGFβ-receptor-1 expression and combined 
application of TGFβ and BMP6 eliminated the reduced chondrogenic potential of ADSCs 
inducing a gene expression profile similar to differentiated BMSCs. Similar to BMSCs, 
chondrogenesis of ADSCs was associated with hypertrophy according to premature collagen X 
 10 
 
(COL10A1) expression, upregulation of ALP activity, and in vivo calcification of spheroids after 
ectopic transplantation in SCID mice (15). Although this study did not use SDSCs (in addition to 
BMSCs and ADSCs) to similarly compare their hypertrophy or calcification fates, SDSCs have 
been evaluated in other studies. In a report using an osteogenic induction medium, SDSCs 
exhibit a 5- to 10-fold decrease compared to BMSCs in the levels of osteocalcin (OCN) and ALP 
(16), which are known to contribute to calcification and pro-osteoblast activity; however, the 
generation of articular cartilage without hypertrophic terminal differentiation still remains a 
current challenge in the field (17). 
Several studies have compared the in vivo efficacy and capabilities of SDSCs for 
cartilage regeneration and repair of osteochondral defects in rabbit models. After initially 
demonstrating that SDSCs were superior stem cells for chondrogenesis, Koga and colleagues 
transplanted donor-matched ASCs to repair cartilage defects created in a rabbit model and found 
that SDSCs and BMSCs produced significantly greater amounts of cartilage matrix than other 
cells of adipose and muscle tissue origins; when SDSCs were transplanted at a higher cell 
density and with a periosteal patch, more abundant cartilage matrix was observed. They also 
noted that SDSCs had a clear advantage in terms of proliferative potential, giving SDSCs an 
additional edge over BMSC counterparts for therapeutic applications (18). In another similar in 
vivo experiment, Pei and colleagues set out to repair full-thickness rabbit cartilage defects via 
allogeneic in vitro engineered SDSC cartilage constructs. Six months after implantation of 
SDSC-based constructs, the femoral condyle defects were filled with smooth hyaline-like 
cartilage, did not exhibit collagen I, and possessed high levels of collagen II and 
glycosaminoglycan (GAG), with well integrated new tissue formation. These results are 
contrasted by control groups which possessed fibrous tissue (14). A third study using a rabbit 
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model for defective articular cartilage repair, Lee and colleagues also tested SDSCs’ in vivo 
effectiveness. For this study, SDSCs were seeded in a platelet-rich plasma (PRP) gel, which 
could be injected into the femoral defect. After 24 weeks, results very similar to the Pei et al. 
study were obtained, with fibrous tissue in the control group and hyaline cartilage in both the 
PRP group and the PRP-SDSC group. The PRP with seeded SDSCs possessed greater GAG 
content than the non-SDSC groups, as well as the greatest collagen II expression (19). In another 
relevant study, hydrogel encapsulated porcine SDSCs, BMSCs, and ADSCs were compared for 
in vitro and in vivo chondrogenesis, SDSCs were once again found to be the most chondrogenic. 
SDSCs yielded mechanically stiffer constructs and as others have found, SDSC hydrogels 
exhibited the greatest GAG and collagen expression of any group (20). 
SDSCs’ success in chondrogenesis seems to lie in their inherent cellular properties and 
growth characteristics (17, 21). One study found that chondrocytes and intraarticular tissue stem 
cells (including SDSCs) from human donors exhibited a higher expression of proline arginine-
rich end leucine-rich repeat protein (PRELP), a connective tissue glycoprotein of the leucine-rich 
repeat family abundant in cartilage rather than in cultured fibroblasts, which was absent in 
extraarticular tissue stem cells, such as ADSCs and MDSCs; BMSCs increased PRELP 
expression during in vitro chondrogenesis (22). After many passages, ASCs tend to undergo a 
process marked by telomere shortening and replicative senescence, leading to impaired ability to 
differentiate into specific tissues (23). SDSCs retain multipotency for up to ten passages with 
limited cell senescence and retained chondrogenic capacity (24). This characteristic presents a 
reasonable explanation for SDSCs’ remarkable ability to successfully differentiate into 
cartilaginous tissue and, to a lesser degree, yet notably, the ability to produce muscle, bone, and 
adipose tissue. It is also notable that the in vitro microenvironment can influence SDSC 
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differentiation toward chondrogenesis, particularly the extracellular matrix (ECM). ECM 
deposited by SDSCs has been shown to improve SDSC expansion in vitro and shift the SDSCs at 
a greater propensity toward the chondrogenic lineage, while decreasing osteogenesis and 
adipogenesis (25, 26). 
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1.1d Myogenesis 
Several potential therapeutic applications for myogenically differentiated stem cells exist, 
including dystrophic diseases and orthopaedic surgery (27). Therapies which produce viable 
muscle tissue have the potential to aid against the pathogenicity of muscle diseases and elucidate 
natural mechanisms for muscle repair via ASCs. The contribution of MDSCs to myogenic 
differentiation in vitro have been investigated, as well as their ability to contribute to muscle 
tissue in vivo. Following a similar trend as other tissue-specific stem cells, MDSCs seem to most 
effectively undergo myogenesis than other types of lineage specification (Figure 1). 
Several muscle progenitor populations have been identified in muscle which do not 
express satellite cell markers such as Pax7, and some of these populations have been shown to be 
myogenic in vivo and in vitro. One such population located in the interstitium of postnatal 
muscle, expressing PW1, a cell stress mediator, is referred to as PW1+/Pax7− interstitial cells 
(PICs). Mitchell and colleagues found that PICs exhibited comparable levels of myogenesis to 
that of satellite cells in vivo and engaged in the stem cell process of self-renewal. Interestingly, 
PICs require Pax7 for myogenic specification, as none of the Pax7-deficient PICs was deemed 
myogenic (28). Differing from the commonly researched and highly myogenic populations of 
Pax7+ muscle satellite cells (27, 29), other MDSCs can be multipotent and have the capacity to 
differentiate into many cell types such as myocytes, chondrocytes, adipocytes, and osteocytes 
under the necessary conditions (30). Aside from PICs, other muscle-derived cell populations 
have been discovered and evaluated for their contributions to muscle repair (31–34). Some of 
these muscle-derived side populations may be able to form new myotubes and contribute to 
muscle repair and regeneration (35). It should be noted that, despite the fact that several 
populations expressing mesenchymal stem cell markers have been identified and can engage in 
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multilineage differentiation, their stem cell status is currently debated in the field; however, it is 
accepted that non-satellite muscle cells accumulate in the interstitium following muscle injury 
and can contribute to muscle repair in the presence of necessary environmental or outside factors 
(31), leading some investigators to speculate about their roles in the repair of damaged muscle. 
In a study by Meligy and colleagues, ADSCs, BMSCs, and skeletal MDSCs were 
harvested from six-week-old rats for in vitro myogenic comparative studies. Flow cytometry data 
showed that all stem cells exhibited positive expression of CD90 and CD44 and lacked 
expression of CD35, CD41, and CD34. Under myogenic induction, the greatest myogenic 
marker expression was exhibited by the skeletal MDSC population with peak myogenin 
expression of 93% in the myogenically differentiated MDSCs, 83.3% in the BMSCs, and 77% in 
the ADSCs (36). The similarity of myogenic potential between BMSCs and ADSCs was also 
demonstrated in another report using rats. After four passages, investigators observed high 
expression of CD90 in both ADSCs and BMSCs and a reduction of CD44 expression in ADSCs. 
They also observed significantly higher expression of myogenic differentiation 1 (MyoD1) in 
BMSCs compared to ADSCs (37). In a related comparative study conducted by Lei and 
colleagues, after a 28-day myogenic induction, higher expression levels of skeletal muscle-
specific genes were observed in adult mouse MDSCs than fetal counterparts (p < 0.01) and the 
lowest expression levels were demonstrated in ADSCs (p < 0.01). All stem cells were detected 
for both CD29 and CD90 positive and CD45 negative phenotype, and exhibited fibroblast-like 
spindle morphology in cell cultures. In addition, muscle-specific cadherin (M-Cad) and myosin 
heavy chain (MyHC) expressions in ADSCs were not detected by immunofluorescence or 
quantitative real-time PCR (38). These results suggest that some inherent properties may exist in 
non-satellite MDSC populations, which allowing the MDSC populations to more readily 
 15 
 
upregulate myogenic genes and progress along the myogenic lineage than stem cells from 
alternative sources. 
Satellite cells and other MDSC side populations seem to be the most natural choice for 
producing quality myotubes; however, other stem cells have been utilized, despite the fact that 
ADSCs appear to be a poor choice. In two separate experiments by De Bari and colleagues, 
SDSCs were evaluated for myofiber incorporation and myogenic capacity (24, 39). In the earlier 
study from 2001, five SDSC clones were evaluated for adipogenic, myogenic, chondrogenic, 
osteogenic, and myogenic differentiation capacity. All clones were determined to be fully 
capable of chondrogenesis, adipogenesis, and osteogenesis; however, this myogenic 
differentiation was described as a “few scattered, rudimentary myotubes” (24). In their later 2003 
study, using the in vivo mdx mouse model and tibialis anterior muscle injection of human 
SDSCs, they found that SDSCs possessed the capacity to contribute to myofiber formation, 
independent of fusion with muscle cells. Successful myogenesis occurred and the implanted 
SDSCs were able to contribute to the local satellite cell population (39). More research is needed 
to truly elucidate the complete differential capabilities of non-satellite muscle-derived cell 
populations, as well as an accurate method for classifying the status of these populations as stem 
cells. 
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1.1e Osteogenesis 
In conjunction with cartilage engineering studies, experiments which aim to produce bone tissue 
are crucial and invaluable to the medical community. Bone constructs produced from stem cells 
can be used in fracture repair, as well as treating bone tissue defects (40). Although BMSCs have 
been evaluated for multilineage potential, especially chondrogenesis, they most effectively 
undergo osteogenic differentiation (Figure 1). 
Several in vitro studies have been performed which demonstrate the superior capabilities 
of BMSCs to differentiate into bone tissue. A comparison study by Im and colleagues set out to 
determine the difference between the chondrogenic and osteogenic capacity of ADSCs and 
BMSCs by differentiating these cells on a monolayer culture. Based on the results of Von Kossa 
matrix mineralization assay and alkaline phosphatase (ALP) staining for osteoblastic 
differentiation, the BMSCs proved to be superior to the ADSCs (41). This conclusion was also in 
agreement with another comparative study by Vishnubalaji and colleagues (11). In a study which 
took a less common approach to evaluate osteogenesis, Park and colleagues used Chip-Based 
assays to measure osteogenic markers and gene expression to compare the potential of human 
BMSCs and ADSCs for bone formation. Using hydraulic pressure to add cell stress, they saw 
increases in bone matrix formation in both cell types; however, stimulated BMSCs showed 
greater staining in Alizarin Red S and ALP assays which is indicative of osteogenesis. They 
concluded that BMSCs were more susceptible to changes in osteogenic differentiation under 
mechanical stimulation than ADSCs (42). This conclusion seems reasonable when one considers 
the weight bearing responsibility and mechanical stability demand of the human skeletal system, 
which is likely a manifestation of the susceptibility and responsiveness of osteoblastic precursor 
and BMSC populations to such mechanical forces. 
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These growth and differentiation characteristics may also contribute to their natural and 
specific inclination toward the osteogenic lineage, as well as their role as effective ASCs for 
bone growth and formation. This idea was tested by Muraglia and colleagues with BMSCs for 
osteogenesis, chondrogenesis, and adipogenesis after producing non-immortalized clones. In two 
clone groups, 60% and 80% of clones in each respective group were bipotent toward the 
osteochondrogenic lineage. They found that some groups of BMSC clones do in fact possess 
trilineage potential at the clonal level; however, the BMSCs studied seem to favor the osteogenic 
lineage, as they shed their multipotency and all clones progressed toward osteogenic 
differentiation. All clones exhibited this osteogenic bias. Notably, certain clonal phenotypes were 
not observed in the study, such as clones which expressed the chondrogenic or adipogenic 
phenotypes exclusively (43). 
Other support for BMSCs’ superiority in osteogenesis is highlighted in a report that, 
compared with ADSCs and SDSCs, equine BMSCs exhibited significant five-fold increases in 
runt-related transcription factor 2 (RUNX2) levels on day 7 of osteogenic differentiation and a 
six-fold increase in expression by day 14; levels of osteoblast-specific marker Osterix (OSX), 
were much higher (greater than 10 times) at basal levels in BMSCs versus ADSC and SDSC cell 
groups and Osteomodulin (OSM), a protein found in mature osteoblasts which links cells to the 
ECM, showed levels that were twice as high in BMSC cultures as well (44). Another earlier 
study by Jansen and colleagues found that there were large differences between the genetic 
profiles of ASCs derived from differing sources; human BMSCs appear to be more genetically 
prepared to undergo skeletal development than human ADSCs (45). With the consideration of 
apparent differences in gene expression in predifferentiated states of various ASCs, as well as 
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unique features based solely upon harvest location and cell type, questions regarding genetic 
predisposal and natural capability are valid. 
Although ADSCs and MDSCs can differentiate into osteoblasts in vitro, they have not 
been demonstrated as contributing to bone repair in vivo (46), although some controversy exists 
as to whether muscle may also contribute stem cells to repair. Cells derived from adipose and 
muscle tissues that are more accessible can potentially serve as autologous transplants. ADSCs 
have been expanded in vitro and tested in vivo for cartilage and bone formation (47). When 
transplanted in muscle, ADSCs induce ectopic bone (48). In a canine defect model, ADSCs did 
not have a significant effect on repair when transplanted locally even after osteogenic 
differentiation; however, ADSCs could augment bone regeneration after genetic modification to 
overexpress BMP2 (49). Shen et al. demonstrated that MDSCs expressing BMP4 could heal a 
critical-sized skull bone defect in immunocompetent mice; MDSCs could still be found in the 
repair site at 3 weeks post implantation, but were mostly gone by 4 weeks, although some of the 
cells appeared to differentiate into osteoblasts in the new bone (50). Thus, MDSCs and ADSCs 
can act mainly as carriers, producing osteogenic factors to recruit endogenous cells. 
In addition to the in vitro experiments which lend support to the osteogenic success of 
BMSCs, in vivo studies have also proven similar conclusions. In experiments testing the ability 
of BMSCs to repair bone defects in the mid-diaphysis of rabbits, the BMSC treatment groups, 
either from an autologous or allogeneic source, were determined to be more effective in 
osteogenesis and bone formation in vivo (51). Sato and colleagues obtained similar results, with 
successful administration of BMSCs to rabbit periosteal distraction. BMSCs significantly 
contributed to increases in bone height, volume, mineral density, and bone mineral content (52). 
Success of BMSCs was not only demonstrated in animal models, but also in an earlier clinical 
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study by Quarto and colleagues. They used bone marrow progenitors harvested from bone 
marrow and expanded the cells ex vivo to repair large bone defects in three patients. Implants 
were aided by macroporous hydroxyapatite scaffolds. In all patients, radiography and computed 
tomography confirmed successful bone-implant integration and callus formation at the repair 
sites (53). Just as with SDSCs and chondrogenesis, the ECM microenvironment can help dictate 
differentiation. A BMSC-based ECM enhanced osteogenesis of BMSCs expanded on this ECM, 
which seems to reflect the ASCs’ capacities for differentiation toward their “intended” lineages 
based on their individual matrix properties as tissue-specific stem cells (54). With successful 
integration into the bone tissue for in vivo repair, undeniable successful differentiation, and 
studies suggesting their favoritism toward the osteogenic lineage in vitro, BMSCs appear to be 
an ideal choice for ASC osteogenesis. 
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1.1f Mechanisms of Lineage Preference 
Several studies have found proteonomic, transcriptonomic (16, 55–60), and epigenomic (61, 62) 
heterogeneity in stem cells from different tissues which may account for the source-dependent 
lineage preferences. In an effort to provide plausible mechanistic explanations for the lineage 
preferences of ASCs discussed above, we reviewed studies that compared the molecular 
properties of stem cells taken from different tissues and, when possible, discussed the 
significance of these differences in the context of stem cell differentiation. Given the number of 
recent reviews on this topic (63–65), the question has not been addressed: “Why do adult stems 
cells from different tissues preferentially differentiate into different lineages?”, which is central 
to the premise of this paper. Consequently, we focused on reviewing the molecular differences 
between stem cells taken from different tissues, drawing parallels, where possible, to studies that 
have investigated the mechanistic impact of the genes, proteins, and mRNA that vary in the stem 
cells based on tissue of origin. 
Differences in Gene Expression 
The stem cells from different sources have unique genetic profiles that inherently affect 
their ability to differentiate along various lineages (45). Investigation of genetic differences in 
ASCs has revealed differences in the expression of several genes, some of which have been 
directly implicated in differentiation mechanisms. For instance, the expression of the osteogenic 
genes OSX and OPN was higher in human BMSCs than in human ADSCs, while the expression 
of the adipogenic genes LEPTIN and ADIPSIN was highest in ADSCs, which has led some to 
conclude that ASC lineage preference is affected by their tissue of origin (66). Furthermore, a 
comparison of human BMSCs with cord blood-derived stem cells and ADSCs demonstrated that 
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expression of ALP and RUNX2 was the greatest in BMSCs at all stages of osteogenic 
differentiation (65). Although BMSCs expressed the highest levels of collagen I (COL1A1), 
osteonectin (ON), and BMP2 during osteogenic induction, it was observed that ADSCs 
expressed higher levels of COL1A1, ON, and BMP2 prior to differentiation, which suggests that 
the expression profile of “resting” stem cells is not necessarily predictive of lineage preference 
(67). The findings are in accord with earlier studies that, under osteogenic induction, elevated 
osteocalcin (OCN, an osteogenic, non-collagenous protein) levels and ALP (a ubiquitously used 
marker of osteogenesis) activities per DNA in rat BMSCs were observed in comparison with 
ADSCs; further in vivo study by subcutaneously implanting the composites of these cells and 
hydroxyapatite ceramics into syngeneic rats for 6 weeks demonstrated that the bone volume of 
BMSC composites was more than that of ADSC composites (p < 0.001), quantified by micro-
computed tomographic analysis (68). Moreover, Djouad et al. observed a statistically 
insignificant increase in the upregulation of collagen II (COL2A1) and aggrecan (ACAN) during 
chondrogenesis by human SDSCs relative to BMSCs, and a statistically significant increase in 
the upregulation of OCN and ALP during osteogenesis of human BMSCs relative to human 
SDSCs (16). It has also been reported that human SDSCs exhibited greater expression of 
platelet-derived growth factor receptor alpha (PDGFRα) than human BMSCs; due to human 
serum containing high levels of PDGF, neutralizing PDGF decreased the proliferation of SDSCs 
with autologous human serum (69), while human ADSCs expressed higher levels of integral 
membrane protein 2A (ITM2A) than human BMSCs, and forced expression of ITM2A inhibited 
chondrogenesis in a murine mesenchymal stem cell line (C3H10T1/2) (70). 
Noel and colleagues observed differential expression between human BMSCs and 
ADSCs of genes (WNT11, WNT7B, and SOX6) involved in Wnt signaling and differentiation, 
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an interesting finding in light of the osteogenic function of Wnt signaling (55). Canonical Wnt 
signaling elevates intracellular levels of β-catenin, which transposes to the nucleus and 
heterodimerizes with lymphoid enhancer-binding factor/T cell factor (LEF/TCF), eventually 
triggering translation of genes that affect lineage choice (71), while non-canonical Wnt signaling 
is independent of β-catenin (65). Both, however, are widely regarded to be mostly osteogenic 
(72), suggesting that the differential expression of Wnt signals may help predispose BMSCs 
toward osteogenesis. This supposition is in line with a recent report that the signaling pathways 
enriched in human BMSC-TERT [transduced with human telomerase reverse transcriptase gene 
(hTERT)] included pathways involved in bone formation (e.g. Wnt, TGFβ) and mitogen-
activated protein kinase (MAPK) signaling while signaling pathways enriched in human ADSCs 
belonged to adipocyte-relevant metabolic functions (e.g. steroid hormone biosynthesis and 
linoleic acid metabolism) (73). This finding is in agreement with other studies of human ASCs, 
which have found greater expression of genes relevant to bone formation or osteoblast 
differentiation in BMSCs relative to ADSCs, and a higher expression of genes relevant to lipid 
metabolism in ADSCs relative to BMSCs (74, 75). The studies referenced above demonstrate 
that heterogeneity in gene expression exists in stem cells from different tissues, and the tissue 
specific profile of gene expression correlates with differentiation preference. 
Differences at the Epigenetic Level 
The heterogeneity of ASC epigenetics may explain the differences in gene expression 
among ASCs of differing origins (Figure 2). Collas and colleagues noted hypomethylation in the 
promoters of four adipogenic ADSC genes (76) and asked whether ASCs were pre-programmed 
toward a certain lineage by DNA methylation (77). At least in part, the answer to the above 
question appears to be in the affirmative; as Boquest et al. noted, human ADSCs are 
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hypermethylated in the promoters for the myogenic differentiation gene myogenin (MYOG) and 
the endothelial genes CD31 and CD144 (also called vascular endothelium cadherin or CDH5), 
and, relative to adipogenic genes, are also hypermethylated at the promoter of the osteogenic 
gene osteoglycin (OGN) (76–78). Mouse BMSCs were shown to undergo demethylation and 
gene upregulation at the OPN promoter following mechanical stimulation (a well-recognized 
osteogenic stimulus) and it was hypothesized that the absence of epigenetic changes to OCN and 
COL1A1 promoters resulted from these regions having already been primed for osteogenesis by 
methylations occurring prior to mechanical stimulation (79). In human SDSCs, it was found that 
10 of 11 chondrogenic genes tested were promoter hypomethylated (80), which may partially 
account for the preference of human SDSCs to differentiate into chondrocytes (6). 
Furthermore, it was shown that promoters of osteogenic transcription factors are 
hypermethylated in the murine myoblast C2C12 cell line relative to promoters of myogenic 
transcription factors, and that chemically induced demethylation enhances osteogenesis and 
adipogenesis of C2C12 cells. Hupkes et al. postulated that DNA methylation preprogramming 
could underlie the default differentiation of C2C12 cells toward the myogenic lineage (81). 
Collas described 400–700 hypermethylated genes specific to ADSCs, BMSCs, and muscle 
progenitor cells (MPCs) and commented that these methylation patterns might be determined by 
the tissue-specific stem cell niche (82). 
While CpG methylation is a well-studied epigenetic modification to DNA, research 
indicates poor correlation between gene expression and promoter methylation, suggesting that 
other epigenetic mechanisms may also be important determinants for lineage preference (77, 81, 
83). Additionally, many studies have discovered general hypomethylation of lineage-specific 
promoter regions in mesenchymal and non-mesenchymal ASCs, regardless of origin (61, 84, 85). 
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These observations helped clarify the role of CpG island methylation in lineage-specific 
promoters; it appears that hypomethylation of these promoters is permissive, but not necessarily 
predictive, of lineage preference (62, 82). 
The functional significance of methylation patterns outside promoter regions is 
incomplete and poorly understood. Irizarry et al. showed that most tissue-specific methylation 
changes do not occur in CpG islands, but rather in nearby “CpG island shores”, and that gene 
expression is tightly linked with these methylation patterns (86). However, others have found 
that tissue-specific methylation often occurs within coding sequences or entirely downstream of 
known genes (87) and have postulated that such sites might contain standard methyl-sensitive 
repressor elements that are able to operate at a distance to silence adjacent promoters (87). 
Intragenic methylation may also enhance transcription of noncoding RNA (87), a theory with 
interesting implications in light of our growing appreciation for the roles of micro RNA (miRNA 
or miR) in stem cell differentiation (88–90). 
Histone modifications may also play a large role in influencing the lineage preference of 
ASCs (91). In human BMSCs, the promoter regions of the master adipogenic transcription 
factor, PPARG, is histone 3 lysine 9 (H3-K9) methylated, an epigenetic modification that 
repressed transcription, leading Tan et al. to hypothesize, “adipogenic lineage-specific genes 
regulated by PPARG may be silenced by the H3-K9 hypermethylation at their promoter regions” 
(92). Later research indicates the promoters of 70% of underexpressed genes in human BMSCs 
were indeed H3-K9 methylation enriched (93). In human ADSCs, both the permissive H3-K4M3 
and repressive H3-K27M3 marks have been noted on promoters for lineage-specific genes (94), 
which led Collas et al. to theorize that adipogenic promoters are preprogrammed for activation 
upon adipogenic stimulation (83). Human BMSCs are also hypomethylated as well as H3-K4M3 
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and H3-K27M3 enriched (61) and this pattern may also regulate myogenesis (95). It is believed 
that this “bivalent” histone modification pattern positions a cell to rapidly respond to 
differentiation inducing stimuli; the loss of this bivalent pattern may correspond to diminished 
stem cell potency and differentiation (61, 85, 96, 97). 
A recent study by Ragni et al. compared the miRNA profiles of human ASCs taken from 
sources including bone marrow, adipose tissue, and umbilical cord blood. The authors noted that 
the miRNA expression patterns between ASCs from unmatched donors were mostly consistent 
(98). In contrast to earlier studies which found only a single miRNA, miR-424, differentially 
expressed between human ADSCs and BMSCs (96), Ragni and coworkers concluded that, 
although the miRNA expression patterns of the various ASC types are similar, there appear to be 
at least 20 differentially expressed miRNAs between human ADSCs and human BMSCs (66). 
Interestingly, they noted expression differences in several miRNAs that may be involved in 
lineage choice. 
First, they noted that the expression of miR-135b is nearly 48 times higher in BMSCs 
than ADSCs (66). Studies have suggested that miR-135b was downregulated in unrestricted 
somatic stem cell osteogenic differentiation (99); mesenchymal stem cells from multiple 
myeloma patients exhibited an abnormal upregulation of miR-135b, showing meanwhile 
impaired osteogenic differentiation and a decrease of mothers against decapentaplegic homolog 
5 (SMAD5) expression, which is the target of miR-135b involved in osteogenesis (100). As 
reviewed by Cook et al., SMADs 1, 5, and 8 usually transmit BMP signaling, which activates 
distal-less 5 (DLX5), resulting in the downstream activation of RUNX2 and OSX (63). miR-135 
targeting SMAD5 could effectively inhibit osteogenesis (88, 101). 
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Second, it was found that miR-138 was 11 times more highly expressed in BMSCs than 
in ADSCs (66). miR-138 has been implicated in inhibiting adipogenesis (102) as well as 
osteogenesis (103). Focal adhesion kinase (FAK), which regulated the osteogenesis of stem cells 
(104), has been identified as a target of miR-138 in human BMSCs (103). Another miRNA of 
interest, miR-31, was expressed at fivefold greater levels in BMSCs than in ADSCs. miR-31 
downregulated the adipogenic CEBPA (88, 105) as well as osteogenic OSX (106). Deng and 
colleagues investigated the role of miR-31 in rat ADSCs and concluded that miR-31, which was 
suppressed by elevated Runx2 expression, inhibits osteogenesis, possibly by decreasing the 
translation of special AT-rich sequence-binding protein 2 (Satb2) (107), a conclusion similar to 
earlier work demonstrating that miR-31 was diminished in osteo-differentiated BMSCs relative 
to BMSCs and that transfection with antisense miR-31 increased expression of Runx2 and BMP 
receptor 2 (BMPR2), promoting osteogenesis (108). 
Finally, Gao et al. showed that miR-424, which was expressed 5.5 times more in ADSCs 
than BMSCs (66), was diminished in osteo-differentiated BMSCs, and predicted that miR-424 
played a role in inhibiting osteogenesis (108). The combination of these findings suggests that, 
although much of the tissue-specific miRNA expression in stem cells functions to prevent the 
premature differentiation of these stem cells, the unique profile of different tissue-specific stem 
cells may also help to determine lineage preference. Ragni and colleagues concluded that 
differential expression of miRNA may provide a molecular explanation of stem cell niche 
memory (66). Although the above findings may not be sufficient to completely explain, 
mechanistically, the observation that stem cells from different tissues exhibit lineage preferences, 
it is clear that there is extensive epigenetic variability between stem cells based upon origin, and 
it seems likely that these differences, such as the restrictive promoter hypermethylation or the 
 27 
 
repression of a signaling molecule implicated in differentiation (FAK, for example), play a role 
in the mechanisms underlying lineage preference. 
Differences at the Protein Level 
There is evidence that stem cells from different tissues differ in their expression of ECM 
proteins and secreted factors. Researchers compared the surface proteins of stem cells from 
different origins and concluded that, while expression of many surface markers is similar, 
differences do exist. For example, CD146 was more highly expressed in human BMSCs than 
human ADSCs (73), and CD49d was less pronounced in adult human BMSCs than perinatal 
human stem cells from amniotic membrane, though this finding could be influenced by donor 
age (60). Further, ADSCs have been found to express CD34 after isolation, while BMSCs do not 
(109). 
Mesenchymal stem cells’ secretion and responses to soluble factors may vary depending 
on the tissue of origin. A comparison of human BMSCs and ADSCs revealed that, at early 
passages (P2-P4 or up to 14–15 in vitro population doublings), BMSCs secreted more vascular 
endothelial growth factor (VEGF), stromal cell-derived factor 1 (SDF-1), monocyte chemotactic 
protein-1 (MCP-1), and TGFβ1 than ADSCs did (110). TGFβ1 is of particular interest given its 
important role in regulating stem cell differentiation. TGFβ1 signals through multiple pathways, 
including SMAD2/3, MAPK, and Wnt. Zhao and Hantash have provided a thorough review of 
TGFβ1 regulation of BMSC differentiation to which the reader is referred for a detailed 
discussion. In short, TGFβ1 inhibited adipogenesis in fibroblasts (and possibly BMSCs), but 
stimulated chondrogenesis and osteogenesis of BMSCs (111). TGFβ1 may also trigger 
chondrogenesis in human ADSCs (112), but the chondrogenic commitment of TGFβ1-treated 
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ADSCs is delayed relative to their BMSC counterparts (113). Afizah and colleagues 
demonstrated that human BMSCs synthesized more GAG and collagen II following TGFβ3 
treatment than donor-matched ADSCs (114). It has further been shown that dexamethasone 
augmented the TGFβ1-induced chondrogenesis in 4-month-old bovine BMSCs, but not in 4-
month-old bovine SDSCs (115). Human BMSCs exhibited greater expression of HLA-DR (an 
MHC class II cell surface receptor encoded by the human leukocyte antigen complex on 
chromosome 6 region 6p21.31) than stem cells from amniotic membrane after stimulation by 
tumor necrosis factor alpha and interferon gamma (60). The combination of heterogeneous 
receptor profiles and secretomes exhibited by stem cells from different tissues may underlie the 
previously discussed differences in sensitivity to differentiation-inducing stimuli, while also 
contributing, mechanistically, to lineage preference. 
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1.1g Conclusions and Perspectives 
Stem cell therapies are undoubtedly treatment options in various areas of the biomedical 
field; however, each stem cell population’s characteristics and source are commonly overlooked 
factors. Overall, we can conclude that ASCs are best suited for differentiation along their natural 
prospective lineages for the formation of quality bone, cartilage, adipose, and muscle tissues. 
The theory that various multipotent stem cell subpopulations exist within a given tissue, as well 
as subpopulations possessing various capacities for quality differentiation, also supports the idea 
that ASCs from their resident locations are the most effective contributors to a particular lineage. 
These populations are naturally functioning and thriving in vivo with respect to the surrounding 
tissues in which they exist. Although the current literature offers expansive support for this idea 
based on fundamental in vitro data, there is still an overall lack of in vivo studies which compare 
a wide variety of ASCs for multilineage differentiation capacity. In order to draw more 
conclusive results from in vitro experiments, it would be beneficial to utilize ASC clones; these 
clones can eliminate the possibility of progenitor cell heterogeneity which can skew the results of 
multilineage studies. Another great deficiency in current multilineage studies is the lack of in 
vivo and in vitro studies which investigate multilineage characteristics from the same donor. 
Studies of this nature could give insight into variability between organisms and, more 
importantly, highlight, strengthen, and uncover trends and tendencies of tissue-specific stem cells 
as they progress toward lineages outside their respective conventional differentiation fates. 
Although studies have independently demonstrated the ability of ASCs for cross-
differentiation to other lineages, studies which compare several ASCs directly, rather than 
retrospectively, are generally more valuable. Direct comparison methods and using multiple cell 
types simultaneously can offer more direct assessment and circumvent experimental variability 
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to produce more reliable conclusions regarding the differentiation potential of ASCs from 
separate tissues. Through our current knowledge about the specific properties of each type of 
ASC and future in vivo experimentation, the possibility of elucidating and revealing a cellular 
hierarchy for ASCs and lineage-specific differentiation is feasible. 
Despite noteworthy advancement in the study of niche-specific regulation of ASC lineage 
preference, mechanistic research remains active. Further comparative analysis of tissue-specific 
miRNA expression, histone modifications to lineage-specific genes, and non-promoter 
methylation patterns is needed. For instance, to our knowledge, the miRNA expression profile of 
SDSCs has not been thoroughly compared to ADSCs or BMSCs. We believe that such studies 
could yield important findings, especially in light of the extensively demonstrated success in 
SDSC chondrogenesis studies. Additionally, it is interesting to note that tissue-specific histone 
modifications are far more abundant in enhancer regions than in promoter regions (116), and 
these modifications are made prior to cell fate commitment (117), raising the possibility that 
lineage preference, at least in part, is a consequence of enhancer modifications. It remains likely 
that tissue-specific epigenetic patterns play a role in the preference of ASCs for certain lineages 
(91) and such modifications may underlie the differential lineage preference of ASCs derived 
from various anatomical tissues. Finally, although the studies considered earlier have 
demonstrated that stem cells from different tissues are not identical in their responses to chemical 
differentiation stimuli, the molecular explanation for this observation is incomplete. It would be 
interesting to compare, at a molecular level, the responses of stem cells from various tissues to 
important differentiation factors, such as BMP, Wnt, and insulin-like growth factor (IGF), as 
evidence exists that stem cells from different tissues might respond in subtly different ways to 
the same molecular stimulus. Studies further addressing differences in signaling cascades, 
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secretion of soluble factors, and matrix receptors might help elucidate the underlying molecular 
heterogeneity among stem cells of different tissues. The implications and impacts of such 
discoveries would certainly span a wide array of biomedical disciplines and help shape the future 
of stem cell therapy and regenerative medicine. 
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Fig. 1.1.1 Adult stem cells can be derived from various tissues in the body. These viable and 
undifferentiated stem cell populations can be expanded in vitro and induced to undergo lineage-
specific differentiation for chondrogenesis (C), osteogenesis (O), myogenesis (M), or adipogenesis 
(A). Although the cells may appear similar in morphology upon harvest, they are anything but 
identical. From the data presented in the section “Tissue Specific Stem Cells Benefiting Lineage-
Specific Differentiation”, the efficacy of ASCs in lineage-specific differentiation is greatly 
affected by the type of resident tissue from which they are harvested. In the heatmap, the 
differentiation capacity is visualized by color ranging from low differentiation (blue) to high 
differentiation (red). 
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Figure 1.1.2: 
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Fig. 1.1.2 Epigenetic determination of niche-specific lineage preference. CpG methylation of 
promoters creates a permissive, but non-predictive state, while non-promoter CpG methylation, 
histone modifications, and differentially expressed miRNAs may combine to determine lineage 
preference. 
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The Intervertebral Disc & Nucleus Pulposus 
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1.2 The intervertebral disc 
Tissue Morphology 
The nucleus pulposus (NP) tissue is located at the innermost spaces of each intervertebral disc 
(IVD) of the spinal column. The mature NP tissue and NP cells (NPCs), which compose the tissue, 
are similar to chondrocytes, and have been previous described as “chondrocyte-like cells” [1] [2]. 
The IVDs themselves lie between each vertebrae, and should be viewed as dynamic, heterogeneous 
structures that are designed to respond to dynamic mechanical loading cycles integral to disc 
function [3], ultimately allowing for the complex movements of humans such as twisting and 
bending [4] [5]. The outer structure of the IVD that encompasses the NP tissue is called the annulus 
fibrosis (AF), which is by definition a ring of fibrocartilage [5]. This helps to add structural support 
to the disc and contain the inner NP tissue. Together, the NP and AF, as well as their anatomical 
relationship with the adjacent cartilage end plate (CEP) and bone end plate (BEP) form the basic 
anatomical structure known as the intervertebral disc (IVD) (Fig. 1) [4].  
The development of the mature NP tissues and parallels between NP and other chondrocytic tissues 
have been extensively reviewed previously [6] [7]. Briefly, mature NP cells arise from cells of the 
developing notochord. These notochordal cells ultimately allow for proliferation of chondrocyte-
like cells and the stimulation of proteoglycan expression [7] [8]. Brachyury (T), transforming 
growth factor-beta TGFβ, Noggin (Nog), and several factors others contribute to the development 
of the mature NP phenotype as well [9]. Early IVD degeneration may be partially initiated by the 
loss of these regulatory notochordal cells and the associated paracrine factors seem to have roles 
in the disc, proteoglycan synthesis, and overall disc integrity [10] [11]. 
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Figure 1.2.1: 
 
Intervertebral Disc Degeneration (IVDD) 
Nearly three decades ago, Humzah and Soames described the IVD as a tissue capable of self-
maintenance and “considerable regenerative properties”, and that IVDs could be dramatically 
affected by changes to the disc structure, resulting in downstream effects on vertebral column 
kinematics [5]. This IVD degeneration has been previously linked to low back pain [1] [6] and 
sciatica [11] [12], representing a significant socioeconomic burden [13]. Furthermore, early 
literature by Urban and Roberts noted that IVDs are quite susceptible to degeneration at an 
accelerated pace compared to other cartilaginous tissues, leading to complete loss of function in 
Figure 1.2.1 Gross anatomy of a disc. (A) Cross section of a disc in the coronal plane, (B) 
diagram of a transversely sliced IVD and (C) diagram showing the alternating fibre 
alignment in successive lamellae. AF: anulus fibrosus; CEP: cartilaginous endplate; BEP: 
bony endplate; NP: nucleus pulposus. 
[4] N. Newell,  JP Little,  A. Christou,  MA Adams,  CJ Adam,  SD Masouros. 
Biomechanics of the human intervertebral disc: A review of testing techniques and results. 
Journal of the Mechanical Behavior of Biomedical Materials, Volume 69, 2017, 420–434.  
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the most severe cases [2]. Haefeli and colleagues have reported that degeneration can occur very 
early life, at the second decade or even before [14] and unlike any other musculoskeletal tissue, 
suffers from extensive age-related degeneration [15]. Unfortunately, once degeneration occurs, the 
regeneration capacity and ability to regenerate NP tissue without external intervention is a 
significant challenge [16]. Part of the IVD aging process and IVDD- associated degenerative 
progression occurs as a function of disc tissue degradation due to the inflammatory 
microenvironment [17], decreased protein solubility and insoluble type I collagen accumulation 
[11] and upregulation of catabolic matrix metalloproteases [17] [18] and multitude of factors 
destabilizing disc and matrix homeostasis. This process is typically associated with IVDD, but 
degeneration can also occur following acute injury such as an intervertebral disc herniation [19] 
[20] [21] [22], often informally referred to as a “slipped disc.” 
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Figure 1.2.2: 
 
Figure 1.2.2 Schematic of the intervertebral disc and anatomic sub-structures. Abbreviations: 
AF, anulus fibrosus; IVD, intervertebral disc; NP, nucleus pulposus. (A) Forces of load bearing 
and motion contribute to axial loading of the IVD that is balanced by a hydrostatic pressure 
generated in the gelatinous NP. Pressure in the NP gives rises to a tensile stress in the surrounding 
AF or a “hoop stress” as depicted. (B) Multiple factors contribute to the onset of degeneration and 
matrix changes in the IVD, including aging, wear and tear of daily loading, inheritance patterns, 
and environmental factors such as pH, oxygen, and nutrient supply. (C) Anatomic changes in the 
substructures of the IVD can give rise to pain or disability due to proximity of the IVD with major 
sensory and motor nerves. Age- or pathology-related changes can contribute to an increased 
innervation of the IVD by sensory neurons branching from the dorsal root ganglion that are a 
purported cause of discogenic pain. (D) Disc degeneration is classified based on anatomic changes 
that may be distinguished by imaging appearance or gross morphology, as shown here. (i) Healthy 
[22] Robert D. Bowles,  Lori A. Setton. Biomaterials for intervertebral disc regeneration and 
repair. Biomaterials, Volume 129, 2017, 54–67. 
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young adult disc with a defined NP. (ii) Middle age adult disc that is slightly aged but not yet 
degenerated. (iii) Moderately degenerated young adult disc. (iv) Severely degenerated young adult 
disc.  
 
 
IVD and cell-based therapies 
Because IVDD can lead to disc herniation and tears in the AF and the generation of herniated NP 
fragments, protrusions, and prolapses then can lead to nerve root pressure and pain [23] [24], 
making treatment is often a necessary step for patients. There is a wide-range of strategies for 
treatment of disc herniation and IVDD, ranging from conservative and non-surgical methods such 
as spinal manipulation [25] [26] [27] and minimally-invasive surgical microdiscectomy [28] [29] 
to more invasive surgeries such as spinal fusion [30] [31]. 
While many of these treatment options address structural concerns of the IVD, it is also 
increasingly important to consider the regenerative potential and compromised tissue environment 
of the disc. Cell-based therapies aim to address these concerns by replacing the lost cellularity of 
the NP space [32] [33]. Although repopulating the tissue with cells is an excellent strategy, it can 
be an initial challenge to harvest the necessary cell numbers due to limitations in replicative 
lifespan and cells with a healthy phenotype and regenerative potential to contribute to tissue 
regeneration for use in therapeutic interventions [34] [35] [36]. Preconditioning strategies, 
including hypoxia, extracellular matrix expansion, and growth factor supplementation aim to 
address these concerns to increase cell numbers and redifferentiation potential [37] [38] [39]. With 
[22] Robert D. Bowles,  Lori A. Setton. Biomaterials for intervertebral disc regeneration and 
repair. Biomaterials, Volume 129, 2017, 54–67. 
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these factors in mind, and as a part of this dissertation, we aimed to compare emerging methods of 
cellular preconditioning with potential implications in future therapies seeking to improve NP 
regeneration and IVD repair. 
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Wnt Signaling Pathways 
Canonical wnt signaling 
Canonical signaling relies on the molecule β-catenin for downstream signaling and is a well-
conserved cellular pathway in humans and other animals [1]. Several other key molecules, such 
as axin, APC, CKIα, glycogen synthase kinase 3β are also involved in canonical signaling, and 
are responsible for combining with one another to form a “destruction complex,” which allows 
for the phosphorylation of β-catenin to occur in the absence of a canonical Wnt ligand, ultimately 
leading to its protease-dependent degradation in the cell cytoplasm [1] [2] [3]. When a 
stimulating Wnt ligand is present, it is bound to a transmembrane receptor called Frizzled (FZD) 
and its associated low density receptor protein, LRP5/6 to transmit the signal, recruiting 
intracellular disheveled (Dvl) [4]. This leads to the cytoplasmic sequestration of both Axin and 
glycogen synthase kinase, preventing the formation of the “destruction complex,” allowing the 
persistence and accumulation of β-catenin in the cell nucleus to modulate gene expression [2] 
[4]. (Fig 1.3.1) 
Nonanonical wnt signaling 
In noncanonical signaling, signaling occurs through different groups or individual Wnt signals 
than canonical signals, acting in mechanisms independent of β-catenin [5] Another major 
difference in the two branches of Wnt signaling is that the noncanonical signaling requires FZD, 
but does not rely on LRP, or β-catenin [5]. One noncanonical pathway mechanism is known as 
the Planar Cell Polarity (PCP) pathway, controlling tissue polarity [6], and is regulated through 
small GTPases to promote actin cytoskeleton reorganization [7]. The other noncanonical 
mechanism is the Wnt/Ca2+ pathway, in which calcium release activates protein kinase C (PKC) 
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and calmodulin-dependent kinase II [8] , inhibiting canonical signaling. Because of the several 
mechanisms in place allowing for Wnt signal transduction to both occur and carry out its own 
regulation, it may be most accurately viewed as a set of non-distinct pathways, with 
consideration for the simultaneous and heavily integrated inputs at the receptor and intracellular 
levels of activation [8] (Fig 1.3.1) 
 
Roles for wnt signaling 
Interestingly, recent literature has suggested that crosstalk between canonical and noncanonical 
Wnt pathways can occur, where noncanonical signals can serve as “fine-tuning” signals to 
regulate canonical β-catenin/TCF activity [9]. Also, crosstalk between Wnt pathways, mitogen 
activated protein kinase (MAPK) signaling, and in processes regulating cell proliferation, 
homeostasis, and tissue development have been reviewed in cartilage regeneration and 
chondrogenesis [10].  In addition to the regulatory roles and crosstalk with other established 
pathways, Wnt signaling pathways have been implicated in the self-renewal of stem cell 
populations [11] [12] [13] as well as regulation of cancer, including the progression, dormancy, 
immunity, and maintenance of cancer stem cells [14]. With the multifaceted roles of canonical 
and noncanonical signals across many tissue types, and the crosstalk with other pathways, it 
seems that Wnt signaling plays a central and vital role in cell metabolism.  
Although many biochemical signaling pathways are responsible for the regulation of cell 
metabolism and stem cell differentiation, both canonical and non-canonical Wnt/β-catenin 
pathways are potential regulators of NP redifferentiation. These are well-conserved pathways 
that have been extensively studied and implicated in tissue homeostasis [15], NPC apoptosis [16] 
as well as cell migration and differentiation [17], with particularly notable roles in 
 64 
 
chondrogenesis [18] [19] [20]. Wnt/β-catenin pathway signals have been previously implicated 
in IVDD of canine discs [21] as well as disc aging, tissue degeneration, and proper development 
of murine IVD tissues [22] [23] [24]. More recently, Wnt (Wingless protein family) signaling 
abnormalities have also been associated with intervertebral disc ossification and subsequent disc 
inflammation [25]. Winkler and colleagues found that canonical Wnt and Shh signaling were 
decreased in the aging adult human IVD, and suggested that the Wnt pathway could be a 
potential therapeutic target for disc degeneration therapy [26]. Although several studies have 
suggested that Wnt signals play key roles in human disc, there are much fewer studies using 
human-derived IVDs or NPCs to fully support such hypotheses, especially studies that directly 
compare multiple Wnt signals at once during NPC redifferentiation. Furthermore, recently 
published studies have suggested that the progression of degenerative disc disease may be related 
to the communication and crosstalk between Wnt and TGF-Beta signaling pathways [27] [28], a 
well-known differentiation stimulating signal, occurring naturally in cartilaginous tissues, and 
commonly used to perpetuate the chondrogenic and redifferentiated NP phenotypes in vitro [29] 
[30]. Additionally, Wnt3A, Wnt5A, and Wnt11 have each been shown to be involved in 
mesenchymal stem cell (MSC) differentiation. Wnt3A has been implicated in MSC proliferation, 
increasing differentiation potential, and suppression of differentiation [31] [32] [33] [34], while 
Wnt5A and Wnt11 have been more extensively implicated in differentiation and cartilage 
development [20] [35] [36] [37] [38] [39].   
With well-identified roles of Wnt signaling in cartilage and stem cell differentiation [10] [20] 
[35] as well as the inherent similarities and shared properties between the chondrogenic 
differentiation of chondrocytic tissues [40] the relatively ubiquitous roles in stem cell 
differentiation, we hypothesized that both canonical and noncanonical signals could serve as 
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potential regulators for nucleus pulposus cell redifferentiation in humans. With a greater 
understanding for the roles of both canonical WNT3A and noncanonical WNT5A and WNT11 
ligands in NP tissue, it may be possible to modulate these signals in the future to increase 
redifferentiation capacity of harvested cells for regenerative therapies. 
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Figure 1.3.1: 
 
Fig 1.3.1 Three Wnt-dependent pathways have been categorized: canonical Wnt/β-catenin 
and non-canonical Wnt/PCP as well as Wnt/Ca2+ pathways. Canonical Wnt/β-catenin pathway: 
In cells, with an inactive state of canonical Wnt signaling, cytosolic β-catenin is targeted to 
Zhang Y, Pizzute T, Pei M. A review of crosstalk between MAPK and Wnt signals and its 
impact on cartilage regeneration. Cell Tissue Res. 2014 Dec;358(3):633-49. 
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proteolytic degradation through phosphorylation by the APC–Axin–GSK3β complex and further 
ubiquitination through action of βTrCP-dependent E3 ubiquitin ligase complex. On stimulation 
by Wnt ligands through binding to Fzd receptors and its co-receptor Lrp, Fzd recruits and 
phosphorates Dsh, and inhibits APC–Axin–GSK3β complex formation by the recruitment and 
inhibition of GSK3β. Consequently, β-catenin can accumulate in the cytoplasm and enter the 
nucleus, activating transcription of target genes through association with the Lef1/Tcf 
transcription factor family. Non-canonical Wnt/Ca2+ pathway: Interaction of Wnt ligands with 
Fzd receptors can lead to an increase in intracellular calcium level, through possibly the 
activation of phospholipase C (PLC). Intracellular calcium will subsequently activate 
Ca2+/calmodulin-dependent protein kinase II (CAMKII) and protein kinase C (PKC) in cells, as 
well as the transcription factor NFAT. This pathway is particularly important for convergent-
extension movements during gastrulation. Additionally, Fzd receptors can also activate JNK, 
promoting expression of specific genes through activation of AP-1. Non-canonical Wnt/PCP 
pathway: This pathway is characterized by an asymmetric distribution of Fzd and related 
receptors, resulting in the polarization of the cell. Also, Wnt-signaling activates Cdc42, RhoA, 
and Rac1 leading to cytoskeleton rearrangement. Rac1 can also activate JNK, activating specific 
gene transcription through modulation of the AP-1 protein complex. 
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Abstract  
Intervertebral discs are susceptible to acute injuries and degenerative diseases that frequently lead 
to persistent back pain and significant morbidity. At the cellular level, the nucleus pulposus (NP) 
cells located at the inner disc space undergo changes that ultimately result in deleterious 
consequences for self-repair of the affected NP tissue, particularly evident following injury or 
severe disruption of the disc microenvironment. Recently, cell preconditioning strategies have 
been shown to rejuvenate NP cells for successful redifferentiation; however, the impact of such 
strategies on immunity has not been extensively emphasized. This review highlights the emerging 
strategies that utilize fibroblast growth factor 2 (FGF-2) media supplementation and three-
dimensional (3D) growth substrates and presents potential immunological effects resulting from 
preconditioning applications. Ultimately, it is imperative that preconditioning methods aimed at 
increasing redifferentiation and regenerative capacity of cells need to preserve immune tolerance. 
Prospective areas of interest for the preliminary detection of immune issues in preconditioned cells 
are also briefly discussed. 
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Introduction 
Disease of the intervertebral disc and acute injuries such as disc herniation lead to 
significant patient morbidity including disc degeneration and back pain, causing significant 
socioeconomic burden (Ito & Creemers, 2013). One of the most common procedures to repair 
discs following herniation is surgical discectomy of the herniated nucleus pulposus (NP) tissue; 
however, a wide range of complications accompanied by generally unfavorable or dissatisfying 
outcomes are frequent occurrences with the procedure (Belykh et al., 2016). Additionally, another 
major concern surrounding disc disease and herniation is the loss of disc height (Gunzburg et al. 
1992; Rohlmann et al., 2006; Sakai & Grad, 2015), accompanied by matrix decomposition, 
decrease in cellularity, and disc dehydration (Sakai & Grad, 2015). Unfortunately, degenerative 
discs become largely unbalanced in their anabolic and catabolic signals for matrix regulation, 
further perpetuated by the release of inflammatory factors in the disc (Wuertz et al., 2012). These 
conditions can make it challenging for NP tissue in the degenerative disc to heal or to rejuvenate 
the existing cell population, which typically degenerates further without proper intervention.  
Promising repair strategies that utilize the patients’ own cells (autologous cells) to stabilize 
the disc microenvironment and repopulate it with new NP cells is an attractive solution; however, 
it requires the patients’ cells to be rejuvenated to an improved condition to beneficially contribute 
to the repair process. Rejuvenation can potentially be achieved through in vitro preconditioning of 
autologous NP cells to increase their proliferative and redifferentiation capacities for future 
therapeutic applications. “Preconditioning” is an encompassing term for the various growth 
strategies utilized to increase overall cell health, morphology, proliferation rates, and, for NP cells, 
their redifferentiation potential.  
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Although a number of cell preconditioning studies focused on NP repair have been 
performed, the majority do not address potential immune concerns of preconditioning strategies. 
Interestingly, despite the intervertebral disc’s status as an immune privileged site (Takada et al., 
2002; Ma et al., 2015), compromised and degenerated discs have exhibited noticeable changes in 
the immunophenotypes of cells residing in the disc tissues; these include increases in Fas (APO-
1/CD95) and decreases in CD178 (Fas ligand) in degenerated or herniated discs (Ma et al., 2015). 
Furthermore, preconditioning strategies used to increase redifferentiation and proliferative 
potential could pose unidentified immune concerns similar to those observed in the degenerative 
disc.  
Despite the multitude of potential options for preconditioning strategies to increase cell 
potency and overall rejuvenation (Pei 2017), this review focuses primarily on the emerging and 
more popular preconditioning strategies for NP regeneration and other chondrocytic tissues, 
including media supplementation with fibroblast growth factor 2 (FGF-2) and the use of three-
dimensional (3D) growth substrates and potential immune concerns arising from preconditioning 
methods. 
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FGF-2 Preconditioning 
Because expansion of NP and chondrocytic cells in monolayer culture alone can cause 
dedifferentiation, such as decreasing proliferation rate and loss of the NP phenotype with serial 
passaging (Martin et al., 1999), supplementation with cell culture media serves as one potential 
preconditioning approach to improve the quality of harvested cells. Fibroblast growth factor 2 
(FGF-2), also known as basic fibroblast growth factor, has been shown to increase cell 
proliferation in many cell types (Ellman et al., 2008); for example, recent studies have 
demonstrated its potential use as a preconditioning supplement for NP cell expansion. Tsai and 
colleagues tested serially passaged porcine NP cells in the presence of FGF-2, reporting increased 
expression of sulfated proteoglycans, an important matrix component in NP tissue, as well as 
slowed turnover for aggrecan compared to untreated controls. Interestingly, FGF-2 treatment 
resulted in a dose-dependent reduction of actin stress fiber formation (Tsai et al., 2007) which, 
when increased, is typically associated with a decreased ability of chondrocytic cells to reexpress 
their differentiated phenotype (Martin et al., 1999; Tsai et al., 2007). Another study comparing 
various preconditioning strategies in NP cells harvested from degenerated human discs revealed 
that FGF-2 preconditioning increased cell proliferation in NP cells from moderately degenerated 
discs. After preconditioning, cells were redifferentiated in pellet culture and exposed to TGF-beta3 
differentiated media. FGF-2 preconditioned NP cells from moderately degenerated discs exhibited 
increases in ACAN (aggrecan) expression but decreased COL1A1 (type I collagen) expression after 
21 days of redifferentiation (Pizzute et al., 2017).  
 Although these studies support plausible applications for FGF-2 as a preconditioning 
stimulus, fewer studies have investigated the potential roles of FGF-2 to modulate immune 
responses (Liu et al., 2015) or alter immune responses to cells preconditioned with FGF-2. A recent 
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study investigating the association of cytosolic FGF-2 with RIG-I, a protein associated with 
detection and signaling responses to viral infections and inflammatory cytokine production, 
reported that cytosolic FGF-2 mediated the reduction of type 1 interferon production and had an 
unexpected role in innate immunity (Liu et al., 2015). HLA-DR (major histocompatibility complex 
II) expression in preconditioned cells is another area of interest given its well-established role in 
T-cell mediated immune responses and antigen presentation. A study by Dighe and colleagues 
found that passaging of human bone marrow mesenchymal stem cell cultures in the presence of 
FGF-2 did not significantly correlate to HLA-DR expression; rather, duration of culture 
maintenance was an influential factor in HLA-DR expression (Dighe et al., 2013). A similar result 
was reported by Pizzute and colleagues in a human NP cell preconditioning study following 
application of 10 ng/mL of FGF-2, with no significant increases in HLA-DR expression versus 
controls (Pizzute et al., 2017).  
Another noteworthy surface marker involved in cell-mediated apoptosis is the Fas (APO-
1/CD95) receptor (Westendorp et al., 1995), which is thought to contribute to immune privilege in 
the intervertebral disc (Sun et al., 2013; Wang et al., 2007) and in caspase-mediated apoptosis (Fu 
et al., 2016; Imai et al., 1999). This pathway could pose a serious threat to preconditioned cells 
and their utilization in regenerative applications in the disc since CD95 expression could make 
them susceptible targets of Fas-mediated apoptosis by infiltrating cytotoxic T-cells (Stich et al., 
2015). In a recent preconditioning study, it was reported that human NP cells supplemented with 
10 ng/mL of FGF-2 were able to significantly decrease CD95 surface expression versus untreated 
controls (Pizzute et al., 2017). To date, few studies have examined the effects of preconditioning 
on CD95 expression; however, it could serve as a potential predictor of NP survival and tolerance 
in the disc. 
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An alternative to the overlying goals of many cancer cell studies, where success is typically 
derived from the death of targeted cancer cells, regenerative therapies benefit from the survival of 
administered cells for repair of damaged or depleted tissues. With this notion at hand, it may be 
reasonable to suggest that parallels can be drawn between the two areas of study, where a cell 
survival mechanism represents a hurdle for one, but can be beneficially exploited for the other. In 
a study investigating FGF-2 treated mouse fibroblasts and tumor immunotherapy, Li and 
colleagues reported that cells treated with 100 ng/mL of FGF-2 in immunocompetent mice 
exhibited immunoprotective effects, but not with untreated fibroblasts. Results included delayed 
onset of tumor growth, which largely contributed to an antibody-mediated autoimmune response 
to both FGF-2-activiated fibroblasts and tumor cells (Li et al., 2014). Interestingly, another cancer 
study also implicated an FGF-2-dependent survival pathway, the FGFR1/PKCδ/ERK effector 
pathway, and API5 gene expression as a means for tumoral immunity. Ultimately, this pathway 
results in the downstream degradation of the proapoptotic molecule, BIM, which was also reported 
to be dependent upon FGF-2 secretion (Noh et al., 2014). This same pathway and receptor were 
reported in bovine NP cells, with FGF-2 acting through the receptor FGFR1, ultimately implicating 
FGF-2 in matrix homeostasis and intervertebral disc degeneration (Li et al., 2008). Other studies 
have reported similar results, with FGF-2 naturally released during injury of cartilage and in 
chondrocytic tissues (Vincent et al., 2002; Li et al., 2008). Since recent literature suggests that 
FGF-2 pathways play a role in tumoral immunity, similar biochemical mechanisms may be 
involved in FGF-2 preconditioning; however, more studies using NP and chondrocytic cells are 
necessary to validate this hypothesis. 
Although few studies directly implicate FGF-2 as a major immune regulator, it seems 
reasonable to suggest that FGF-2 plays a background role in immune tolerance and apoptosis, and 
 79 
 
could even potentially provide protective effects for preconditioned cells. Future studies more 
completely elucidating the role of FGF-2 preconditioning on immune tolerance in cultured cells 
are necessary and could provide new clinically relevant data to complement the already well-
demonstrated applications of FGF-2 supplementation as an expansion strategy for cell-based 
regenerative therapies. 
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Three-dimensional substrate preconditioning 
Culturing chondrocytic cells in an environment that can prevent cell flattening and help express 
differentiation genes is important to maintain the cells’ phenotype (Martin et al., 1999) and also 
serves as an alternative approach to monolayer culture. Although many 3D culture procedures can 
provide a preconditioning environment to increase the differentiation and proliferative capacities 
of seeded cells (Pei 2017), the concern that culturing cells in a 3D substrate, especially those 
derived from biological origins, may alter immunogenic properties of expanded cells, which has 
recently been hypothesized (Stich et al., 2015; Zhang et al., 2015). A notable study by Stich and 
colleagues compared human mild and severely degenerated cervical NP, evaluated their 
regenerative properties, and assayed the resulting immunogenic responses following 3D-culture 
(Stich et al., 2015). Their results indicated that 3D fibrin/poly (lactic-coglycolic) acid culture 
resulted in increased proliferation of immune cells following 3D expansion, as indicated by the 
co-culture and analysis of labeled peripheral blood mononuclear cells (PBMCs) in a mixed 
lymphocyte reaction (MLR). Furthermore, the authors noted an increase in this trend with severely 
degenerated NP cells versus mildly degenerated NP cells (Stich et al., 2015). In a study using 
human synovial stem cells and decellularized extracellular matrix (dECM) substrates derived from 
human and porcine cells as a preconditioning/expansion strategy, Zhang and colleagues reported 
significant changes in HLA-DR surface marker expression for porcine dECM preconditioned cells. 
Interestingly, human-derived dECM did not increase HLA-DR expression in allogeneic stem cells 
expanded on its surface, but reported a greater than six-fold increase in HLA-DR expression 
following expansion on porcine dECM versus controls (Zhang et al., 2015). Similarly, Yuan and 
colleagues reported that microenvironment and scaffolding can modulate HLA-DR expression in 
chondrocytes (Yuan et al., 2011). A recent study also showed that mesenchymal stem cells seeded 
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in various collagen-based scaffolds, hydrogel and sponge, exhibited increases in the production of 
immunoregulatory factors indoleamine 2,3-dioxygenase (IDO), nitric oxide synthase (NOS), 
prostaglandin-endoperoxide synthase (PTGS), and hepatocyte growth factor (HGF) compared to 
2D culture (Yang et al., 2017), and are paracrine immunomodulators implicated in tissue 
regeneration (Bassi et al., 2012). Similar results were further confirmed and exemplified in a later 
study from the same group, where they reported that rabbit chondrocytes seeded on hydrogel-ECM 
scaffolds could control and lessen adverse immunogenicity of these preconditioned cells (Yuan et 
al., 2014). Although these studies have individually suggested that the 3D structure, mechanical 
properties, and composition of 3D scaffolds play roles in the immune-related changes of seeded 
cells, it remains to be determined in comparative studies which of these properties are predominant 
influences. 
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Detection of immune issues and future directions 
Despite the known potential benefits of various preconditioning strategies for cell culture (Pei 
2017), it is imperative that these cells do not elicit immune responses when introduced or 
reintroduced to a patient. For this reason, more studies are needed to fully evaluate the 
immunophenotypic changes in preconditioned cells and to perform the necessary experiments to 
ultimately elucidate the immune-related benefits and caveats of each preconditioning strategy. One 
of the initial experiments for assaying immune changes should include flow cytometry for immune 
surface marker analysis following preconditioning, particularly HLA-DR, complemented with T-
cell costimulatory markers CD80 and CD86, as well as apoptosis-related markers CD95 (Fas) and 
CD178 (FasL), which have been implicated in intervertebral disc immunity (Chen et al., 2015; Ma 
et al., 2015). Furthermore, studies investigating the relationships between preconditioning and Fas-
mediated apoptosis could uncover new, clinically relevant results for future therapeutic 
applications in intervertebral disc regeneration. To date, few studies have compared the 
immunomodulatory properties of various preconditioning methods in a single well-controlled 
study. One common approach to model potential immune response to preconditioned cells is an 
MLR assay using labeled immune cells, typically isolated from a blood sample. Several groups 
have used a version of this technique to test preconditioned cells (Stich et al., 2015; Yuan et al, 
2011). Notably, there is a great demand for in vivo studies to investigate the role of preconditioned 
cells for safe intervertebral disc tissue repair, especially those that can further evaluate the effects 
of preconditioning-induced changes in immune characteristics. It is reasonably suspected that one 
preconditioning strategy is unlikely to be most superior or ideal for all tissues in terms of 
immunomodulation, especially since various tissues are dominated by distinct immunoregulatory 
factors and different immune cells (Yang et al., 2011).  With clinical applications in mind, an ideal 
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preconditioning method or combination strategy should consider the multifaceted and specific 
nature of the immune reactions present in a particular target tissue, as well as the potentially altered 
immune properties of the preconditioned cell population.   
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Figure 1.4.1: 
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Figure 1.4.1: Cell preconditioning and potential immune effects. Although preconditioning 
strategies can be effective for cell rejuvenation, they may elicit changes in the preconditioned cells’ 
immunophenotypes or immune-related characteristics. 
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Abstract 
Cell expansion techniques commonly utilize exogenous factors to increase cell proliferation and 
create a larger cell population for use in cell-based therapies. One strategy for cartilage 
regenerative therapies is autologous stem cell expansion and fibroblast growth factor (FGF) 
supplementation during cell expansion, particularly FGF-2. However, it is unknown whether 
FGF-10, another FGF implicated in limb and skeletal development, can elicit the same 
rejuvenation responses in terms of proliferation and differentiation of human synoviumderived 
stem cells (SDSCs). In this study, we expanded SDSCs in either FGF-2 or FGF-10 for 7 days; a 
control group had no treatment. FGF-2 and FGF-10 supplementation was also exclusively tested 
during the differentiation phase. Expanded SDSCs were evaluated for their ability to successfully 
engage in chondrogenic and osteogenic differentiation. We found that FGF-2 supplementation 
during proliferation, but not differentiation, was able to increase glycosaminoglycan deposition, 
pellet size, and chondrogenic gene expression following chondrogenic induction, as well as 
increased calcium deposition, alkaline phosphatase activity, and expression of vital osteogenic 
differentiation genes following osteogenic induction. FGF-10 did not elicit a similar 
preconditioning effect. We also observed changes of both Wnt signals and mitogen-activated 
protein kinase expression during SDSC chondrogenesis, which occurred in a manner dependent 
upon the supplementation phase of FGF-2 administration. These results indicated that FGF-2, but 
not FGF-10, may be supplemented during stem cell expansion to prime cells for successful 
chondrogenesis and osteogenesis. 
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Introduction 
Adult Mesenchymal Stem Cells (MSCs) are promising alternative cell sources for cartilage tissue 
engineering due to the shortage of autologous chondrocytes for cell-based regenerative 
therapies.1 However, adult stem cells obtained from tissues have either less chondrogenic potential 
despite large amounts such as adipose stem cells or higher endochondral ossification and limited 
sample size such as bone marrow stromal cells (BMSCs).2 One promising MSC population found 
in the joint, known as synovium-derived stem cells (SDSCs), has recently been characterized as 
tissue-specific stem cells for chondrogenesis.3 Strategies that allow for MSC proliferation may be 
necessary to achieve a substantial and usable cell number for therapies; however, the initial MSC 
numbers are low and their differentiation potential can be compromised following excessive ex 
vivo expansion, with notable increases in cell senescence marker expression and decreased 
proliferative capacity.4 This situation can be further complicated when combined with other 
preexisting and potentially detrimental factors such as donor age and disease pathology.5 
It is known that the fibroblast growth factor (FGF) family is involved in limb and joint 
development, as well as various stages of skeletal and cartilage formation and maturation.6 For 
instance, FGF-2 is involved in early cartilage development and can cause dramatic increases in 
cell proliferation in chondrocytes and osteoblasts.7 In addition, another member of the FGF family, 
FGF-10, is known to be vital to limb bud initiation and development,8,9but less is known about the 
ability of FGF-10 to modulate chondrogenic activity, although a recent report indicated that FGF-
10 promoted Meckel's cartilage regeneration in rats.10 Interestingly, FGF signaling has been shown 
to maintain MSCs in an undifferentiated state during proliferation while preserving their 
multipotentiality,11 which further establishes the FGF family's potential benefits for 
preconditioning strategies. 
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Our recent findings suggest that decellularized extracellular matrix (dECM) deposited by stem 
cells could also provide a preconditioning strategy that stem cells could be greatly expanded with 
enhanced chondrogenic potential12 or endochondral ossification.13 Interestingly, microarray data 
from these dECM studies have shown that, among all FGFs, FGF-2 and FGF-10 are the most 
significantly regulated factors in human SDSCs following their expansion on dECM (Fig. 1). It is 
unknown whether a similar rejuvenating effect can be achieved on human SDSC chondrogenesis 
and osteogenesis through FGF-2 and FGF-10 supplementation in the cell expansion phase, as well 
as supplementation in the differentiation phase. Due to the importance and potential impacts in 
stem cell-mediated chondrogenesis,14,15 the content of both Wnt and mitogen-activated protein 
kinase (MAPK) activation, which have been demonstrated in our earlier dECM preconditioning 
study,16 will also be assessed in this study following FGF ligand rejuvenation. 
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Materials and Methods 
 
Evaluation of cell proliferation, surface phenotypes, and differentiation gene 
 
Cell culture and proliferation 
Human adult SDSCs obtained from Asterand (North America Laboratories, Detroit, MI) were 
cultured in growth medium containing alpha-minimum essential medium, 10% fetal bovine serum, 
100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL fungizone as described 
previously.16–18 Passage 4 SDSCs were treated with 10 ng/mL of FGF-2 or FGF-10 (PeproTech, 
Inc., Rocky Hill, NJ) during cell expansion/proliferation (F2P and F10P, respectively) or 
differentiation (F2D and F10D, respectively) (Fig. 2A). Cells cultured with no FGF treatment acted 
as a control (CNTL). Cell number was counted in 175 cm2 flasks (n = 6) using a hemocytometer. 
To determine proliferation index, before cell expansion, SDSCs were labeled with CellVue® 
Claret at 2 × 10−6 M for 5 min according to the manufacturer's protocol (Sigma-Aldrich, St. Louis, 
MO). After 6 days of proliferation, expanded cells were collected and measured using a BD 
FACSCalibur™ flow cytometer (dual laser) (BD Biosciences, San Jose, CA). Twenty thousand 
events of each sample were collected using CellQuest Pro software (BD Biosciences), and cell 
proliferation index was analyzed by ModFit LT™ version 3.1 (Verity Software House, Topsham, 
ME). 
 
Surface phenotypes of expanded cells 
The following primary antibodies were used in flow cytometry analysis to detect expanded SDSC 
surface immunophenotype profiles: CD29 (Abcam, Cambridge, MA), CD90 (BD Pharmingen, 
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San Jose, CA), CD105 (BioLegend, San Diego, CA), the stage-specific embryonic antigen 4 
(SSEA4; BioLegend), and isotype-matched immunoglobulin Gs (IgGs; Beckman Coulter, 
Fullerton, CA). The secondary antibody was goat anti-mouse IgG (H + L) R-phycoerythrin 
conjugated (Life Technologies, Carlsbad, CA). Samples (n = 3) of each 2 × 105 expanded cells 
were incubated on ice in cold phosphate-buffered saline containing 0.1% ChromPure Human IgG 
whole molecule (Jackson ImmunoResearch Laboratories, West Grove, PA) and 1% NaN3 (Sigma-
Aldrich) for 30 min. The cells were then sequentially incubated in the dark in the primary and 
secondary antibodies for 30 min. Fluorescence was analyzed by a FACSCalibur (BD Biosciences) 
using FCS Express 4 software package (De Novo Software, Los Angeles, CA). 
Senescence and differentiation gene expression 
Expanded cells were evaluated using real-time polymerase chain reaction (PCR) for senescence 
and differentiation-related gene changes. Total RNA was extracted from representative samples 
(n = 4) using an RNase-free pestle in TRIzol® (Life Technologies). Two micrograms of mRNA 
were used for reverse transcriptase with a High-Capacity cDNA Archive Kit (Applied Biosystems, 
Foster City, CA) at 37°C for 120 min. Senescence-related genes (cyclin-dependent kinase inhibitor 
2A [P16; Assay ID Hs00923894_m1], cyclin-dependent kinase inhibitor 1A [P21; Assay ID 
Hs00355782_m1], and tumor protein p53 [TP53; Assay ID Hs01034249_m1]), chondrogenic 
marker genes (SRY [sex determining region Y]-box 9 [SOX9; Assay ID Hs00165814_m1], 
aggrecan [ACAN; Assay ID AIQJAP5], and type II collagen [COL2A1; Assay ID 
Hs00156568_m1]), and osteogenic genes (Runt-related transcription factor 2 [RUNX2; Assay ID 
Hs00231692_m1]; Osterix [SP7; Assay ID Hs01866874_s1]; Secreted Phosphoprotein 1 [SPP1; 
Assay ID hs00959010_m1]; Bone sialoprotein [IBSP; Assay ID hs00173720_m1]; and Bone 
Gamma-Carboxyglutamate [Gla] Protein [BGLAP; Assay ID Hs01587814_g1]) were customized 
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by Applied Biosystems as part of their Custom TaqMan® Gene Expression Assays. 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH; Assay ID Hs02758991_g1) was carried 
out as the endogenous control gene. Real-time PCR was performed with the iCycler iQ™ 
Multicolor RT-PCR Detection and calculated by computer software (PerkinElmer, Wellesley, 
MA). Relative transcript levels were calculated as χ = 2−ΔΔCt, in which ΔΔCt = ΔE − ΔC, 
ΔE = Ctexp − CtGAPDH, and ΔC = Ctct1 − CtGAPDH. 
Chondrogenic induction and evaluation 
Chondrogenic induction 
Expanded cells (3.0 × 105) were centrifuged at 500 g for 5 min in a 15-mL polypropylene tube to 
form a pellet. After overnight incubation (day 0), the pellets were cultured in a serum-free 
chondrogenic medium consisting of high-glucose Dulbecco's modified Eagle's medium, 40 μg/mL 
proline, 100 nM dexamethasone, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.1 mM ascorbic 
acid-2-phosphate, and 1 × ITS™ Premix (BD Biosciences) with the supplementation of 10 ng/mL 
transforming growth factor beta3 (TGF-β3, PeproTech, Inc.) in a 5% O2 incubator as long as 21 
days. F2D and F10D groups were also supplemented with 10 ng/mL FGF-2 or FGF-10, 
respectively. The pellets were evaluated using real-time PCR for chondrogenic marker genes 
(ACAN and COL2A1), type I collagen (COL1A1; Assay ID Hs00164004_m1), hypertrophic 
genes (type X collagen [COLXA1; Assay ID Hs00166657_m1] and alkaline phosphatase [ALP; 
Assay ID Hs01029144_m1]), histology and immunohistochemistry (IHC) for staining, and 
biochemical analysis for both DNA and glycosaminoglycan (GAG) amounts. 
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Histology and immunostaining 
Representative pellets (n = 2) were fixed in 4% paraformaldehyde at 4°C overnight, followed by 
dehydrating in a gradient ethanol series, clearing with xylene, and embedding in paraffin blocks. 
Five-micrometer thick sections were stained with Alcian blue (counterstained with fast red) for 
sulfated GAGs. For IHC, the sections were immunolabeled with primary antibody against type II 
collagen (Col2; II-II6B3, Developmental Studies Hybridoma Bank, Iowa City, IA], followed by 
the secondary antibody of biotinylated horse anti-mouse IgG (Vector, Burlingame, CA). 
Immunoactivity was detected using VECTASTAIN ABC reagent (Vector) with 3, 3′-
diaminobenzidine as a substrate. 
Biochemical analysis for DNA and GAG contents 
Representative pellets (n = 4) were digested at 60°C for 4 h with 125 μg/mL papain in PBE buffer 
(100 mM phosphate, 10 mM ethylenediaminetetraacetic acid, pH 6.5) containing 10 mM cysteine. 
To quantify cell density, the amount of DNA in the papain digestion was measured using the 
Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies) with a CytoFluor® Series 4000 
(Applied Biosystems). GAG was measured using dimethylmethylene blue dye and a Spectronic™ 
BioMate™ 3 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA) with bovine 
chondroitin sulfate (Sigma-Aldrich) as a standard. 
Expression of both Wnt and MAPK signals following FGF-mediated chondrogenesis 
Expanded cells and subsequent pellets were dissolved in the lysis buffer (Cell Signaling, Danvers, 
MA) with protease inhibitors. Total proteins were quantified using BCA™ Protein Assay Kit 
(Thermo Fisher Scientific). Thirty micrograms of protein from each sample were denatured and 
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separated using NuPAGE® Novex® Bis-Tris Mini Gels in the XCell SureLock™ Mini-Cell (Life 
Technologies) at 120 V at 4°C for 3 h. Bands were transferred onto a nitrocellulose membrane 
using an XCell II™ Blot module (Life Technologies) at 15 V at 4°C overnight. The membrane 
was incubated with primary monoclonal antibodies in 5% bovine serum albumin in TBST buffer 
(10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% TWEEN 20) for 1 h (β-actin served as an internal 
control), followed by the secondary antibody of horseradish peroxidase–conjugated goat anti-
mouse (Thermo Fisher Scientific) for 1 h. SuperSignal West Femto Maximum Sensitivity 
Substrate and CL-XPosure Film (Thermo Fisher Scientific) were used for exposure. The primary 
antibodies used in immunoblotting included the MAPK Family Antibody Sampler Kit 
(extracellular signal-regulated protein kinases 1 and 2 [Erk1/2], Jun N-terminal kinase [Jnk], and 
p38), phosphorylated (p-) MAPK Family Antibody Sampler Kit, and Wnt Signaling Antibody 
Sampler Kit (Cell Signaling). Wnt11 polyclonal antibody was obtained from Thermo Fisher 
Scientific. Wnt signals were also evaluated using real-time PCR (WNT3A; Assay ID 
Hs00263977_m1, WNT5A; Assay ID Hs00998537_m1, and WNT11; Assay ID Hs00182986_m1) 
following cell expansion and chondrogenic differentiation. 
Osteogenic induction and evaluation 
Expanded cells (n = 3) cultured for 21 days in osteogenic medium (growth medium supplemented 
with 0.1 μM dexamethasone, 10 mM β-glycerol phosphate, 50 μM ascorbate-2-phosphate, and 
0.01 μM 1,25-dihydroxyvitamin D3) were collected for ALP activity assay with a reagent kit 
(Sigma-Aldrich) by measuring the formation of p-Nitrophenol from p-nitrophenyl phosphate 
following the manufacturer's instructions. For evaluation of calcium deposition, induced cells 
(n = 3) were fixed with 70% ice-cold ethanol for 1 h and then incubated in 40 mM Alizarin Red S 
(ARS) at pH 4.2 for 20 min with agitation. After rinsing, matrix mineral-bound staining was 
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photographed. Quantification of staining was performed by staining density using ImageJ 
software. 
Statistical analyses 
Analysis of variance with pairwise comparison and t-test was used to compare measurements 
between different groups. All statistical analyses were performed with SPSS 13.0 statistical 
software (SPSS, Inc., Chicago, IL). p-Values <0.05 were considered statistically significant. 
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Results 
Addition of FGF-2 but not FGF-10 during the expansion phase promoted SDSC proliferation 
After 7 days of monolayer expansion, SDSCs without FGF treatment exhibited enlarged cell 
morphology which, in the presence of FGF-2, became notably smaller and fibroblast-like shaped 
cells with a glistening outline. Both proliferation index (Fig. 2B) and cell number counting data 
(Fig. 2C) suggested that FGF-2 significantly enhanced SDSC proliferation, while FGF-10 
supplementation did not induce greater cell proliferation compared to the control group. This 
result is also supported by SSEA4 expression levels evaluated by flow cytometry (Fig. 2D). 
Surprisingly, other stem cell markers (Fig. 2D), including CD29, CD90, and CD105, exhibited 
decreases in median fluorescence intensity when SDSCs were expanded in the presence of FGF-
2. Similar to the cell proliferation data, FGF-10 treatment did not elicit any meaningful 
differences in the expression of stem cell markers. 
Addition of FGF-2 led to changes in expression of senescence and differentiation-related genes 
TaqMan® real-time PCR data showed that FGF-2 treatment upregulated P16 expression level in 
expanded cells compared with the control group but downregulated senescent genes P21 and 
TP53 expression levels (Fig. 3A). We also found that FGF-2 treatment significantly increased 
transcriptional factor SOX9, and FGF-10 treatment decreased SOX9 expression. This result was 
also accompanied by early and dramatic decreases in chondrogenic marker gene expression 
(ACAN and COL2A1) (Fig. 3B). For osteogenic genes, FGF-10 preconditioning significantly 
decreased RUNX2 expression, while FGF-2 produced similar RUNX2 expression levels as the 
control. Interestingly, FGF-2 supplementation, but not FGF-10, led to significant increases in 
SP7, SPP1, IBSP, and BGLAP gene expression versus other groups (Fig. 3C). 
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Addition of FGF-2 but not FGF-10 during the expansion phase promoted SDSC chondrogenic 
potential 
After 21-day chondrogenic induction, FGF-2 pretreated SDSCs yielded pellets with the largest 
size and most intense staining for sulfated GAGs by Alcian blue and Col2 by IHC compared to 
the other four groups, which exhibited similar pellet sizes and staining intensities (Fig. 4A). 
These findings were confirmed by biochemical analysis data in which the FGF-2 pretreatment 
group yielded the highest DNA ratio by day 0, GAG amount per pellet, and ratio of GAG to 
DNA, known as the chondrogenic index (Fig. 4B). TaqMan real-time PCR data showed that, 
after 21-day chondrogenic induction, FGF-2 pretreated cells yielded the lowest expression of 
COL1A1, but the highest levels of COL2A1 and ACAN, while FGF-2 treated cell pellets yielded 
the second lowest level of COL1A1 and the lowest levels of COL2A1 and ACAN. Both FGF-10 
treatment groups, regardless of supplementation phase, yielded similar expression of COL1A1 
and ACAN, which was lower than the control group (Fig. 4C), but still significantly greater than 
either FGF-2 treatment group. We also found that FGF-2 pretreatment yielded cells with the 
highest level of COL10A1 and ALP, while FGF-2 treatment yielded cells with the lowest level 
of ALP mRNA (Fig. 4D). 
Wnt and MAPK signals following FGF-2 preconditioning and chondrogenic differentiation 
TaqMan real-time PCR data showed that FGF-2 pretreated SDSCs displayed a significant 
upregulation of WNT5A and WNT3A and downregulation of WNT11 (Fig. 5A), which was 
confirmed by Western blot data (Fig. 5B); compared to significant upregulation of both p-p38 
and p-Jnk signals in FGF-2 pretreated SDSCs, total Erk1/2 was markedly reduced with a modest 
suppression in p-Erk (Fig. 5C). Following chondrogenic differentiation, FGF-2 pretreated 
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SDSCs showed decreased levels of Wnt5a, but increased levels of Wnt11; however, FGF-2 
treatment in chondrogenic induction exhibited an opposite trend (Fig. 5D, E). Interestingly, FGF-
2 pretreated SDSCs also showed decreased levels of p38, Jnk, and Erk1/2 compared to other 
groups (Fig. 5F). 
Effect of FGF-2 and FGF-10 on SDSC osteogenic differentiation 
After 21-day osteogenic induction, FGF-2 pretreated SDSCs exhibited the highest density of 
both ARS (Fig. 6A) and ALP staining (Fig. 6B), indicating stronger calcium deposition and ALP 
expression, respectively. Interestingly, FGF-2 treatment in osteogenic induction significantly 
decreased ARS staining compared to other groups, while FGF-10 treatment either during cell 
expansion or osteogenic induction had no evident effect on osteogenic differentiation of 
expanded SDSCs (Fig. 6C, D). 
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Discussion 
In this study, we sought to determine whether FGF-2 or FGF-10 supplementation during the 
proliferation phase or the differentiation phase could improve human SDSC chondrogenesis and 
osteogenesis. In addition, we wanted to determine if both Wnt and MAPK signals were involved 
in FGF ligand-mediated SDSC proliferation and lineage differentiation. The present study 
suggested that FGF-2 supplementation during the proliferation phase can precondition SDSCs to 
undergo more successful chondrogenesis and osteogenesis following differentiation induction, 
which was superior to FGF-10 supplementation, no treatment, and the addition of either FGF 
during differentiation. The early upregulation of Wnt3a and Wnt5a and early downregulation of 
Wnt11 are likely to be influential mechanisms involved in FGF preconditioning and successful 
differentiation along the chondrogenic and osteogenic lineages. Chondrogenic differentiation was 
complimented by an upregulation of SOX9, a known transcription factor for chondrogenic activity, 
with FGF-2 supplementation during proliferation. Interestingly, FGF-2 preconditioning during the 
proliferation phase led to a RUNX2-independent mRNA upregulation of several vital osteogenic 
genes and more successful osteogenesis in vitro than all other groups. These findings suggested 
that FGF-2 supplementation during the early proliferation phase can prime human SDSCs for 
successful chondrogenic and osteogenic differentiation, which may be, in part, modulated through 
Wnt and MAPK signaling, but not when supplemented with FGF-2 during differentiation or with 
FGF-10 at any stage. 
Unlike human germ cells, most human somatic cells do not express telomerase and, therefore, lose 
telomeric DNA during each round of DNA replication.19 Stress conditions could cause cell 
senescence20 resulting from DNA damage triggered by telomere shortening through the p53-
mediated signaling pathway; on the contrary, p53 inactivation prolongs the lifespan of human 
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fibroblasts.21 The expression of p21, a p53 target gene, increases in senescent cells.22 Since 
targeted deletion of the p21 gene is sufficient to escape senescence in human fibroblasts,23 p21 
may have a major role in the induction of cellular senescence in human fibroblasts by inhibiting 
the activity of cyclin-dependent kinases. In this study, preconditioning using FGF-2 dramatically 
decreased P21 and TP53, indicating a rescue of telomere-dependent intrinsic senescence. 
Interestingly, both FGF-2 and FGF-10 pretreatment dramatically increased P16 expression in 
expanded cells, which is usually raised through extrinsic senescence such as reactive oxygen,19 
suggesting that the rescue dominated by FGF-2 pretreatment was independent of the p16/pRb 
pathway. Future studies will be necessary to fully validate these trends, determine whether these 
changes are consistent over several cell passages, and discover a possible mechanism in which 
FGF-2 may be regulating cell senescence. 
In this study, we found that FGF-2 rather than FGF-10 promoted SDSC proliferation. The potential 
underlying mechanisms could be selection of a particular subset of cells by telomere length in 
FGF-2-expanded MSCs.24,25 Despite the role in regulating the proliferation and maintenance of 
dental epithelial stem cells,26 in this study, FGF-10 did not act as a proliferation promoter like 
FGF-2. Interestingly, FGF-2 pretreatment decreased CD29, CD90, and CD105 expression, but 
increased SSEA4. This finding is consistent with a report by Hagmann et al. in which they found 
that CD90, CD105, and CD146 were significantly decreased in human BMSCs after treatment 
with FGF-2.27 One potential explanation is that FGF-2 could decrease the expression of TGF-β, 
which is a promoter of cell senescence.28 Sacchetti et al. found that FGF-2 pretreatment decreased 
the expression of CD105 (endoglin), a TGF-β coreceptor.29 Furthermore, Ito et al. found that 
downregulation of TGF-β signaling was responsible for the rejuvenating effect of FGF-2 
pretreatment in terms of osteogenic and chondrogenic potential in human MSCs.30 A similar trend 
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in surface phenotypes was observed in human SDSCs after expansion on dECM deposited by stem 
cells.17,18 Like pretreatment with FGF-2, this dECM expansion approach also plays a role in the 
preconditioning of expanded stem cells in both proliferation and differentiation capacity.31 Since 
CD29, CD90, and CD105 are considered traditional surface markers for stem cells,32 the decrease 
in these markers during stem cell rejuvenation raises questions regarding their defined roles as 
they pertain to stem cell “stemness.” 
Despite the fact that both chondrogenic and osteogenic potentials were significantly increased after 
FGF-2 pretreatment, we did find a discrepancy in the expression of transcriptional and 
differentiation genes for a specific lineage in expanded cells. In terms of osteogenesis, FGF-2 
pretreated SDSCs exhibited an upregulation of both transcriptional gene (SP7) and matrix genes 
(SPP1, IBSP, and BGLAP), despite no significant change in another transcriptional gene (RUNX2). 
This finding might be explained by negative feedback modulation through addition of exogenous 
FGF-2, which can lower endogenous FGF-2 expression,33 resulting in a decrease of the 
osteogenesis inhibitory effect exerted by FGF-2 during subsequent osteogenic induction.34,35 In 
terms of chondrogenesis, however, FGF-2 pretreated cells exhibited an upregulation of a 
transcriptional gene (SOX9), but downregulation of matrix genes (ACAN and COL2A1). This 
finding could be explained by a recent report in which pretreatment with FGF-2 could significantly 
enhance reprogramming efficiency by downregulating matrix genes such as collagen.36 
Due to the importance of both Wnt and MAPK signaling in cartilage regeneration,15 the signals 
associated with these two pathways were characterized during FGF-2 pretreatment and subsequent 
chondrogenic induction. Following FGF-2 supplementation during the proliferative phase, we 
found that WNT3A and WNT5A mRNAs were markedly increased, while WNT11 mRNA was 
decreased. Interestingly, a contrasting trend, with WNT5A mRNA expression significantly 
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decreased and WNT11 mRNA significantly increased versus other groups, occurred following 21-
day pellet differentiation culture. This result appears to support the notion that Wnt signals are 
stage-specifically expressed during chondrogenesis.37 For instance, Wnt5a has been previously 
implicated as an early promoter38 and Wnt11, which has been shown to stimulate Col2 
deposition,39 is a late promoter of chondrogenesis.40 Another study reported that Wnt3a-canonical 
and noncanonical Wnt pathways counteracted one another in MSC chondrogenesis.41 This notion 
seems well supported by other studies, which suggest that Wnt3a can prevent or inhibit 
chondrogenesis, while Wnt5a supports cartilage formation, but can impede Col2 expression and 
induce dedifferentiation.39,42,43 These findings support the Wnt expression trends observed in our 
data, where both Wnt3a and Wnt5a were expressed in earlier stages following proliferation and 
FGF-2 supplementation but, following chondrogenic differentiation, Wnt3a and Wnt5a mRNAs 
and proteins were either significantly decreased or undetected. This expression is likely important 
in maintaining the “stemness” of the SDSCs, which may promote successful responses to 
chondrogenic media, as well as later expression of Col2, aggrecan, and greater GAG deposition. 
In addition, it is worth noting that preconditioning methods, which directly or indirectly regulate 
Wnt signaling, could hold great potential; however, a study by Hoang44 raises a valid point that 
therapies targeting Wnt may have significant side effects due to their defined roles in tissue 
regeneration and stem cell self-renewal, as well as osteosarcoma. Although aberrant Wnt signaling 
does not seem to be a concern in this study, specifically with FGF-2 treatment of SDSCs, as 
evidenced by the reversed trend in the Wnt real-time PCR results from the expansion phase to the 
differentiation phase, it is a caveat which should be noted when considering therapies which 
modify Wnt signaling. 
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Interestingly, RUNX2 was not significantly increased in either of the FGF supplemented groups 
versus the control in expanded cells before osteogenic induction. Furthermore, Western blotting 
revealed that expanded cells treated with FGF-2 during proliferation had robust levels of p-p38 
and p-Jnk, but little p-Erk1/2 or Erk1/2. It is known that RUNX2, a transcriptional regulator of 
osteogenesis, is heavily regulated through the Erk signaling pathway45,46; however, it may not be 
required for osteogenic differentiation to occur. A study using rat BMSCs reported results 
demonstrating that inhibition of p38 activity alone did not interfere with osteogenesis and 
suggested that mechanical strain-induced osteogenic differentiation was a result of Erk1/2 and 
RUNX2 activation.47 Additional studies have reported that the inhibition of Erk1/2 and Jnk, but 
not p38, has resulted in inhibited osteogenic differentiation48; also, decreased RUNX2 expression 
was observed in BMSCs with the inhibition of Erk1/2 phosphorylation.46 Furthermore, it has been 
confirmed that RUNX2 activation occurs through the Erk pathway.45 Although p38 is undeniably 
implicated in osteogenesis, studies targeting the Erk and Jnk pathways through inhibition seem to 
suggest that the Erk pathway may be more closely related to RUNX2 activation and regulation. 
Given the growing number of studies reporting RUNX2 activation without p38 signaling, the lack 
of RUNX2 expression could very likely be directly related to Erk1/2 signaling, which was 
significantly decreased in our current study compared to robust levels of p-p38 and p-Jnk in the 
FGF-2 pretreatment group following cell expansion, as evidenced by Western blotting. It is very 
possible that increases in ALP and ARS staining following successful osteogenic induction in the 
FGF-2 pretreatment group are the result of increased gene expression of other key osteogenic genes 
such as SP7, SPP1, IBSP, and BGLAP, which were all significantly increased in the FGF-2 
pretreatment group versus control and FGF-10 pretreatment groups, but not through mechanisms 
related to RUNX2 or Erk1/2 activation. Overall, it seems that the strong ALP activity, calcium 
 107 
 
deposition, and upregulation of several key osteogenic genes in the FGF-2 pretreatment group 
were primarily driven through RUNX2-independent and Erk1/2-independent signaling and likely 
occurred through p38, Jnk, and potentially other signaling mechanisms. More studies need to be 
performed to fully assess the necessity of Erk1/2 and RUNX2 roles in SDSC osteogenesis. 
In conclusion, FGF-2 preconditioning led to superior cell proliferation, chondrogenesis, 
osteogenesis, and overall rejuvenation versus no treatment or FGF-10 preconditioning. Cells 
preconditioned with FGF-2 during the proliferative phase led to robust chondrogenic pellet 
formation, accompanied by significant GAG deposition and upregulation of vital chondrogenic 
gene expression. Likewise, FGF-2 preconditioning produced unmatched osteogenesis, leading to 
cells with increased gene expression following proliferation, and led to significant increases in 
ARS and ALP staining for the differentiated cell cultures versus other groups. FGF-2, but not FGF-
10, preconditioning was able to elicit significant changes in Wnt signal expression, as well as 
pronounced p38 signaling. FGF-2 seems to be an optimal choice as a preconditioning stimulus for 
human SDSC chondrogenesis and osteogenesis. 
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Figure 1: Gene expression of FGF ligands in cell expansion phase and chondrogenic markers in 
chondrogenic induction phase following the dECM pretreatment. The study design was detailed 
previously.18 Briefly, human SDSCs were expanded on either dECM or Plastic for one passage 
followed by a 2-week chondrogenic induction. Microarray analysis was used to evaluate FGF 
ligand genes in expanded cells (A) and chondrogenic marker genes in differentiated cells (B). 
The raw data were uploaded into Partek (St. Louis, MO) software for initial analysis. After raw 
intensity was background-subtracted, robust multiarray analysis was normalized, log 
transformed, and fold changes were determined. Heatmap.2 in R was used to show the effects on 
FGF ligand and chondrogenic genes, annotated in Ingenuity Pathway Analysis (IPA, Redwood 
City, CA) as affecting cell proliferation and chondrogenic differentiation, respectively. dECM 
expanded cells were referred to as Ec, while Plastic expanded cells were referred to as Pc (A). 
The pellets from dECM expanded cells were referred to as Ep, while those from Plastic 
expanded cells were referred to as Pp (B). FGF, fibroblast growth factor; dECM, decellularized 
extracellular matrix; SDSC, synovium-derived stem cell.  
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Figure 2: 
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Figure 2: FGF ligand mediated human SDSC proliferation. (A) Experimental design. Five 
groups in total: FGF-2 and FGF-10 were only included in a 7-day cell expansion phase (F2P and 
F10P, respectively) or in a 21-day differentiation phase (F2D and F10D, respectively) with non-
FGF treatment as a control (CNTL). (B) Flow cytometry was used to measure proliferation 
(prolif.) index of expanded SDSCs. (C) Cell number was counted ( × 106) after a 7-day cell 
expansion on 175 cm2 flasks (n = 6). (D). Flow cytometry was used to measure both percentage 
and median fluorescence intensity of mesenchymal stem cell surface markers (CD29, CD90, 
CD105, and SSEA4) of expanded SDSCs. SSEA4, stage-specific embryonic antigen 4. 
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Figure 3: 
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Figure 3: FGF ligand mediated senescence and differentiation-related gene expression in 
expanded SDSCs. TaqMan® real-time PCR was used to quantify mRNA levels of senescent 
genes (A): P16, P21, and TP53, chondrogenic genes (B): SOX9, ACAN, and COL2A1, and 
osteogenic genes (C): RUNX2, SP7, SPP1, IBSP, and BGLAP. Data are shown as average ± SD 
for n = 4. Groups not connected by the same letter are significantly different (p < 0.05). PCR, 
polymerase chain reaction; SD, standard deviation; SOX9, SRY (sex determining region Y)-box 
9; ACAN, aggrecan; COL2A1, type II collagen; RUNX2, Runt-related transcription factor 2; 
SP7, Osterix; SPP1, secreted phosphoprotein 1; IBSP, bone sialoprotein; BGLAP, bone gamma-
carboxyglutamate (Gla) protein. 
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Figure 4: 
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Figure 4: FGF ligand mediated SDSC chondrogenic differentiation. After a 21-day 
chondrogenic induction, SDSC pellets were evaluated using Alcian blue staining for sulfated 
GAGs and immunohistochemical staining for Col2 (A), biochemical analysis for both DNA and 
GAG amounts in a pellet (B), and TaqMan real-time PCR for mRNA levels of chondrogenic 
genes (C): COL1A1, COL2A1, and ACAN and hypertrophic genes (D): COL10A1 and ALP. 
Data are shown as average ± SD for n = 4. Groups not connected by the same letter are 
significantly different (p < 0.05). GAG, glycosaminoglycan; Col2, type II collagen; ALP, 
alkaline phosphatase. 
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Figure 5: 
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Figure 5: FGF ligand mediated Wnt and MAPK signal changes in SDSC chondrogenesis. 
During cell expansion (A–C) and chondrogenic induction (D–F), Wnt signals were evaluated 
using both TaqMan real-time PCR (A, D) and Western blot (B, E), while MAPK signals were 
evaluated using Western blot (C, F). GAPDH was used as an internal control. Data are shown as 
average ± SD for n = 4. Groups not connected by the same letter are significantly different 
(p < 0.05). MAPK, mitogen-activated protein kinase; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase. 
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Figure 6: 
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Figure 6: FGF ligand mediated SDSC osteogenic differentiation. After a 21-day osteogenic 
induction, both ARS (A) and ALP staining (C) were used to evaluate osteogenic differentiation. 
ImageJ software was used to semiquantify the density of staining (B, D, respectively). Data are 
shown as average ± SD for n = 4. Groups not connected by the same letter are significantly 
different (p < 0.05). ARS, Alizarin Red S. 
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Abstract 
Cell expansion and preconditioning strategies are a growing area of interest for therapies targeting 
intervertebral discs (IVDs), primarily aimed at increasing rejuvenation and proliferative capacities 
of nucleus pulposus cells (NPCs). Although therapies designed for such applications seem 
promising, it is unknown whether the signals and potential therapeutic targets of the Wnt pathways 
previously implicated in chondrogenesis, Wnt3A, Wnt5A, and Wnt11, play further key roles in 
the promotion or regulation of human NPC redifferentiation. In this study, NPCs were harvested 
and isolated from herniated disc patients, cultured in vitro, and transduced with lentiviral vectors 
that overexpress the WNT3A, WNT5A, and WNT11 genes, or Cas9/sgRNA vectors that knock 
out these genes. Following expansion, transduced NPCs, for both gene knockout and 
overexpression groups, were redifferentiated toward the NP phenotype and assessed via flow 
cytometry, quantitative polymerase chain reaction (qPCR) for redifferentiation genes, and 
biochemically for glycosaminoglycan (GAG) content. The overexpression of specific WNT 
factors led to increases in both GAG deposition and expression of redifferentiation genes. These 
effects were attenuated by CRISPR-Cas9 vectors targeting these same WNT genes. These results 
indicate that specific WNT signals can regulate the expression of redifferentiation genes, unequally 
impact GAG deposition, and contribute to the redifferentiation of human NPCs. 
 
Keywords: nucleus pulposus, wnt signaling, intervertebral disc, lentivirus, CRISPR-Cas9 
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Introduction 
Located inside the intervertebral disc (IVD), nucleus pulposus (NP) tissue provides structural 
support and shock absorbing capacity along the spinal column (Urban and Roberts, 1995). NP 
tissue functions through a hydrated collagen and proteoglycan-rich extracellular matrix. 
Unfortunately, IVD herniation and degeneration are among the most prevalent causes for back 
pain; interestingly, low back and neck pain represented the third-highest amount of US health care 
spending from 1996 to 2013 (Dieleman et al., 2016). These conditions can negatively impact the 
properties and function of the IVD due to the loss of disc height, NP cellularity, matrix remodeling, 
cell dedifferentiation, and other deleterious biochemical conditions (Bowles and Setton, 2017; 
Hegewald et al., 2011; Hiyama et al., 2010; McCann and Seguin, 2016; Tworney and Taylor, 
1987).  
Recently, the preconditioning of NP cells (NPCs) and autologous NPC-mediated therapies have 
aimed to rejuvenate and replenish the depleted NP tissue following injury or degeneration 
(Hegewald et al., 2011; Pei, 2017; Shoukry et al., 2013). However, many of the biochemical 
pathways and signals that allow for successful redifferentiation and therapeutic targeting have yet 
to be fully elucidated (Srivastava et al., 2017). These are well-conserved pathways which have 
been extensively studied and implicated in tissue homeostasis (Arai et al., 2012), NP apoptosis 
(Wang et al., 2016), and, more specifically, in cell migration and differentiation (Garcin & Habib, 
2017), with particularly notable roles in chondrogenesis (Green et al., 2015; Pizzute et al., 2016; 
Zhong et al., 2015). The roles of both canonical and noncanonical Wnt (Wingless protein family) 
signals in chondrocytic tissues have been extensively reviewed (Mohammad et al., 2016; Zhang 
et al., 2014) and are well-demonstrated regulators in the development and differentiation of these 
cells into mature tissues. 
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From a degenerative standpoint, Wnt/β-catenin pathway signals have been implicated in canine 
IVD degeneration (Smolders et al., 2013), as well as murine IVD aging, degeneration, and 
development (Dahia et al., 2009; Jia et al., 2016; Kondo et al., 2011). More recently, the 
abnormalities caused by Wnt signaling have also been associated with local inflammation and IVD 
ossification (Shao et al., 2017). In a study by Winkler and colleagues, canonical Wnt signals were 
shown to be decreased, along with Sonic hedgehog (Shh) signaling in the aging human adult disc, 
and it was suggested that the Wnt pathway could be a therapeutic target for disc degeneration 
(Winkler et al., 2014). Although several studies have suggested that Wnt signals play key roles in 
human disc, there are fewer studies using human-derived IVDs or NPCs to fully support such 
hypotheses, especially studies that directly compare multiple Wnt signals at once during NPC 
redifferentiation.  
Furthermore, recently published studies have suggested that the progression of degenerative disc 
disease may be related to the crosstalk between Wnt and TGF-β signaling (Cleary et al., 2015; 
Matta et al., 2017), This signaling, a well-known differentiation stimulating signal, occurs 
naturally in cartilaginous tissues and is commonly used to perpetuate chondrogenic and 
redifferentiated NPC phenotypes in vitro (Cai et al., 2017; Chen et al., 2006). Additionally, 
Wnt3A, Wnt5A, and Wnt11 have each been shown to be involved in mesenchymal stem cell 
(MSC) differentiation. Wnt3A has been implicated in MSC proliferation, increasing differentiation 
potential, and suppression of differentiation (Buchtova et al., 2015; Lee et al., 2016; Narcisi et al., 
2015; Narcisi et al., 2016), while Wnt5A and Wnt11 have been more extensively implicated in 
differentiation and cartilage development (Hosseini-Farahabadi et al., 2012; Liu et al., 2014; 
Pizzute et al., 2016; Thorfve et al., 2012; Usami et al., 2016; Zhu et al., 2012).  
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Due to the identified roles that Wnt signaling pathways play in cartilage and stem cell 
differentiation (Cleary et al., 2015; Hosseini-Farahabadi et al., 2012; Pizzute et al., 2016; Zhang 
et al., 2014), as well as the inherent similarities and shared properties between the chondrogenic 
differentiation of chondrocytic tissues (Chen et al., 2017), such as those derived from the synovium 
(synovium-derived stem cells or SDSCs) with NPC redifferentiation (Shoukry et al., 2013), we 
hypothesize that specific Wnt signals are also significant regulators of NP redifferentiation in 
humans. We expect that noncanonical signals, Wnt5A and Wnt11, will each exhibit a more 
dramatic effect on NPC redifferentiation than canonical Wnt3A. 
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Materials and Methods 
Cloning of overexpression and knockout vectors 
We used VSV-G pseudotyped lentiviral vectors in this study. To construct overexpression (OE) 
vectors, the open reading frames (ORF) sequences of human WNT3A, WNT5A, and WNT11 
genes or control green fluorescence protein (GFP) were cloned into a lentiviral vector backbone 
Lenti SFFV-X-Wpre by Gibson Assembly® from New England BioLabs Inc. (NEB, Ipswich, 
MA). WNT3A, WNT5A, and WNT11 cDNAs were purchased from DNASU Plasmid Repository 
(Tempe, AZ). To knock out human WNT3A, WNT5A, and WNT11, we cloned the spacer 
sequence of single-guide RNA (sgRNA) into backbone Lenti-U6-sgRNA-SFFV-Cas9-E2A-Puro, 
in which the U6 promoter drives the expression of sgRNA and the spleen focus-forming virus 
(SFFV) promoter drives the expression of both CRISPR associated protein 9 (Cas9) and 
puromycin-resistant gene. The spacer sequences are as follows: sgWNT3A-1, 
GGCCATCGCCGCGCGAG; sgWNT3A-2, GCAGCTACCCGATCTGG; sgWNT3A-2, 
GGCACGGCCGCCATCTG; sgWNT5A-1, GACGGCCTTCACATACG; sgWNT5A-2, 
GGATGCGCTCCCGCTCG; sgWNT5A-3, GCTCACCGCGTATGTGA; sgWNT11A-1, 
GGGGGCGAGCTCAATGG; sgWNT11A-2, GGCGTGGCTGATGGCGG; sgWNT11A-3, 
GTGGCTCACCTGGGACG. The sgRNA design and vector cloning have been detailed elsewhere 
(Zhang et al., 2016; Zhang et al., 2017a). All the inserts were confirmed by Sanger sequencing. 
The DNA-calcium phosphate co-precipitation method was used for packaging lentiviral vectors. 
After 100-fold concentration by ultracentrifugation, the biological titers of vectors were 
determined by transducing HT1080 cells. 
Cell culture and lentiviral transduction 
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Human adult NP cells were obtained from the NP tissue of herniated disc patients following patient 
consent and Institutional Review Board (IRB) approval. Cells were cultured in T25 cell culture 
flasks and growth medium containing Alpha Minimum Essential Medium (αMEM), 10% fetal 
bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL fungizone.  
Lentiviral vectors were produced by previously described methods (Meng et al., 2012; Zhang et 
al., 2016). After reaching 40-60% confluence in cell culture flasks, cell numbers were visually 
estimated based upon apparent density and lentiviral vectors targeting each respective WNT-gene 
were added at a multiplicity of infection (MOI) of 2 in αMEM containing 10% FBS, and 1× 
Protamine Sulfate (PS) and incubated at 37°C under 21% oxygen in a cell culture incubator for 24 
h. After 24 h, viral vector-containing medium was removed and normal growth medium was added 
for cell expansion. For CRISPR-Cas9 vectors, an additional selection for 4 days was performed 
with puromycin-enriched (1 ug/mL) selection culture media to kill non-transduced cells and 
increase efficiency. GFP expression, visualized by an Invitrogen™ EVOS™ FL Auto Imaging 
System (Thermo Fisher Scientific, Waltham, MA) at 24, 48, and 72 h, was used as a positive 
control for viral transduction. 
Cell proliferation 
To determine the proliferation index of each group, before cell expansion, NPCs were labeled with 
CellVue® Claret at 2×10-6 M for 5 min according to the manufacturer’s protocol (Sigma-Aldrich, 
St. Louis, MO). After six days of proliferation, expanded cells were collected and measured using 
a BD FACS LSRFORTESSA  flow cytometer (BD Biosciences, San Jose, CA). Twenty thousand 
events of each sample were collected using CellQuest Pro software (BD Biosciences); cell 
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proliferation index was analyzed using ModFit LT  version 3.1 (Verity Software House, 
Topsham, ME).  
Redifferentiation induction and evaluation 
Expanded cells (3×105) were centrifuged at 500 g for 5 min in a 15-mL polypropylene tube to 
form a pellet. After overnight incubation (day 0), the pellets were cultured in a serum-free 
chondrogenic medium consisting of high-glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM), 40 μg/mL proline, 100 nM dexamethasone, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 0.1 mM L-ascorbic acid-2-phosphate, and 1×ITS™ Premix (BD Biosciences) with 
the supplementation of 10 ng/mL transforming growth factor beta3 (TGFβ3) (PeproTech, Inc., 
Rocky Hill, NJ) in a 5% O2 incubator as long as 28 days. The pellets were evaluated for NPC 
redifferentiation using biochemical analysis and quantitative real-time polymerase chain reaction 
(qPCR). 
Representative pellets (n=4) were digested at 60°C for 4 h with 125 μg/mL papain in PBE buffer 
(100 mM phosphate, 10 mM ethylenediaminetetraacetic acid, pH 6.5) containing 10 mM cysteine. 
To quantify cell density, the amount of DNA in the papain digestion was measured using the 
QuantiT   PicoGreen® dsDNA assay kit (Life Technologies, Carlsbad, CA) with a CytoFluor® 
Series 4000 (Applied Biosystems, Foster City, CA). GAG was measured using dimethylmethylene 
blue (DMMB) dye and a Spectronic   BioMate   3 Spectrophotometer (Thermo Fisher Scientific) 
with bovine chondroitin sulfate (Sigma-Aldrich) as a standard.  
Total RNA was extracted from representative samples (n=4) using an RNase-free pestle in 
TRIzol® (Life Technologies). Two micrograms of mRNA were used for reverse transcriptase with 
High-Capacity cDNA Archive Kit (Applied Biosystems) at 37°C for 120 min. NPC 
 137 
 
redifferentiation related genes, type I collagen (COL1A1; Assay ID Hs00164004_m1), aggrecan 
(ACAN; Assay ID Hs00153936_m1), type II collagen (COL2A; Assay ID Hs00156568_m1), 
paired box 1 (PAX1; Assay ID Hs01071293_g1), and forkhead box F1 (FOXF1; Assay ID 
Hs00230962_m1) were customized by Applied Biosystems as part of their Custom TaqMan® 
Gene Expression Assays. Wnt signals were also evaluated using qPCR (WNT3A; Assay ID 
Hs00263977_m1, WNT5A; Assay ID Hs00998537_m1, and WNT11; Assay ID Hs00182986_m1) 
following cell expansion of virally transduced cells and after NP redifferentiation. 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH; Assay ID Hs02758991_g1) was carried 
out as the endogenous control gene. TaqMan® real-time PCR was performed with iCycler iQ   
Multi Color Real-Time PCR Detection and calculated by computer software (Perkin-Elmer, 
Wellesley, MA). Relative transcript levels were calculated as χ=2-∆∆Ct, in which ∆∆Ct=∆E-∆C, 
∆E=Ctexp-CtGAPDH, and ∆C=Ctct1-CtGAPDH. 
 
 
 
 
 
 
 
 
 138 
 
Statistical analysis 
Analysis of variance (ANOVA) analysis with pairwise comparison and t-test was used to compare 
measurements between different groups. All statistical analyses were performed with SPSS 13.0 
statistical software (SPSS Inc., Chicago, IL). p values less than 0.05 were considered statistically 
significant. 
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Results 
Lentiviral vectors effectively overexpressed WNT genes 
The lentiviral vectors were successfully transduced with protamine sulfate (PS) supplemented in 
culture media to increase transduction efficiency, which did not cause any observable differences 
in cell morphology or proliferation. The successful transduction of a GFP-containing vector in 
NPCs was demonstrated using immunofluorescence with a greater intensity of green color in the 
transduced cells at the MOI of five versus one (Fig. 1A). MOI of two was chosen for this study 
given the notable success in WNT gene expression in the MOI of one group and a potential 
reduction of cell death and proliferation capacity. Our qPCR result suggested that both PS 
supplementation and GFP transduction did not result in WNT gene expression and either WNT 
gene transduction did not cause a significant change of another WNT signal (Fig. 1B). A successful 
transduction of three WNT signals (WNT3A, WNT5A, and WNT11) was verified in both 
expanded cells (Fig. 1B) and the following redifferentiation induced pellets for up to 28 days (Fig. 
1C). WNT3A-OE was the only group that expressed any detectable WNT3A mRNA at each 
timepoint (Fig. 1C). Similarly, WNT5A-OE expressed 500-2800-fold greater WNT5A mRNA 
compared to controls (CNTL) during redifferentiation (Fig. 1C), and WNT11-OE expressed 
upwards of 25,000-fold greater WNT11 mRNA (Fig. 1C) at each timepoint during 
redifferentiation induction in pellet culture versus CNTL. 
Overexpression of WNT3A enhanced NPC proliferation 
Proliferation Index (PI) and generational analysis of stained NPCs by flow cytometry (Fig. 2) 
revealed that WNT3A-OE (PI = 10.65) caused the greatest increase in proliferation versus CNTL 
(PI = 6.70). WNT5A-OE (PI = 3.74) proliferated significantly less than CNTL and WNT11-OE 
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(PI = 7.48) was slightly elevated compared to CNTL. Also, CNTL, WNT5A-OE, and WNT11-OE 
predominantly proliferated to the third generation, wheareas WNT3A-OE produced a peak in the 
fourth generation. 
Overexpression of noncanonical WNT signals promoted NPC redifferentiation 
After viral transduction and cell expansion, all WNT-OE groups significantly decreased COL1A1 
expression versus CNTL; however, in the condensation at day 0 of redifferentiation, all WNT 
transduced groups exhibited a significant increase of COL1A1 expression, which later attenuated 
for up to 28 days (Fig. 3A). For NPC markers, despite a lower expression in cell expansion phase, 
PAX1 expression significantly increased in day 0 pellets of all WNT-OE cells but not in the 
following chondrogenic induced pellets except the WNT11-OE group at day 11 (Fig. 3B). Other 
marker genes, such as FOXF1 (Fig. 3C) and COL2A1 (Fig. 3D), were detected a significant 
increase in both WNT5A-OE and WNT11-OE groups at day 11 but not at day 28. Interestingly, 
the WNT11-OE group also exhibited a significant increase of FOXF1 and COL2A1 in day 0 pellets 
(Fig. 3C/D), indicating that noncanonical WNT signals, particularly WNT11, play a critical role 
in the early stage of NPC redifferentiation. This finding was further corroborated by ACAN 
expression in NPCs, which significantly increased in all WNT-OE groups at all pellet culture time 
points except no significant change at day 28 in the WNT11-OE group (Fig. 3E).   
Despite no visible difference in the size of all pellet groups (Fig. 4A), the overexpression of 
noncanonical signals, WNT5A-OE and WNT11-OE, exhibited significantly increased GAG/DNA 
ratios at day 28 versus CNTL, but not in canonical WNT3A-OE (Fig. 4B). Similarly, WNT5A-OE 
exhibited the greatest raw GAG content per pellet at day 28 (Fig. 4C) versus CNTL. Interestingly, 
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WNT3A-OE NPCs increased their DNA ratio versus CNTL at days 11 and 28 and conversely, 
WNT11-OE significantly decreased DNA content at these same time points (Fig. 4C). 
CRISPR-Cas9 lentiviral transduction knocked out WNT genes 
After viral transduction of NPCs with CRISPR-Cas9 vectors, guided by sgRNA sequences 
targeting WNT3A, WNT5A, and WNT11 exons, selection was conducted via puromycin 
supplementation for the knockout (KO) groups. Three different lentiviral vectors designed in this 
study for each WNT gene, targeting different exon sequences, were compared for the most 
effective KO effect in NPCs. For the selected WNT-KO groups (WNT3A-1, WNT5A-3, and 
WNT11-2), each respective KO target was found most significantly diminished in both expanded 
cells and redifferentiation induced pellets compared to CNTL throughout the study. After 
determining WNT3A expression was significantly decreased (nondetectable, ND) in WNT-KO 
versus CNTL in NPCs following transduction in cell samples and redifferentiation pellets (Fig. 
5A). WNT5A-KO expressed a nearly 10- to 40-fold decrease of WNT5A mRNA versus CNTL at 
each time point during redifferentiation (Fig. 5B). Similarly, WNT11-KO exhibited 5-fold or 
greater decrease of WNT11 expression compared to CNTL at day 0, day 11, and day 28 of 
redifferentiation induction (Fig. 5C). 
Knockout of noncanonical WNT signals decreased redifferentiation capacity 
All WNT-KO groups exhibited increased COL1A1 expression in cell samples following expansion 
(Fig. 6A). WNT5A-KO and WNT11-KO most significantly increased COL1A1 mRNA expression 
at day 0 versus CNTL; however, this expression was significantly attenuated at day 11 of 
redifferentiation but not in WNT3A-KO (Fig. 6A). Although the knockout of each respective WNT 
gene led to significant decreases in PAX1 (Fig. 6B) and FOXF1 (Fig. 6C) expression in all groups 
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except an increase of PAX1 in WNT5A-KO at day 11 (Fig. 6B), COL2A1 expression was 
significantly decreased versus CNTL in both WNT5A-KO and WNT11-KO groups at cell samples 
and day 28 pellets, but not with the knockout of WNT3A gene (Fig. 6D). A similar trend was 
observed in ACAN expression, with both WNT5A-KO and WNT11-KO most significantly 
(approximately 5-fold) decreased versus CTNL (Fig. 6E). 
Both WNT5A-KO and WNT11-KO groups exhibited a small size of pellets compared to CNTL 
(Fig. 7A). This finding was corroborated with biochemical analysis data, in which both WNT5A-
KO and WNT11-KO groups displayed a dramatically decreased GAG/DNA ratios (Fig. 7B) and 
GAG amounts per pellet (Fig. 7C) as well as lower DNA ratios except no significant difference of 
WNT11-KO versus CNTL at day 28 (Fig. 7D). Intriguingly, the WNT3A-KO group exhibited a 
significantly decrease of GAG/DNA ratio at day 28 rather than day 11 (Fig. 7B); however, both 
GAG amount per pellet (Fig. 7C) and DNA ratio (Fig. 7D) of the WNT3A-KO group had no 
significant difference compared to CNTL. 
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Discussion 
Although current literature has suggested roles of Wnt signaling in the intervertebral disc, few 
studies have determined roles for specific Wnt signals, particularly the potential roles of Wnt3A 
in NPC redifferentiation. In this study, we sought to directly compare the expression of specific 
Wnt signals to the redifferentiation of NPCs through lentiviral-mediated transduction. Following 
transduction, the results of this study conclude that the virally-mediated overexpression or 
knockout of noncanonical Wnt signals, Wnt5A and Wnt11, were much more influential in their 
collective impact on the redifferentiation gene expression than the effect of CRISPR-Cas9-
mediated knockout of canonical (WNT3A) expression in human NPCs. To our knowledge, this 
study is the first in directly comparing the influences of WNT3A, WNT5A, and WNT11 gene 
expression in the redifferentiation of human NPCs.  
We found that WNT3A-OE was the only group during WNT-gene overexpression that expressed 
any detectable WNT3A mRNA at each timepoint. In previous preliminary experiments, WNT3A 
gene expression was consistently lower than other wnt signals, or usually undetectable by qPCR 
(not shown). This result was similarly reported by Smolders et al., who reported in a degenerative 
disc study that “gene expression of the Wnt3a was undetectable in all groups” (Smolders et al., 
2013). Despite generally less robust expression when compared to noncanonical signals, in this 
study, WNT3A overexpression increased both proliferation index and peak generation number 
compared to other groups and was the only group to significantly increase DNA content during 
redifferentiation. These results seem to be consistent with other reports. Narcisi and colleagues, 
reported that Wnt3A has increased proliferation in MSCs (Narcisi et al., 2015), and similar results 
have been reported in which Wnt3A has been shown to promote the proliferation of pancreatic 
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stem cells (He et al., 2015), neural stem cells (Yang et al., 2014), bone sarcoma cells (Chen et al., 
2015), and HEK293T cells (Reischmann et al., 2015).  
As expected, the knockout of all WNT genes led to significantly decreased PAX1 and FOXF1 
expression, markers suggested to be representative of the healthy, mature nucleus pulposus 
phenotype (Minogue et al., 2010; Thorpe et al., 2016). Interestingly, the overexpression of 
WNT5A and WNT11 genes increased PAX1 expression by five-fold and nine-fold, respectively, 
versus control at day 0 of redifferentiation; however, this effect was attenuated by day 28. 
Similarly, WNT11-OE was the only group to significantly increase FOXF1 expression (6.5-fold) 
at the day 0 time point, while the other groups were significantly decreased versus CNTL, further 
suggesting WNT11’s role as an early regulator of NPC redifferentiation. At day 11, noncanonical 
WNT overexpression (WNT5A-OE and WNT11-OE) were both significantly increased versus 
CNTL for FOXF1 expression, but not WNT3A-OE. By day 28, these effects were abolished, and 
in fact, significantly decreased for noncanonical signal overexpression groups. Overall, as 
expected, WNT5A-OE and WNT11-OE produced more dramatic changes in ACAN mRNA versus 
CNTL than WNT3A-OE in early to middle-stage of redifferentiation.  
 Cumulative trends in these redifferentiation data seem to suggest that, early in redifferentiation, 
noncanonical signals can increase markers representative of mature NPCs. This trend does not 
remain consistent through day 28, however, and is likely due to the persistent overexpression of 
these Wnt signals, as they are more tightly regulated to increase and decrease appropriately in non-
transduced cells. This same early to middle-stage expression trend is apparent in COL2A1 
expression of WNT-overexpressing NPCs, particularly notable for WNT5A and WNT11 signals. 
WNT11-OE seems most influential in early NPC redifferentiation. This notion of stage-specific 
Wnt regulation of differentiation is supported by evidence from a study by Sinha and colleagues, 
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where they implicated WNT11 as an early expression gene in tissue development and 
differentiation (Sinha et al., 2015). In another study investigating mouse limb development, both 
Wnt5A and Wnt11 were implicated in early limb development and chondrogenesis, whereas 
Wnt3A was undetectable throughout (Witte et al., 2009). Another recent study investigating the 
role of miRNA-410 in MSCs found that miRNA-410, a promoter of chondrogenesis, slightly 
increased at day 15 of differentiation and significantly elevated at day 25. They report that this 
miRNA also pairs with Wnt3A mRNA and that increases in miRNA-410 negatively correlates 
with Wnt3A protein expression (Zhang et al., 2017b). Further studies are needed to investigate the 
stage-specific expression of Wnt signals and Wnt agonists/regulators, and could provide more 
detailed evidence for Wnt regulation in differentiation. 
Despite the positive results in redifferentiation gene expression, we recognize the limitations of 
this study. It remains to be determined whether WNT5A or WNT11 are individually superior to 
one another or to combination gene therapy, which was not clearly distinguishable in our results. 
Future studies which more thoroughly evaluate other downstream targets of both canonical and 
noncanonical Wnt signals, such as axin, cyclin D1, APC, and β-catenin could provide further 
evidence to support the findings of this study and in the redifferentiation of human nucleus 
pulposus cells. Furthermore, a study which uses both overexpression and targeted knockout of 
WNT genes at various stages of differentiation (early, middle, and late) in the same NPCs could 
more accurately and completely elucidate the stage-specificity of Wnt signals in NPC 
redifferentiation, rather than the relatively static methods of genetic manipulation used in our 
study. This design is especially important when consideration is given to the natural expression 
patterns of both canonical and noncanonical Wnt signals during differentiation. 
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Although many studies aim to highlight the apparent differences between canonical and 
noncanonical Wnt signals for cell differentiation, it is important to recognize the interplay, 
crosstalk, and potential advantageous utilization of each of the Wnt signaling pathways. 
Interestingly, Hsu and Huang reported that Wnt5A-mediated and Wnt3A-mediated MSC 
differentiation could each be directed based on distinct, three-dimensional substrate and culture 
environments (Hsu & Huang, 2013), and raises new concerns for NPC expansion and 
intervertebral disc tissue engineering. A recent study by Alok and colleagues has suggested that 
Wnt signals, particularly those of the noncanonical variety, can synergistically activate β-catenin 
in several cell types as a combinatory mechanism regulating wnt signaling (Alok et al., 2017). It 
is possible that noncanonical signals in this study, WNT5A and WNT11, can work together in a 
similar, potentially stage-specific manner during redifferentiation of nucleus pulposus cells. This 
concept of stage-specific expression has been recently suggested in human SDSCs during their 
expansion in the presence of fibroblast growth factor 2 or chondrogenic differentiation (Pizzute et 
al., 2016). Another recent study has provided evidence that several noncanonical signals in the 
liver, including WNT5A, can act as antagonists to Wnt3A-induced β-catenin/TCF signaling to 
promote tissue differentiation, suggesting noncanonical signals can “fine-tune” the effects of 
canonical Wnt signaling (Fan et al., 2017). Additionally, studies that can uncover further 
regulatory intricacies and the crosstalk between canonical and noncanonical wnt pathways would 
be beneficial; for example, recent studies have demonstrated canonical suppression can occur 
through PTK7 (Berger et al., 2017), as well as crosstalk with the Smad/TGF-Beta pathway 
(Webber et al., 2016), known to promote differentiation. Overall, it seems likely that both 
canonical and noncanonical Wnt signals are significantly involved in the redifferentiation of 
human NPCs; however, based on our results, it seems that WNT3A can potentially contribute to 
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NPC proliferation, whereas noncanonical signals promote early redifferentiation. In conclusion, 
changes in Wnt signal expression can modulate the redifferentiation of human NPCs. It may be 
most effective to promote noncanonical Wnt pathway activation through WNT5A and WNT11 
than canonical WNT3A. Each signal represents potential targets for NPC redifferentiation and for 
future therapeutic strategies aiming to improve NP tissue regeneration. 
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Figure 3.1 
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Figure 3.1: Overexpression of WNT genes during redifferentiation. Following transduction, 
GFP-expression was visualized by immunofluorescence (A) and by qPCR (B) in cell samples. 
After pellet formation, samples were analyzed at each timepoint (Day 0, 11, & 28) of 
redifferentiation via qPCR for WNT3A (A), WNT5A (B), and WNT11 (C) mRNA expression. 
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Figure 3.2 
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Figure 3.2: Proliferation of WNT-KO cells. Flow cytometry generational analysis of claret red 
proliferation for CNTL, WNT3A-KO, WNT5A-KO, and WNT11-KO after 5 days in culture. 
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Figure 3.3 
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Figure 3.3 Redifferentiation gene expression in WNT-OE. Expression of COL1A1 (A), PAX1 
(B), FOXF1 (C), COL2A1 (D), and ACAN (E) mRNA in pellets overexpressing WNT genes across 
each timepoint (Day 0, 11, & 28) of redifferentiation. 
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Figure 3.4 
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Figure 3.4: Redifferentiation of WNT-OE pellets. Representative pellets for each group at Day 
11 and Day 28 of redifferentiation (A), GAG/DNA (B), DNA ratio (C), and GAG content (D) were 
analyzed. 
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Figure 3.5 
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Figure 3.5 Knockout of WNT genes. Following transduction, cell expansion, and pellet 
formation, samples were analyzed in cell samples and at each timepoint ( Day 0, 11, & 28) of 
redifferentiation for WNT3A (A), WNT5A (B), and WNT11 (C) mRNA expression for each set 
of respective knockout vectors. 
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Figure 3.6 
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Figure 3.6: Redifferentiation gene expression in WNT-KO. Expression of COL1A1 (A), PAX1 
(B), FOXF1 (C), COL2A1 (D), and ACAN (E) mRNA in pellets knocked out for WNT genes across 
each timepoint (Day 0, 11, & 28) of redifferentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 169 
 
Figure 3.7 
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Figure 3.7: Redifferentiation of WNT-KO pellets. Representative pellets for each group at 
Day 11 and Day 28 of redifferentiation (A), GAG/DNA (B), DNA ratio (C), and GAG content 
(D) were analyzed. 
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Abstract 
BACKGROUND: After herniation occurs, the intervertebral disc begins a progressive 
degenerative process where the inner nucleus pulposus (NP) tissue is compromised, failing to 
regenerate on its own if left untreated. Current treatment strategies typically focus on pain 
management rather than regeneration of the degenerated discs.  
PURPOSE: An attractive strategy for disc regeneration and repair is autologous NP cell expansion 
and ultimately tissue repair, for which, unfortunately, replicative senescence is a significant hurdle. 
Recent studies indicate that preconditioning strategies, including pretreatment with fibroblast 
growth factor 2 (FGF2) supplementation, hypoxia (HYPO), or decellularized extracellular matrix 
(DECM), can promote expanded cell based tissue regeneration. However, it is unknown whether 
variability exists in NP cells from herniated disc donors in response to varied preconditioning 
strategies. This study sought to determine the impact of preconditioning strategies on NP cells. We 
also collected preliminary data for determining the correlation between the severity of disc 
degeneration (clinical data) and potential NP regeneration (biological performance).  
STUDY DESIGN: This study is a laboratory investigation.  
METHODS: NP cells were harvested from two representative herniated disc patients with 
different degenerative severity. The cells subjected to preconditioning treatments including FGF2 
supplementation, HYPO, DECM expansion, or plastic expansion were evaluated and their 
proliferation and redifferentiation potentials were compared.  
RESULTS: NP cells harvested from donors with both moderately degenerated and severely 
degenerated discs increased their proliferative potential and decreased their CD95 expression in 
response to both FGF2 and DECM preconditioning. Donor cells from moderately degenerated 
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discs increased redifferentiation potential with FGF2 and DECM treatments characterized by 
increased glycosaminoglycan (GAG) deposition, pellet size, and redifferentiation gene expression 
following redifferentiation induction. Interestingly, large discrepancies were found in donor disc 
cells upon FGF2 preconditioning between the two grades of degeneration.  
CONCLUSIONS: Our results suggest that specific preconditioning strategies unequally impact 
redifferentiation of NP cells from human herniated discs. We also found that NP cells from 
moderately degenerated discs had a better redifferentiation capacity than those from severely 
degenerated discs in response to preconditioning treatment. This finding raises new questions that 
need to be further validated with large sample size.  
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Introduction 
Low back pain represents a significant worldwide health and financial burden and its occurrence 
is projected to substantially increase over the next several decades [1]. In fact, musculoskeletal 
pain has been reported to affect one in four adults and is the most common cause of physical 
disability and long-term pain [2]. Nucleus pulposus (NP) tissue, located at the innermost space of 
each intervertebral disc, is composed of NP cells surrounded by their proteoglycan and collagen 
rich, well-hydrated extracellular matrix (ECM). In addition to NP’s functional responsibilities as 
part of the disc anatomy, including compressive force resistance and shock absorption, the NP 
ECM helps to nourish NP cells and maintain disc homeostasis [3,4]. When NP ECM is lost due to 
disc herniation, aging, or degeneration, the disc can be significantly compromised. Once 
degeneration occurs, it is difficult to regenerate NP tissue [5], in part due to the slow turnover rates 
of some major NP matrix macromolecules which further compromises the disc’s structural 
integrity [4]. 
In order to combat the problems surrounding degenerative disc disease and herniation repairs, 
autologous NP cell-based therapies have gained increasing attention [6,7]. Hegewald and 
colleagues compared cells from the NP compartment with herniated disc tissue and found that the 
cells from herniated disc tissue demonstrated a weaker redifferentiation process in a three-
dimensional (3D) culture system [8]. By culturing NP cells harvested from the patient, in vitro 
expansion strategies can produce a large number of cells for therapeutic applications; however, 
these strategies present their own set of challenges, such as replicative senescence [9] and 
inflammation [10]. Therefore, rejuvenation of herniated disc cells through preconditioning is of 
great importance so that in vitro cell expansion may offer a valuable opportunity to achieve a large, 
sustainable cell population while simultaneously improving the NP cells’ regenerative capacity 
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[11,12]. In this study, we sought to determine whether variability existed in NP cells from herniated 
disc donors in response to independent preconditioning expansion strategies including hypoxic 
culture (5% O2), decellularized ECM (DECM), fibroblast growth factor 2 (FGF2) 
supplementation, and plastic monolayer culture. Furthermore, we wanted to collect preliminary 
data for future determination of the correlation between the severity of disc degeneration and 
potential NP regeneration.   
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Materials and Methods 
Preparation of ECM-Coated Flasks 
Plastic cell culture flasks were prepared as previously described [13]. Briefly, flasks were pre-
coated with 0.2% gelatin (Sigma-Aldrich, St. Louis, MO) at 37°C for 1 h and seeded with passage 
4 human adipose stem cells (Zen-Bio, Inc., Research Triangle Park, NC) at 6000 cells per cm2. 
After cells reached approximately 90% confluence, 250 μM of L-ascorbic acid-2-phosphate (Wako 
Chemicals USA, Inc., Richmond, VA) was added for 10 days. The deposited ECM was incubated 
with 0.5% Triton X-100 containing 20 mM ammonium hydroxide at 37°C for 5 min to remove the 
cells; DECM was stored at 4°C in phosphate buffered saline (PBS) containing 100 U/mL 
penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL fungizone until use. 
Cell Culture, Proliferation Analysis, and Immune Marker 
Human adult NP cells were obtained from the tissues of herniated disc patients (32-year-old male 
and 35-year-old female, no history of smoking, cardiac disease, or diabetes) following Institutional 
Review Board (IRB) approval and patient consent. Cells were cultured in growth medium 
containing Alpha Minimum Essential Medium (αMEM), 10% fetal bovine serum (FBS), 100 
U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL fungizone. Passage 3 NP cells from a 
grade II moderately degenerated (M-D) and grade IV severely degenerated (S-D) disc donors, 
respectively, were seeded onto four substrates with different conditions: plastic flasks (Control or 
“CNTL”) only; plastic flasks with 10 ng/mL of FGF2 (PeproTech Inc., Rocky Hill, NJ) (“FGF2”); 
DECM-coated cell culture flasks (“DECM”); and plastic flasks in a 5% O2 cell culture incubator 
(hypoxia or “HYPO”). All groups except the HYPO group were cultured in 21% O2 (normoxia) 
and 5% CO2 in a 37°C incubator during the cell expansion phase. 
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To determine proliferation index, before cell expansion, NP cells were labeled with CellVue® 
Claret at 2×10-6 M for 5 min according to the manufacturer’s protocol (Sigma-Aldrich). After six 
days of proliferation, expanded cells were collected and measured using a BD FACS 
LSRFORTESSA  flow cytometer (BD Biosciences, San Jose, CA). Twenty thousand events of 
each sample were collected using CellQuest Pro software (BD Biosciences); cell proliferation 
index was analyzed using ModFit LT  version 3.1 (Verity Software House, Topsham, ME).  
The following primary antibodies were used in flow cytometry analysis to detect expanded NP 
cell immunophenotype profiles: fluorescein isothiocyanate (FITC) conjugated CD95 (BioLegend, 
San Diego, CA), Phycoerythrin (PE) conjugated HLA-DR [major histocompatibility complex 
(MHC) class II] (BioLegend), and isotype-matched IgGs (Beckman Coulter, Fullerton, CA). 
Samples (n=3) of each 2×105 expanded cells were incubated on ice in cold PBS containing 0.1% 
Chrom-Pure Human IgG whole molecule (Jackson ImmunoResearch Laboratories, West Grove, 
PA) and 1% NaN3 (Sigma-Aldrich) for 30 min, followed by incubation in the dark in the primary 
antibody for 30 min. Fluorescence signals were analyzed using a BD FACS LSRFORTESSA  
flow cytometer and FCS Express 4 software package (De Novo Software, Los Angeles, CA). 
Redifferentiation Induction and Evaluation 
Expanded cells (3×105) were centrifuged at 500 g for 5 min in a 15-mL polypropylene tube to 
form a pellet. After overnight incubation (day 0), the pellets were cultured in a serum-free 
chondrogenic medium consisting of high-glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM), 40 μg/mL proline, 100 nM dexamethasone, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 0.1 mM L-ascorbic acid-2-phosphate, and 1×ITS™ Premix (BD Biosciences) with 
the supplementation of 10 ng/mL transforming growth factor beta3 (TGFβ3, PeproTech, Inc.) in a 
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5% O2 incubator as long as 21 days. The pellets were evaluated for NP cell redifferentiation using 
pellet size, biochemical analysis, and quantitative real-time polymerase chain reaction (qPCR). 
Representative pellets (n=4) were digested at 60°C for 4 h with 125 μg/mL papain in PBE buffer 
(100 mM phosphate, 10 mM ethylenediaminetetraacetic acid, pH 6.5) containing 10 mM cysteine. 
To quantify cell density, the amount of DNA in the papain digestion was measured using the 
QuantiT   PicoGreen® dsDNA assay kit (Life Technologies, Carlsbad, CA) with a CytoFluor® 
Series 4000 (Applied Biosystems, Foster City, CA). GAG was measured using dimethylmethylene 
blue (DMMB) dye and a Spectronic   BioMate   3 Spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA) with bovine chondroitin sulfate (Sigma-Aldrich) as a standard.  
Total RNA was extracted from representative samples (n=4) using an RNase-free pestle in 
TRIzol® (Life Technologies). Two micrograms of mRNA were used for reverse transcriptase with 
High-Capacity cDNA Archive Kit (Applied Biosystems) at 37°C for 120 min. NP cell 
redifferentiation related genes, type I collagen (COL1A1) (Assay ID Hs00164004_m1), aggrecan 
(ACAN) (Assay ID AIQJAP5), type II collagen (COL2A1) (Assay ID Hs00156568_m1), and type 
X collagen (COL10A1) (Assay ID Hs00166657), were customized by Applied Biosystems as part 
of their Custom TaqMan® Gene Expression Assays. Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) (Assay ID Hs02758991_g1) was carried out as the endogenous control gene. TaqMan® 
real-time PCR was performed with the iCycler iQ   Multi Color Real-Time PCR Detection and 
calculated by computer software (Perkin-Elmer, Wellesley, MA). Relative transcript levels were 
calculated as χ=2-∆∆Ct, in which ∆∆Ct=∆E-∆C, ∆E=Ctexp-CtGAPDH, and ∆C=Ctct1-
CtGAPDH. 
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Statistical Analysis 
Analysis of variance (ANOVA) with pairwise comparison and t-test was used to compare 
measurements between different groups. All statistical analyses were performed with SPSS 13.0 
statistical software (SPSS Inc., Chicago, IL). p values less than 0.05 were considered statistically 
significant. 
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Results 
NP Cells from Herniated Discs with Varied Degeneration Exhibited Dissimilar Characteristics 
Spinal magnetic resonance imaging (MRI) of herniated disc patients prior to surgery and tissue 
collection revealed different degrees of disc degeneration (Fig. 1). M-D disc degeneration was 
deemed Grade II (moderately severe), while the S-D disc degeneration was deemed Grade IV 
(most severe). M-D disc and herniated NP tissue (L4-L5) appeared lighter in color with 
comparable density to the adjacent discs compared to S-D discs and maintained a reasonably 
distinct border between the annulus fibrosus (AF) and NP tissues. The S-D disc and herniated NP 
tissue (L5-S1) appeared to be a solid black color throughout indicating a loss of the AF and NP 
border and more degeneration. In culture, M-D disc cells divided and proliferated much quicker 
than S-D disc cells when expanded on plastic alone, with M-D disc cells exhibiting smaller, less 
flat, fibroblast-like morphology versus the flatter and larger S-D disc cells (not shown). 
DECM and FGF2 Preconditioning Elicited Immunophenotypic Changes 
HYPO preconditioning did not elicit a dramatic decrease in CD95 (Fas/APO-1) expression in 
either M-D or S-D disc cells versus control (~2% reduction for each) (Fig. 2A/B/D). Interestingly, 
both FGF2 and DECM preconditioning significantly decreased the percentage of CD95(+) cells 
from 89.55% (control) to 67.63% with FGF2 treatment, to 69.21% with DECM expansion in M-
D disc cells; FGF2 and DECM preconditioning also significantly decreased the percentage of 
CD95(+) S-D disc cells from 67.98% (control) to 21.04% with FGF2 treatment, to 43.35% with 
DECM expansion (Fig. 2A/B/D). Both M-D and S-D disc cell populations were HLA-DR 
negative, even after DECM treatment (Fig. 2C). 
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DECM Preconditioning Enhanced M-D Proliferation and Redifferentiation 
The proliferation indices measured by flow cytometry were increased by HYPO and FGF2 
preconditioning versus plastic CNTL in M-D disc cells, but was most pronounced in the DECM 
group (Fig. 3). Pellet morphology depicted the largest pellets in the DECM and FGF2 groups for 
M-D disc cell pellets (Fig. 4). In addition to cell proliferation and pellet sizes, DECM contributed 
to the greatest NP redifferentiation of expanded cells as evidenced by biochemistry and qPCR 
assays. M-D disc cells produced the greatest GAG content per pellet and greatest GAG/DNA ratio 
at day 10 and day 21 of redifferentiation (Fig. 5A/C). At day 21, the DECM group was the only 
group significantly increased versus plastic CNTL for GAG content per pellet (p=0.0089), DNA 
ratio (p=0.0168), and GAG/DNA (p=0.0223) (Fig. 5A-C). Although HYPO preconditioning 
produced modest increases in proliferation, it failed to increase GAG content per pellet (p=0.3035), 
DNA ratio (p=0.0802), or GAG/DNA versus plastic CNTL (p=0.9122) (Fig. 5A-C). Both DECM 
and FGF2 produced the most significant decrease in COL1A1 (p=0.0003 and p=0.0003, 
respectively) and increase in ACAN mRNA expression (p=0.0011 and p=0.0241, respectively). 
DECM preconditioning led to unmatched increases in COL2A1 mRNA expression, at 3.5-fold 
greater than plastic CNTL (p=0.0021) (Fig. 6A-C). 
Preconditioning Strategies Failed to Rejuvenate S-D NP Cells 
Although FGF2 and DECM, but not HYPO preconditioning, were able to increase cell 
proliferation versus plastic CNTL (Fig. 2), the S-D disc cells did not increase their redifferentiation 
capacity with any preconditioning treatments. At day 10 of redifferentiation, FGF2 and DECM 
treatments in S-D disc cells both produced the smallest pellets of any group (Fig. 4). Additionally, 
at Day 21, FGF2 pellets seemed to decrease further in size (Fig. 4), and was accompanied by a 
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decrease in DNA ratio (p=0.0000) (Fig. 5E), indicative of a decrease in cell viability; GAG content 
per pellet (p=0.0000) and GAG/DNA (p=0.0000) also decreased, indicative of a decrease in 
deposited matrix, versus plastic CNTL (Fig. 5D/F). This finding is dissimilar to the results obtained 
from M-D disc cells. None of the preconditioning treatments significantly increased GAG content 
per pellet or GAG/DNA versus plastic CNTL (Fig. 5D/F). DNA ratio was only increased in the 
HYPO (p=0.0224) and DECM groups (p=0.0022) at Day 21 (Fig. 5E). Despite preconditioning 
interventions, COL1A1 mRNA was significantly increased in all groups versus plastic CNTL 
(p=0.0055, p=0.0002, and p=0.0174, respectively) (Fig. 6E) and ACAN mRNA was decreased in 
the DECM and FGF2 groups (p=0.0377 and p=0.0010, respectively) (Fig. 6F). Despite these 
failures in increased redifferentiation capacity, COL2A1 expression was significantly increased in 
the HYPO and DECM groups versus plastic CNTL (p=0.0259 and p=0.0048, respectively) (Fig. 
6G). 
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Discussion 
In the current study, we wanted to determine whether there were any discrepancies in the responses 
of NP cells harvested from donors with varying degrees of disc degeneration to FGF2, DECM, or 
HYPO preconditioning during expansion and redifferentiation in vitro. We found that 
preconditioning strategies unequally impacted regeneration of NP cells from human herniated 
discs: cells harvested from a moderately degenerated NP donor responded well to DECM and 
FGF2 treatments, but cells from a severely degenerated donor were not successfully rejuvenated 
and redifferentiated. The present study suggests that specific expansion methods may be more 
appropriate for one patient versus another, supporting the call for attention to personalized medical 
interventions and cell therapies based upon initial medical diagnoses and assessments of NP 
degeneration.  Additionally, it may be necessary for alternative therapies to be developed for the 
expansion and rejuvenation of severely degenerated NP tissues. 
In order to provide preliminary data for determining the correlation between disc degeneration 
clinical data and isolated disc cell biological performance, two representative disc degeneration 
models, Grade II (moderately severe) and Grade IV (most severe), were used and defined based 
on well-established T2-MRI grading classifications [14,15] with the assistance of orthopaedic 
spine surgeons. A previous report suggested that young and healthy DECM is a promising cell 
expansion system for stem cell rejuvenation [16]; however, an allogeneic source of DECM from 
young and healthy donors, an ideal and commercializable approach, might cause immune concerns 
for the expanded cells after transplantation. This concern may diminish due to this study’s finding 
that both moderately and severely degenerated NP cells remained HLA-DR negative after 
pretreatment with allogeneic DECM, in line with the results from another human degenerated disc 
study [17] and human synovium-derived stem cell (SDSC) study [18].  
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Previous studies have implicated CD95 (Fas receptor) in degenerated and herniated human discs 
[19-21], in disc immune privilege [22,23], and as an important regulator of caspase-mediated cell 
death via apoptosis [24,25]. Furthermore, it has been reported that CD95 expression is greater in 
NP from non-contained versus contained disc herniations and, after herniation occurs, disc cells 
may undergo Fas-mediated apoptosis [20]. In the current study, both FGF2 and DECM 
preconditioning resulted in a decrease in the percentage of CD95(+) cells in both moderately and 
severely degenerated disc cells, but not with HYPO preconditioning. Given the known role of 
CD95 in Fas-mediated apoptosis, this finding suggests that certain preconditioning methods, 
particularly DECM and FGF2 treatments, could potentially rejuvenate NP cells to a younger, less 
immunogenic phenotype.  
Our results indicated that, compared with severely degenerated disc cells, cell viability after 21 
days of redifferentiation induction was not affected by HYPO preconditioning in moderately 
degenerated disc cells, as evidenced by no significant differences in the DNA ratio versus control. 
We also found that both moderately and severely degenerated disc cells were not successfully 
induced for redifferentiation by HYPO preconditioning except for an increase of the COL2A1 
mRNA in the pellets from severely degenerated disc cells after 21-day induction. Our finding is in 
line with a recent study investigating the hypoxic culture of human NP cells; Yang and colleagues 
found that NP cells expanded under 21% oxygen and then later cultured in hypoxia (3.5% oxygen) 
could only be partially “rescued” to increase COL2A1 and ACAN expression versus cells initially 
cultured under 3.5% oxygen exclusively [26]. Despite minimal benefits from HYPO 
preconditioning alone, the combination with FGF2 and DECM exhibited the largest contribution 
in the rejuvenation of porcine SDSCs for both proliferation and chondrogenic potential [27]. Since 
hypoxia-induced factor 1 alpha (HIF1α) has been implicated in NP cell survival and ECM 
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homeostasis in HIF1α knockout mouse models [28], the elucidation of potential mechanisms 
underlying HYPO preconditioning becomes increasingly important in utilizing this strategy for 
cell-based disc regeneration.    
In this study, FGF2 treatment of 10 ng/mL during NP cell expansion modestly increased the 
proliferation indices, which was expected since FGF2 is a well-known mitogen and has been 
utilized in the expansion of NP cells in other studies [8]. This function of FGF2 might be explained 
by its anti-anabolic effects through the upregulation of NOGGIN via the mitogen-activated protein 
kinase (MAPK) and Nuclear Factor-KappaB (NF-κB) pathways [29]. Furthermore, we found that 
supplementation of FGF2 during expansion enhanced the redifferentiation capacity of moderately 
degenerated disc cells but not severely degenerated disc cells. Our results were partially supported 
by a previous investigation, in which FGF2 preconditioning had no effect on cell proliferation, but 
could restore COL2A1, SOX9 [SRY (Sex Determining Region Y)-Box 9], COMP (cartilage 
oligomeric matrix protein), CHAD (chondroadherin), and FMOD (fibromodulin) as well as 
maintain Smad2/3 mediated TGFβ signaling in expanded NP cells during subsequent incubation 
in alginate [30]. Another group found that the addition of 2 ng/mL of FGF2 during expansion 
resulted in a slight increase in proliferation of cervical disc cells harvested from both mildly and 
severely degenerated discs but FGF2 appeared to be insignificant in the redifferentiation process 
[17].  
Overall, NP cells from both donors benefited by DECM expansion versus other pretreatments in 
terms of proliferation and redifferentiation. These effects were more pronounced in the cells from 
the moderately degenerated donor than from the severely degenerated donor. This finding is 
consistent with previous reports, where NP cells expanded on an SDSC DECM increased 
proliferative and redifferentiation potential [31,32]. Interestingly, a recent study found that 
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increasing GAG synthesis and combatting degradation was an effective strategy in mildly 
degenerated, but not severely degenerated disc cells [33]. Although many studies have reported 
successful increases in NP redifferentiation with the use of biomaterial scaffolds and hydrogels, 
extensively reviewed by Priyadarshani and colleagues [34], more comparative research studies are 
needed, especially those investigating the differences between mildly and severely degenerated 
disc cells and their ability to undergo redifferentiation following 3D-expansion strategies.  
Disease pathology and donor specific responses should be considered when choosing appropriate 
cell expansion strategies for cell-based interventions. To our knowledge, this study is the first to 
evaluate and report preconditioning strategies using FGF2 and DECM expansion to decrease 
CD95 (Fas) expression in degenerated NP cells; additionally, this study provides direct comparison 
of several preconditioning strategies in a single controlled study. This study supports the need for 
personalized medicine based on disease pathology and assessment, as evidenced by the donor-
dependent responses to identical preconditioning stimuli. Based on the results from the current 
study, it seems that DECM and FGF2 could be beneficial treatments for NP cells obtained from 
patients with mildly to moderately degenerative intervertebral discs. Further investigation of disc 
degeneration and preconditioning responses is necessary to validate this hypothesis.   
For cell-based treatment interventions in both moderate and severe disc degeneration, clinicians 
should consider the degree of disc degeneration in choosing the most appropriate preconditioning 
strategy. Although this proof of principle study presents new data regarding preconditioning 
strategies for increasing disc cell proliferation and redifferentiation and decreasing CD95 
expression, there were recognized limitations in this study, which include the influence of the 
number of donor tissues, age, gender, herniated type, and disease duration. These limitations 
should be considered when designing future studies to investigate the correlation between the 
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severity of disc degeneration and potential NP regeneration. Ultimately, our goal is to be able to 
predict the regenerative potential of harvested disc cells at a radiological level due to its inherent 
relationship with intervertebral disc health. In the future, defining the correlation between clinical 
MRI data and the potential biological activity of patient NP cells could serve as a significant 
breakthrough from improving cell-based disc therapies.    
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Figure 4.1: 
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Figure 4.1: Patient MRIs. MRI T2 images from herniated disc patients (M-D and S-D) who 
served as representative NP cell donors in this study. The arrow points to the herniated discs.  
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Figure 4.2: 
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Figure 4.2: CD95 and HLA-DR expression of preconditioned NP cells. Following cell 
expansion under varied preconditioning approaches using hypoxia (HYPO), FGF2, and DECM 
with the plastic flask group as a control (CNTL), NP cells from two different severities of 
degenerated donor discs (M-D and S-D) were evaluated for CD95 (A-B) and HLA-DR (C) 
expression via flow cytometry, as well as percentages of CD95(+) NP cells for each treatment and 
donor (D). 
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Figure 4.3: 
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Figure 4.3: Proliferation analysis of expanded NP cells.  Following cell expansion and 
preconditioning, pre-stained NP cells from the donors (M-D and S-D) were evaluated for 
proliferation index by flow cytometry. 
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Figure 4.4: 
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Figure 4.4: NP cell pellet morphology and size following preconditioning expansion and 
redifferentiation induction. After preconditioning under HYPO, FGF2, and DECM, with the 
plastic flask group as a control (CNTL), cell pellets were subjected to redifferentiation media and 
harvested for evaluation at day 10 and day 21 from each preconditioning group. 
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Figure 4.5: 
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Fig. 4.5. Biochemical analysis of redifferentiated pellets. Glycosaminoglycan (GAG) and DNA 
contents were evaluated for M-D (A-C) and S-D (D-F) donors at day 0, 10, and 21 of pellet 
redifferentiation from each preconditioning group. Data are shown as average ± SD for n = 4.           
* indicates a statistical difference compared with the corresponding CNTL group (p<0.05). 
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Figure 4.6: 
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Figure 4.6: TaqMan® real-time PCR of redifferentiation pellets. M-D (A-D) and S-D (E-H) 
donor cell pellets were evaluated for COL1A1, ACAN, COL2A1, and COL10A1 mRNA 
expression for each preconditioning group. Data are shown as average ± SD for n = 4. * indicates 
a statistical difference compared with the corresponding CNTL group (p<0.05). 
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Abstract 
Preconditioning of human cells and the use of three-dimensional (3D), biologically-derived 
substrates to expand them has gained attention in recent years, with the goal of safely increasing 
cell yield to obtain a healthy cell population. This goal is especially important in the 
preconditioning of nucleus pulposus cells (NPCs) of the intervertebral disc (IVD), because their 
use in cell-based regenerative therapies is generally limited by cell number and poor regenerative 
capacity upon harvest. In addition to these potential benefits, it is vital that the preconditioning 
method does not compromise the stemness or increase susceptibility to adverse immune reactions. 
These issues pose serious concerns for preconditioning methods that utilize biologically-derived 
components for cell expansion such as decellularized extracellular matrix (dECM), or other 
methods that allow for allogeneic and xenogeneic exposures. In this study, we compared the 
immunophenotypes of human NPCs, harvested from lumbar IVDs and expanded on plastic 
(Plastic), autologous dECM (AutoECM), allogeneic dECM (AlloECM), and xenogeneic dECM 
(XenoECM) substrates; surface markers assayed included HLA-DR, CD80, CD86, and CD95 
(Fas). After expansion, cells were co-cultured with allogeneic peripheral blood mononuclear cells 
(PBMCs) in mixed lymphocyte reactions and assayed for T-cell proliferation. Xenogeneic and 
allogeneic dECMs were also assayed for redifferentiation following cell expansion. Overall, this 
study presents new data suggesting that dECM expansion, irrespective of source (autologous, 
allogeneic, or xenogeneic cell-based) allowed human herniated NPCs to express similar 
immunophenotypes and immunological responses for T-cell proliferation compared to plastic 
expansion alone. These results suggest that dECMs may be an effective, immunologically 
acceptable method for NPC preconditioning and cell expansion. 
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Introduction 
Healthcare costs and annual spending for back pain related visits are on the rise [1]; a major 
contributor to these increases are attributed to spinal injury and related pain [2], as well as disc 
degeneration and herniation [3]. Therefore, therapies that can provide treatment of ailing discs are 
gaining recent attention. Recently, cell-mediated therapies have gained attention for repair or 
treatment of intervertebral discs (IVDs) [4] [5], with the goals of increasing disc cellularity, lost 
nucleus pulposus (NP) tissue and disc height [6] [7].  Although many preconditioning strategies 
can be employed [8], 3-dimensional (3D) cultures have been a recent area of interest for the 
development of clinical solutions. One preconditioning and expansion method is the use of 
decellularized extracellular matrix (dECM) expansion of harvested patient cells, which has been 
demonstrated as a successful cell expansion method to increase yield and rejuvenation of stem cell 
and nucleus pulposus cells alike [9] [10] [11]. Despite the success of 3D cultures in terms of cell 
differentiation potential [11] [12] [13], few studies have focused on potential deleterious effects 
on the immunogenic properties of expanded cells. It has been suggested that biomaterial-induced 
alterations in immunological responses, particularly those resulting from cell-based approaches, 
are important and frequently overlooked factors that can contribute to immunogenicity [13]. 
Because the inner space of the IVD is an inherently immune-privileged site [14], immunogenicity 
is an area of concern when new cells are introduced [15] [16].  
Due to the known roles of major histocompatibility complex-II (MHC-II or HLA-DR) and its role 
in immune recognition and graft rejection [17] [18] [19], we hypothesize that HLA-DR, as well as 
co-stimulator markers CD80/CD86 [20] may be involved in immune issues related to 
preconditioning and cell expansion. Recent studies support this hypothesis; Yuan and colleagues, 
who have previously reported that seeding cells in collagen hydrogels and their introduction in 
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vivo increased MHC-II (HLA-DR) expression and suggested that fast matrix formation and 
mindful scaffold selection may be useful strategies [21]. Similarly, Zhang and colleagues have 
reported increases in HLA-DR expression in synovial stem cells with xenogeneic dECM 
expansion [22] and conversely, Pizzute and colleagues reported that allogeneic adipose-derived 
stem cell dECM did not elicit this same increase [23]. 
Human NPCs have been shown to express Fas and Fas ligand [24] [25], and serve as a method for 
maintaining immune privilege in the disc through apoptotic interactions with invading immune 
cells [26] [27]. Fas receptor (CD95) is a surface receptor involved in apoptosis [28] [29], and when 
bound by Fas ligand (CD178), leads to downstream activation of caspase-8 [28] [30] and, 
ultimately, apoptosis. Fas has been specifically implicated in degenerative IVD cells [24] [31] and 
despite its role in immune privilege of the IVD, Fas has been further implicated as a 
disadvantageous surface marker for NPCs, primarily due to the potential for cytotoxic T-cell 
activity and cell-mediated apoptosis of disc cells [13]. Overall, in this study, we aimed to provide 
new insight into the potential immune issues surrounding NPC expansion on 3D, biologically-
derived substrates such as allogeneic and xenogeneic dECMs. 
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Materials and Methods 
Preparation of ECM-coated flasks 
Plastic cell culture flasks were prepared as previously described [11]. Briefly, flasks were pre-
coated with 0.2% gelatin (Sigma-Aldrich, St. Louis, MO) at 37°C for 1 h and seeded with passage 
2 human or porcine nucleus pulposus cells at 6000 cells per cm2. After cells reached approximately 
90% confluence, 250 μM of L-ascorbic acid-2-phosphate (Wako Chemicals USA, Inc., Richmond, 
VA) was added for 10 days. The deposited ECM was incubated with 0.5% Triton X-100 containing 
20 mM ammonium hydroxide at 37°C for 5 min to remove the cells; DECM was stored at 4°C in 
phosphate buffered saline (PBS) containing 100 U/mL penicillin, 100 μg/mL streptomycin, and 
0.25 μg/mL fungizone until use. 
Cell culture 
Human adult NP cells were previously obtained from the tissues of herniated disc patients (32-
year-old male and 35-year-old female) following patient consent and Institutional Review Board 
(IRB) approval. Cells were cultured in growth medium containing Alpha Minimum Essential 
Medium (αMEM), 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, 
and 0.25 μg/mL fungizone. After reaching confluence, cells were detached with 1X Trypsin-
EDTA and seeded on plastic (Plastic) flasks as a control, or on previously prepared dECM flasks 
from autologous (AutoECM), allogeneic (AlloECM), or porcine-derived xenogeneic 
(XenoECM) NPC sources under the same culture media conditions, changing media every third 
day. 
 
 209 
 
Flow cytometry and cell proliferation analyses 
To determine the proliferation index of each group (Fig 1), before cell expansion, NP cells were 
pre-labeled with CellVue® Claret at 2×10-6 M for 5 min according to the manufacturer’s protocol 
(Sigma-Aldrich). After six days of proliferation, expanded cells were collected and measured using 
a BD FACS LSRFORTESSA flow cytometer (BD Biosciences, San Jose, CA). Twenty thousand 
events of each sample were collected using CellQuest Pro software (BD Biosciences); cell 
proliferation index was analyzed using ModFit LT version 3.1 (Verity Software House, 
Topsham, ME).  
Following NPC expansion, cells were collected and stained with the following antibodies: CD95 
(BioLegend, San Diego, CA), HLA-DR (MHC-II) (BioLegend), CD80 (B7-1) ) (BioLegend),   
CD86 (B7-2) (BioLegend),  and isotype-matched IgGs (Beckman Coulter, Fullerton, CA). 
Samples (n=3) of each expanded NPC group, 3×105 expanded cells were incubated on ice in cold 
PBS containing 0.1% Chrom-Pure Human IgG whole molecule (Jackson ImmunoResearch 
Laboratories, West Grove, PA) and 1% NaN3 (Sigma-Aldrich) for 30 min, followed by incubation 
in the dark in the primary antibody for 30 min. Fluorescence signals were analyzed using a BD 
FACS LSRFORTESSA flow cytometer and FCS Express 4 software package (De Novo 
Software, Los Angeles, CA).Twenty thousand events of each sample were collected using 
CellQuest Pro software (BD Biosciences) and analyses performed using FCS Express 4 software 
package (DeNovo Software).  
For co-culture and proliferation analysis, the same flow cytometry staining procedure as above 
was used. However, following IRB approval, peripheral blood mononuclear cells (PBMCs) were 
harvested from 20 mL of whole blood (26-year-old healthy male), and separated by density 
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centrifugation for 40 minutes at 300g in 50 mL conical tubes using Ficoll-Paque PLUS (GE 
Healthcare Life Sciences, Marlborough, MA). The PBMC layer was collected, washed with PBS, 
counted for viability using Trypan Blue staining and hemocytometer, and added at a 10:1 ratio (0.2 
x 106 PBMCs/well) in co-culture with expanded NPCs (0.2 x 105/well) in cell culture grade 96-
well plates (Corning®, Corning, NY) for 3 days. NPCs were allowed to attach to wells 24 hours 
prior to addition of PBMCs for co-culture. Cell culture media for this stage of experiments was 
RPMI-1640 with HEPES and L-glutamine (ThermoFisher, USA). Positive proliferation control 
consisted of stained PBMCs with Concanavalin A from Canavalia ensiformis (Sigma-Aldrich, 
USA) at [10 ug/mL] added to media. PBMCs were stained with CellVue® Claret according to 
manufacturer’s instructions prior to co-culturing. After 3 days of co-culture with expanded NPCs, 
PBMCs were collected from each well and stained with the following antibody cocktail: CD3, 
CD4, CD8, and CD45, and LIVE/DEAD® Fixable Red Dead Cell Stain Kit (Invitrogen, Life 
Technologies) per manufacturer instructions, and were collected and measured using a BD FACS 
LSRFORTESSA flow cytometer (BD Biosciences). Twenty thousand events of each sample 
were collected using CellQuest Pro software (BD Biosciences); cell proliferation index was 
analyzed using ModFit LT version 3.1 (Verity Software House) and analyses performed using 
FCS Express 4 software package (DeNovo Software). 
Redifferentiation induction and evaluation 
Expanded cells (3×105) were centrifuged at 500 g for 5 min in a 15-mL polypropylene tube to form 
a pellet. After overnight incubation (day 0), the pellets were cultured in a serum-free chondrogenic 
medium consisting of high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM), 40 μg/mL 
proline, 100 nM dexamethasone, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.1 mM L-
ascorbic acid-2-phosphate, and 1×ITS™ Premix (BD Biosciences) with the supplementation of 10 
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ng/mL transforming growth factor beta3 (TGFβ3, PeproTech, Inc.) in a 5% O2 incubator as long 
as 21 days. The pellets were evaluated for NP cell redifferentiation using pellet size, biochemical 
analysis, and quantitative real-time polymerase chain reaction (qPCR). 
Representative pellets (n=4) were digested at 60°C for 4 h with 125 μg/mL papain in PBE buffer 
(100 mM phosphate, 10 mM ethylenediaminetetraacetic acid, pH 6.5) containing 10 mM cysteine. 
To quantify cell density, the amount of DNA in the papain digestion was measured using the 
QuantiT  PicoGreen® dsDNA assay kit (Life Technologies) with a CytoFluor® Series 4000 
(Applied Biosystems, Foster City, CA). GAG was measured using dimethylmethylene blue 
(DMMB) dye and a Spectronic  BioMate  3 Spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA) with bovine chondroitin sulfate (Sigma-Aldrich) as a standard.  
Total RNA was extracted from representative samples (n=4) using an RNase-free pestle in TRIzol® 
(Life Technologies). Two micrograms of mRNA were used for reverse transcriptase with High-
Capacity cDNA Archive Kit (Applied Biosystems) at 37°C for 120 min. NP cell redifferentiation 
related genes: type II collagen (COL2A1) (Assay ID Hs00156568_m1) and paired box protein 1 
(PAX1) (Assay ID Hs01071291_g1), were customized by Applied Biosystems as part of their 
Custom TaqMan® Gene Expression Assays. Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) (Assay ID Hs02758991_g1) was carried out as the endogenous control gene. TaqMan® 
real-time PCR was performed with the iCycler iQ  Multi Color Real-Time PCR Detection and 
calculated by computer software (Perkin-Elmer, Wellesley, MA). Relative transcript levels were 
calculated as χ=2-∆∆Ct, in which ∆∆Ct=∆E-∆C, ∆E=Ctexp-CtGAPDH, and ∆C=Ctct1-CtGAPDH. 
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Statistical Analysis 
The three response variables of interest (Viable, CD4+ and CD8+) assume the form of proportions 
that are relatively close to zero.  It is well known that is such cases variances between groups are 
non-homogeneous.  For small samples homogeneity of variance is a key assumption associated 
with ANOVA models.  In order to stabilize the variances we used the arcsin of the square root of 
the measured proportions in an Analysis of Variance (ANOVA) to determine significance.  In all 
cases the results were deemed to be significant if the resulting p-value was < .05.  All analyses 
were done using JMP V12.2 (SAS Institute, Cary NC).  The ANOVA model included two factors: 
One factor (Donor) was a blocking or control factor while the other (ECM Type) was the 
experimental factor.  ECM type had 3 levels: Plastic, Allo-ECM and XenoECM.  When the effect 
of ECM type was significant, pairwise difference between the three levels were explored using 
Tukey’s HSD procedure. 
 
 
 
 
 
 
 
 
 213 
 
Results 
dECM expansion increases NPC proliferation 
In proliferation analyses, all dECM expansion conditions were superior in terms of proliferation 
index (PI) to Plastic group (Fig 1). Allo-ECM and Xeno-ECM exhibited the greatest proliferation 
indices, at 14.94 (1.99-fold vs. Plastic) and 14.59 (1.95-fold vs. Plastic), respectively. Additionally, 
all dECM groups exhibited peak generations at Generation 4 or Generation 5, whereas Plastic 
exhibited the greatest peak at Generation 3. 
dECM conditions do not elicit differences in immune responses 
In immunophenotyping experiments, all groups exhibited insignificant differences compared to 
Plastic, with no measurable increases in HLA-DR, CD80, or CD86 expression following dECM 
expansion (Fig 2). Despite similar percentages of CD95+ (Fas) cell expression to Plastic following 
dECM expansion, Plastic exhibited the greatest Mean Fluorescence Intensity (MFI) versus all 
other groups, with Plastic MFI = 704.64; AutoECM = 565.58; AlloECM = 606.88; and XenoECM 
= 529.86 (Fig 3). In co-culture experiments where expanded NPCs and PBMCs were cultured 
together for 72 hours, no significant increases in the percentage of proliferated PBMCs were 
observed between Plastic and either AlloECM or XenoECM groups in T-helper cells 
(CD45+/CD3+/CD4+) (Fig 4C), or in proliferation analysis of viable PBMC population (CD45+) 
(Fig 4B). A small decrease was measured in the percentage of proliferation in cytotoxic T-cells 
(CD45+/CD3+/CD8+) in Xeno-ECM versus Plastic (Fig 4D). Robust PBMC proliferation was 
measured in the ConA stimulated positive control, with 93.45% proliferation occurring (Fig 4A), 
whereas co-culture proliferation did not exceed 3.5% in any group. 
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NPC redifferentiation is enhanced by dECM expansion 
At Day 14, Plastic pellets exhibited rather irregular shapes, compared to the larger, spherical 
AlloECM and XenoECM groups (Fig 5A). The pellet size of AlloECM and XenoECM were both 
marginally larger than Plastic at both Day 14 and Day 28 of redifferentiation. Day 14 AlloECM 
and XenoECM pellets were similar in size and shape to the Plastic pellet at Day 28 (Fig 5A). Both 
Allo-ECM and Xeno-ECM increased DNA ratio versus Plastic group at Day 14 and Day 28 of 
redifferentiation (Fig 5B). Additionally, Allo-ECM and Xeno-ECM both exhibited the greatest 
glycosaminoglycan (GAG) content, significantly greater than Plastic at both Day 14 and Day 28 
(Fig 5B), and exhibited trends toward greater GAG/DNA ratios at Day 28 of redifferentiation (Fig 
5B). Real-time qPCR revealed similar levels of PAX1 mRNA expression across all groups; 
however, both AlloECM and XenoECM exhibited an approximately two-fold significant increase 
in COL2A1 mRNA (Fig 5C). 
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Discussion 
In this study, we compared the immunological properties of dECM, prepared from different donor 
sources, and their ability to expand human nucleus pulposus cells harvested from herniated lumbar 
discs. To our knowledge, there are no other studies which have compared dECM expansion of 
human lumbar NP cultures for immunogenicity via PBMC proliferation. For the first time, we 
showed that dECM, regardless of source, did not significantly increase HLA-DR, CD80, CD86, 
or CD95 expression (Fig 2 & 3). In a previous study, we showed that expansion of NPCs on an 
adipose-derived allogeneic dECM could decrease CD95 expression [23], but did not observe this 
result in the current study. There may be differences in the immunomodulatory properties dECMs 
based upon cell type and source, however, this hypothesis warrants further investigation and 
evidence. Additionally, when dECM expanded cells were co-cultured with PBMCs, no increases 
in proliferation of T-cell or viable PBMC populations were observed (Fig 4). The results of this 
study are similar to those published by Stich and colleagues, who used human cervical NPCs 
cultured in 3D fibrin/poly (lactic-co-glycolic) acid transplants and tested the proliferation of 
CFSE-labeled PBMCs [13]; however, unlike the results from their study, we did not measure any 
elevated proliferation responses following 3D-culture (dECM in the case of our study). They 
suggested that their result could be attributed to potential unidentified stimuli from the cells or 
matrix [13]. Overall, we assume there is low immunogenicity in our own cultures which utilized 
dECM expansion of NPCs. 
In a previous study, it has been shown that xenogeneic, but not allogeneic dECM expansion of 
synovial-derived stem cells could increase HLA-DR expression [22], raising potential questions 
regarding dECMs’ effects on expanded cell immunogenicity with dECM source/composition 
representing a potential immunogenic stimuli. Stich and colleagues reported low HLA-DR 
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expression in NPCs, however, did observe a small increase in more severely degenerated NPCs 
[13]. In the current study, we did not observe any measurable HLA-DR expression, or any increase 
in HLA-DR expression, regardless of dECM expansion condition (Fig 2). Furthermore, in the 
current study, we report the same result for CD80 and CD86, co-stimulatory ligands for T-helper 
cell responses [32]. Recent literature has shown that blockade of CD80 and CD86 co-stimulatory 
signals can result alloantigen-specific anergy of T-cells [33]. Interestingly, it has been suggested 
that lack of expression of these co-stimulatory molecules could partially explain the lack of 
immune response to tumor cells [34], and may also benefit cell-based therapies targeting IVDs. 
Although the results of this study are promising for the future therapeutic applications for dECM 
expansion of human NPCs, we recognize several limitations of the study. These limitations include 
NP and blood donor numbers and overall lack of dECM characterization. Also, future detection of 
HLA-ABC (MHC-I) may be useful to provide more complete immunoprofiles and supporting data 
for T-cyotoxic cell interactions. Studies that more fully validate this model are necessary, 
especially those incorporating more sophisticated in vivo models for immune rejection of dECM-
expanded NPCs, and would vastly improve and support the current findings. Also, despite 
emerging literature implicating degenerative status of NPCs [13] [23], there is still an overall lack 
of literature investigating the predisposition of degenerative status and its effect on the cells’ 
response to preconditioning strategies; therefore, it may be useful to compare the efficacy of 
various preconditioning methods and resulting immunogenicity in future studies. Overall, dECMs, 
particularly those from allogeneic and xenogeneic sources could serve as a potential source of 
commercially available, effective, and safe means of human NPC expansion for future utilization 
in cell-based therapies. 
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Figure 5.1: Proliferation of expanded NPCs. Claret red-labeled nucleus pulposus cells were 
measured via flow cytometry for their proliferation indices and generation analysis at Day 0 (A), 
and after 5 days on either Plastic (B), autologous dECM (C), allogeneic dECM (D), or xenogeneic 
dECM (E). 
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Figure 5.2 
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Figure 5.2: Immune marker expression following expansion. Flow cytometry analysis of 
immune surface marker HLA-DR (MHC-II) expression (left column), CD80 (B7-1) and CD86 
(B7-2) expression (right column) for NPCs expanded on Plastic (A), AutoECM (B), AlloECM 
(C), and XenoECM (D). 
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Figure 5.3 
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Figure 5.3: Expression of CD95 (Fas) by expanded NPCs. Flow cytometry analysis of CD95 
expression in a histogram (top), and in table format (bottom), depicting the percentage of CD95-
positve cells and mean fluorescence intensity (MFI) for each expansion condition. 
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Figure 5.4 
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Figure 5.4: PBMC proliferation following co-culture with expanded NPCs. Stained-PBMCs 
were measured via flow cytometry for their generational and percent proliferation at Day 0, and 
after 3 days of ConA-stimulation as proliferation controls (A). Percent of proliferation of all viable 
(B), CD3+CD4+ (C), and CD3+CD8+ (D) PBMCs populations following 3 days in co-culture 
with NPCs expanded on Plastic, AlloECM, or XenoECM were also measured. 
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Figure 5.5 
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Figure 5.5: Redifferentiation of ECM expanded NPCs. Representative redifferentiated cell 
pellets, formed from each group of expanded NPCs were cultured and collected at Day 14 and Day 
28 for comparison (A).GAG content, DNA, and GAG/DNA ratios were measured at both Day 14 
and 28 for each group (B). Real-time PCR was used to detect the expression of COL2A1 and PAX1 
in expanded and redifferentiated NPCs (C). 
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Chapter 6:  
General Discussion 
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Summary 
The primary objectives of this dissertation were to (1) investigate the roles of WNT3A, WNT5A, 
and WNT11 gene expression in NP redifferentiation, (2) evaluate the efficacy of dECM, FGF-2, 
and hypoxic preconditioning of human NPCs and SDSCs, (3) determine the redifferentiation and 
immunophenotypic changes of human NPCs following allogeneic and xenogeneic (porcine) 
dECM expansion, and (4) determine if allogeneic and xenogeneic (porcine) dECM expansion 
increased T-cell proliferation. The long-term goal of these studies is to provide new insights and 
data to assist in the development of effective cell preconditioning protocols for efficient and safe 
ex vivo expansion of human NPCs for intervertebral disc regeneration and repair. The central 
hypothesis of this work is that preconditioning methods such as dECM expansion and FGF-2 
supplementation can be effectively utilized for harvested NPC expansion without apparent 
immunological concerns; furthermore, this could be done through the modulation of wnt signals 
to improve redifferentiation potential. By understanding the downstream effects of 
preconditioning strategies on NPC rejuvenation, as well as the upstream biochemical signaling 
pathways at work during NPC redifferentiation, mindful and effective approaches can be 
developed for cell-based IVD regeneration. 
In this dissertation, we demonstrated that non-canonical Wnt signals, Wnt5A and Wnt11, are 
important regulators of NPC redifferentiation, and along with canonical Wnt3A, these signals 
appear to be stage-specifically expressed regulators of SDSC chondrogenesis when preconditioned 
with FGF-2 (Pizzute et al., 2016). Furthermore, we demonstrated that preconditioning of human 
NPCs by allogeneic and xenogeneic dECM, as well as FGF-2 supplementation in both SDSCs and 
NPCs can be effectively utilized to increase proliferative and redifferentiation potential. These 
dECM conditions did not elicit apparent increases in the expression of potentially disadvantageous 
 233 
 
immunomarkers (HLA-DR, CD80, CD86, or CD95), nor do they cause increases proliferation of 
viable PBMCs, CD3+CD4+ T-cells, or CD3+CD8+ T-cells in co-culture with dECM-expanded 
substrates. Overall, dECM and FGF-2 preconditioning methods, as well as the proper modulation 
of Wnt signaling pathways during NPC expansion each hold promising outlook and potential 
benefits for future cell-based therapies in IVD repair and orthopaedic interventions.  
Future Directions 
Detecting of potential immune issues in cultures 
Despite the known potential benefits of various preconditioning strategies for cell culture [1], it is 
imperative that these cells do not elicit immune responses when introduced or reintroduced to a 
patient. For this reason, more studies are needed to fully evaluate the immunophenotypic changes 
in preconditioned cells and to perform the necessary experiments to ultimately elucidate the 
immune-related benefits and caveats of each preconditioning strategy. One of the initial 
experiments for assaying immune changes should include flow cytometry for immune surface 
marker analysis following preconditioning, particularly HLA-DR, complemented with T-cell 
costimulatory markers CD80 and CD86, as well as apoptosis-related markers CD95 (Fas) and 
CD178 (FasL), implicated in intervertebral disc immunity [2] [3]. Furthermore, studies 
investigating the relationships between preconditioning and Fas-mediated apoptosis could uncover 
new, clinically relevant results for future therapeutic applications in intervertebral disc 
regeneration. To date, few studies have compared the immunomodulatory properties of various 
preconditioning methods in a single well-controlled study. One common approach to model 
potential immune response to preconditioned cells is an MLR assay using labeled immune cells, 
typically isolated from a blood sample. Several groups have used a version of this technique to test 
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preconditioned cells [4] [5]. Notably, there is a great demand for in vivo studies to investigate the 
role of preconditioned cells for safe intervertebral disc tissue repair, especially those that can 
further evaluate the effects of preconditioning-induced changes in immune characteristics. It is 
reasonably suspected that one preconditioning strategy is unlikely to be most superior or ideal for 
all tissues in terms of immunomodulation, especially since various tissues are dominated by 
distinct immunoregulatory factors and different immune cells [6].  With clinical applications in 
mind, an ideal preconditioning method or combination strategy should consider the multifaceted 
and specific nature of the immune reactions present in a particular target tissue, as well as the 
potentially altered immune properties of the preconditioned cell population.   
Identification of dECM properties 
In this dissertation and in past studies from our laboratory, we have thoroughly studied and 
demonstrated the ability of various dECMs to provide a useful cell expansion substrate for NPCs 
and MSCs alike [7] [8] [9] [10]. These dECMs can cause increased cell proliferation, 
differentiation potentials, and overall cell rejuvenation. Despite the benefits of dECM expansion, 
there is an abundance of unanswered research questions surrounding its use, as well as potential 
factors influencing its efficacy as a cell expansion strategy.  
Some of the areas currently under investigation in our laboratory are the roles of various laminin 
subunits in nucleus pulposus cell, which have been shown to be important in nucleus pulposus 
ECM interactions [11] [12] [13]. Similar to the Wnt signaling studies presented in this dissertation, 
lentiviral transduction of NPCs using CRISPR-Cas9 vectors offers a powerful and accurate means 
to knockout specific laminin subunits, targeting the LAMA1, LAMB1, and LAMC1 genes to study 
dECM interactions. We have been able to efficiently generate knockouts of these genes and 
 235 
 
validate them by immunofluorescence microscopy (Fig 6.1). After generating stable cell lines, it 
will be possible to create laminin-rich, and laminin-deficient dECMs (Fig 6.2) for direct 
comparison in proliferative consequences, redifferentiation potential, and immune-related issues 
associated with dECM-expanded NPC and stem cell populations. Additionally, it may be useful to 
measure and more comparatively study the differences in the physical properties of these dECMs, 
such as elasticity/stiffness [14] (Fig 6.3), and in the future, observe characterize the differences in 
these properties following structural modifications like those facilitated by the knockout of 
structural proteins like laminins. Ideally, future dECM applications and research studies will 
consider facets of ECM, including both form and function; this will ensure researchers and 
clinicians can develop the most effective and conscientious preconditioning strategies and cell-
based approaches.  
Looking Ahead and Clinical Integration  
 
In addition to the physical and immunomodulatory properties of dECM, there are other concerns 
to be addressed before these preconditioning techniques can be appropriately implemented for 
clinical use.  In 2014, Alan Tyndall published his opinions and assessments regarding the current 
state of MSC research and therapeutics, highlighting many noteworthy concerns in the field [15]. 
Some of the resonating concerns presented in this article include a certain level skepticism 
surrounding the optimistic outcomes presented in current MSC literature and the administration of 
MSC-based interventions, which seem to exceed the current scientific knowledge [15][16]. Also, 
the seemingly short-lived immunomodulatory properties of MSCs themselves, experimental 
designs utilizing heterogenous and undefined cell populations, and perhaps most importantly, the 
overall lack of conclusiveness and continuity in the field surrounding MSC treatments are other 
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areas for concern [15]. Additionally, Tyndall makes propositions involving the future adherence 
and consideration of safety and current good manufacturing practices (cGMP) for future MSC 
applications [15]. Interestingly, many of the perspectives and concerns raised by the author of this 
article are relevant to the development and use of preconditioning strategies, and could provide 
direction for future applications of dECM in a clinical environment.  
Although it may be agreeable to propose that desirable immunomodulatory effects provided by 
MSCs may be short-lived as Tyndall suggests [15], in the case of dECM expansion and the use of 
dECM as a preconditioning strategy for IVD repair, the goal is likely better focused on the 
preservation of immune tolerance, rather than directing immunomodulatory applications via 
expanded cells. It seems that MSC applications with immunomodulatory capabilities may hold 
greater promise and sustainable solutions for chronic inflammatory and immunoregulatory 
conditions, such as rheumatoid and osteoarthritis [17], as opposed to IVD repair, which is not 
specifically defined by these characteristics. The results of the studies outlined in this dissertation 
have shown that dECM-expanded NPCs do not increase adverse immune proliferation of T-cells 
in co-cultures, nor do they increase CD95, HLA-DR, CD80, or CD86 expression. From our 
perspective, it seems that the real utility of dECM would be increased proliferation and 
redifferentiation capacity of expanded NPCs, and ultimately increased cellularity of damaged 
tissues, without inducing adverse immune effects. It is likely that other strategies or combination 
therapies, in conjunction with dECM, would be more useful for long-term or sustainable 
immunomodulation. Additionally, well controlled studies which compare the immunomodulatory 
properties of defined cell populations for in situ intervertebral disc repair would provide useful 
insights to this concept.  
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Points raised by Tyndall about the use of defined cell populations and cGMP however, hold much 
greater value, relevance, and are certainly applicable to the design, manufacturing, and utility of 
dECM as a clinical tool. By defining the cell populations used in the production of dECM coatings, 
the components likely have greater potential for standardization and control for future therapeutic 
modifications. Since there are many choices in terms of cell type in which dECM coatings can be 
derived and produced, choosing the most appropriate dECM type would seem like an obvious and 
important consideration. Our studies have suggested that the most appropriate dECM is the one 
that provides the best microenvironment for cell rejuvenation and directed differentiation 
successes in specific cell types [1][8][9][10]. This is most effectively aligned with our review, 
discussing that the most appropriate tissue specific stem cells for MSC therapies are those derived 
from the same tissue origins [18]; however, to date, studies comparing dECMs created from 
defined, well-characterized, and standardized cell lines, or those manufactured under cGMP 
remains unexplored. It should also be noted that the effect of degenerative status in preconditioning 
has yet to be extensively compared in IVD applications and for NPCs directly. Likewise, the 
differences in degenerative status and influence of harvested cells’ overall condition on dECM 
composition (for dECM production) has yet to be studied. Also, as previously stated and in stride 
with the concerns for undue optimism in the future of MSC-based therapies [15], in vivo studies 
providing evidence and support for dECM applications as a vehicle for successful tissue repair are 
necessary. The next stage for dECM studies should be mindful of these considerations to most 
effectively progress the model from the lab to clinic. 
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Figure 6.1 
 
Figure 6.1: Immunofluorescence of wildtype (WT) and laminin knockout (KO) NPCs.   
Laminin wildtype (left column), and laminin gene knockouts (right column) for LAMA1 (α-1 
subunit) , LAMAB1 (β-1 subunit), and LAMC1 (γ-1 subunit). Green = respective Laminin subunit 
stain; Blue = DAPI-stained nuclei. 
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Figure 6.2 
 
Figure 6.2: Preparation of dECM. Decellularized extracellular matrix can be produced by 
seeding a population of adherent cells on coated gelatin flasks, stimulating with ascorbic acid and 
growing to confluence (top). After decellularization, matrix components are left behind (bottom), 
offering an enhanced substrate for the expansion of new cells. 
 
 
Before Decellularization 
After Decellularization 
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Figure 6.3 
 
 
Figure 6.3: Biomechanical evaluation of both culture substrates and expanded cells in the 
duration regimens of AA treatment study. AFM was used to measure stiffness of each dECM 
group (PL, P2E0, P2E10, and P5E10) (average sample size n = 274) (A) and corresponding IPSCs 
(average sample size n = 587) grown on each above substrate (B). The stiffness of PL (A) is 
considered as infinite. * p < 0.05 indicates a statistically significant difference. NS: no statistically 
significant difference. 
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